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Oesophagogastric cancer is associated with poor long term survival; overall five-year survival is 
10-15%. A significant proportion of patients who undergo curative surgery subsequently 
develop metastatic disease. Evidently, local control of the tumour does not eliminate the risk of 
haematogenic recurrence. The cancer cell biology of disseminated disease and the mechanisms 
of its development remain poorly understood. The presence of disseminated tumour cells in 
blood and bone marrow of patients with breast, colorectal and lung carcinoma are associated 
with poor prognosis.  
The aims of the study were to develop a reliable assay to identify circulating tumour cells (CTCs) 
in the blood and disseminated tumour cells (DTCs) in the bone marrow and characterize the 
prevalence, biology and heterogeneity of the cells in patients with oesophagogastric cancer by 
high resolution imaging flow cytometry and fluorescence activated cell sorting. The objective of 
the thesis was to evaluate the prognostic significance CTCs and DTCs in oesophagogastric 
cancer.  
Blood samples were taken from patients undergoing curative and palliative treatment for 
oesophagogastric cancer. Bone marrow from the rib section excised as part of an open 
oesophagetomy was collected. CTCs and DTCs were isolated from the blood and the bone 
marrow by red cell lysis and immunomagnetic removal of white blood cells. Enriched cells were 
incubated with antibodies against epithelial, mesenchymal and predictive biomarkers. CTCs and 
DTCs were identified based upon their morphology and biomarker expression by high resolution 
imaging flow cytometry.  
CTCs and DTCs were present in all patients undergoing curative and palliative treatment for 
oesophagogastric cancer. Post curative surgery, patients with 100 or more CTCs in the blood 
had a significant reduction in relapse free survival (p=0.012).  
The study highlights the prognostic potential of CTCs in the blood and DTCs in the bone marrow 
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AF488 – Alexa Fluor 488 (fluorochrome) 
AF647 -  Alexa Fluor 647 (fluorochrome) 
AT – Anaerobic threshold 
BMTCS – Bone marrow disseminated tumour cells 
CEA – Carcinoembryogenic protein (CEA) 
CK – Cytokeratins 
C-Met – Tyrosine-protein kinase recptor  
CPET – Cardiopulmonary exercise testing 
CT – Computer tomography 
CTC – Circulating tumour cells 
CT-PET – Computer tomography and Postitron emission topography 
DAPI – 4,6-diamino-2-phenylindole 
DMEM – Dulbecco’s modified Eagle medium 
DNA – Deoxyribonucleic acid 
DTC – Disseminated tumour cell 
PBS – phosphate buffered saline 
ECX – Epirubicin, Capecitabine, Cisplatin 
EDTA – Ethylenediaminetetraaceitic acid 
EGFR – Epidermal growth factor receptor 
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EMP – Epithelial to mesenchymal plasticity 
EMR – Endoscopic mucosal resection 
EMT – Epithelial to mesenchymal transition 
EpCAM – Epithelial cell adhesion molecule 
EUS – Endoscopic Ultrasound 
FACS – Fluorescent activated cell sorting 
FGFR2 – Fibroblast growth factor receptor 
FCS – Foetal calf serum 
GOJ – Gastro-oesophageal junction 
HCX – Trastzumab, Capecitabine, Cisplatin 
HER2 – Human epidermal growth factor receptor 2 
HGD – High grade dysplasia 
LGD – Low grade dysplasia 
MIO – Minimally Invasive oesophagectomy 
NCCC – Northern Centre for Cancer Care 
NICR – Northern Institute of Cancer Research 
OGD - oesophgaogastroduodenoscopy 
PE – R-Phyco-erythrin 
RNA – Ribonucleic acid 
RPMI – Rosewell Park Memorial Institute  
RT-qPCR – Reverse transcription quantitative polymerase chain reaction 
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Chapter 1 : Introduction 
1.1 Anatomy and Physiology 
The oesophagus is a muscular tube that is approximately 25-30cm in length and extends from 
the pharynx to the stomach. It is divided into three parts: cervical, thoracic and abdominal. 
Figure 1.1.1 illustrates each segment in relation to the 
anatomical location, bloody supply, nerve supply and 
lymphatic drainage.  
 
 
Figure 1.1.1 – Anatomical description of 
the oesophagus 
The oesophagus is a muscular tube which 
is approximately 25-30 cm in length and 
extends from the pharynx to the 
stomach. It is divided into three parts 
based on its anatomical location and the 
neurovascular supply: cervical, thoracic 
and abdominal.   
The cervical oesophagus extends from 
the cricopharynx to the thoracic inlet. 
The arterial blood supply is from the 
branches of the inferior thyroid artery, 
venous drainage of blood is via the 
inferior thyroid vein and nerve supply 
from the cervical nerves.  
The thoracic oesophagus extends from 
the thoracic inlet to the diaphragmatic 
hiatus. The arterial supply in from 
branches of the descending aorta and 
venous drainage is to azygous veins.  
The abdominal part of the oesophagus 
extends from the diaphragmatic hiatus to 
the gastro-oesophageal junction. Arterial 
blood supply is via the left gastric artery 
and venous drainage is via the left gastric 
vein.  


















The primary function of the oesophagus is the transport of food and liquid from the mouth into 
the stomach. Muscular contractions along the oesophagus propel the luminal contents from the 
pharynx to the stomach. The wall of the oesophagus is divided into seven main layers as 











Figure 1.1.2 : Layers of the oesophageal wall 
The oesophageal wall is divided into seven layers. The four inner layers consists of the epithelium, basement 
membrane, lamina propria and muscularis mucosae. Oesophageal cancers confined within these four layers 
are amenable to endoscopic resection.  
Further extension of the cancer into the submucosal layer increases the risk of lymph node metastases and 
thus is not amenable to endoscopic resection.  
The muscularis propria consists of two layers of muscle – longitudinal and circular. The outer layer of the 
oesophagus consists of the adventitae.  
Figure take from: https://thoracickey.com/wp-content/uploads/2016/08/B9781437715606000433_f043-
006-9781437715606.jpg 
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The transition from the stratified squamous epithelium to the columnar epithelium which lines 
the stomach occurs at the gastro-oesophageal junction. 
1.2 Oesophageal cancer  
Oesophageal cancer is the 8th most common cancer and is the 6th most common cause of 
cancer related death worldwide (1). There are two histological subtypes of oesophageal 
cancer, squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma remains the 
most common subtype of oesophageal cancer worldwide(2). Oesophageal adenocarcinoma is 
the most prevalent subtype of oesophageal cancer in the western population.  It is associated 
with poor long term survival; overall 5 year survival is 10- 15% (3, 4). The incidence of 
oesophageal cancer in the UK has increased over the past two decades as illustrated by Figure 
1.2.1 (5). Oesophageal cancer is more common in males than females (Figure 1.2.1 and Figure 

























































Figure 1.2.1: Age specific incidence rates in the UK per 100 00 cases 2014-2016 
The incidence of oesophageal cancer is the highest in the 65-69 age group. The incidence of oesophageal 
cancer is three times higher in males than in females. Over the last decade the incidence of oesophageal 
cancer in patients over the age of 80 has been increased. Cancer Research UK 
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-





However over the last decade, improved life expectancy has led to an increase in the number of 
patients over the age of 80 being diagnosed with oesophageal cancer. 
Patients present commonly with difficulty swallowing which arises due to the tumour growth 
obstructing the lumen of the oesophagus. Unfortunately this occurs at a late stage of cancer 
development and majority of the patients present with locally advanced disease as illustrated in 
Figure 1.2.3.  
Figure 1.2.2: The incidence of oesophageal cancer in the UK in males and females per 100 000 people 
between 1993-2016  
Incidence of oesophageal cancer in males has steadily increased over the last two decades and is higher than 
in females. The incidence in females has declined over the last 10 years.  






Oesophageal adenocarcinoma arises mainly in the distal oesophagus and gastro-oesophageal 
junction. The primary aetiology factor in the development of oesophageal adenocarcinoma is 
gastro-oesophageal reflux (6-8). Another contributing factor is obesity. The rise in the incidence 
of oesophageal adenocarcinoma in the Western population is related to the obesity epidemic that 
is now prevalent (9). Other risk factor include smoking and alcohol. Gastro-oesophageal reflux 
results in the exposure of the distal oesophagus to gastric contents which contain gastric acid, 
gastric enzymes, ingested food and metabolites. The subsequent inflammatory process is 
thought to contribute to oxidative stress which promotes DNA damage, cellular proliferation 
and telomere shortening, which can increase the risk of developing clones containing small and 
Figure 1.2.3 Proportion of cases diagnosed at each stage of oesophageal cancer at the time of 
presentation, All Ages, England 2014, Scotland 2014 and Northern Ireland 2010-2014 
The majority of patients present with locally advanced cancer, Stage III and IV disease. Approximately 25% 
of patient present with metastatic disease. The number of patients presenting with early cancer in the UK 
remains low, less than 10%. Cancer Research UK, https://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/incidence#heading-Two,   
6 
large-scale genomic alterations, eventually leading to widespread chromosomal instability and 
oesophageal adenocarcinoma(6, 10). One of the steps in the process is the transformation of 
the stratified squamous epithelium to a columnar epithelium similar to that in the stomach, a 
process known as metaplasia(6, 7). This pre-malignant condition is called Barrett’s 
metaplasia of the oesophagus and may progress to dysplasia (11). The risk of progression to 
adenocarcinoma is dependent upon the degree of dysplasia present in the epithelium. The 
annual risk of progression to adenocarcinoma in non dysplastic Barrett’s oesophagus is 0.33% 
a year and rises to 0.9-1% a year in the presence of high grade dysplasia (11, 12).  British Society 
of Gastroenterologists recommendations are for the endoscopic surveillance of patients with 
Barrett’s metaplasia (11). The frequency of surveillance is dependant upon the length of the 
segment of Barrett’s metaplasia. If the maximum length of Barrett’s metaplasia is less than 3 
cm, a repeat OGD is required at 3-5 year intervals. If the maximum length of Barrett’s 
metaplasia is greater than 3 cm, a repeat OGD is required at 2 -3 year intervals(11). 
However, recent studies have shown that in over 95% of patients who present with 
oesophageal adenocarcinoma have had no previous diagnosis of Barrett’s metaplasia of the 
oesophagus(12). A meta analysis concluded that the incidence of oesophageal adenocarcinoma 
in non-dysplastic Barrett’s metaplasia was 1 in 300 patients per year and 1 in 500 patients per 
year in patients with short segment Barrett’s metaplasia of the oesophagus(12). The challenge 
is to identify patients with Barrett’s metaplasia of the oesophagus who are at risk of progression 
to oesophageal adenocarcinoma.  
 
1.4 Management of Oesophageal Cancer 
1.4.1 Investigations 
Patients undergo a series of endoluminal and radiological investigations to accurately stage 
the disease. Endoluminal investigations, consist primarily of endoscopy and biopsy with the 
addition of endoscopic ultrasound (EUS). EUS evaluates the extent of the tumour invasion locally 
and assesses the nodal involvement of the cancer(13). EUS has been shown to be the most 
accurate imaging modality in terms of evaluating nodal status (14, 15). However, the accuracy 
of EUS is dependent upon the operator(13, 15). Computer tomography (CT) of the chest, 
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abdomen and pelvis evaluates the disease locally and is used in conjunction with positron 
emission tomography (PET) to identify the presence of distant metastases(13). Patients with 
cancers at the oesophagogastric junction undergo staging laparoscopy to assess the intra-
abdominal component of the tumour and to exclude peritoneal disease. In addition, 
peritoneal fluid washings taken at staging laparoscopy are analysed for the presence of 
malignant cells within the peritoneal cavity. 
The stage of oesophageal cancer is determined based upon these investigations. Figure 1.4.1 
illustrates the TNM staging based on the tumour invasion, nodal status and the presence of 
metastatic disease (16). Early stage oesophageal cancer is categorised into Tis: high-grade 
dysplasia (HGD) and T1 which is cancer that invades the lamina propria, muscularis mucosae, 
or submucosa and is divided into T1a which is cancer that invades the lamina propria or 
muscularis mucosae and T1b which is cancer that invades the submucosa. Oesophageal cancer 
staged as T2 denotes invasion the muscularis propria. T3 is cancer that invades the adventitia 
and T4 is cancer that invades the local structures. T4 cancer can be further classified as T4a which 
is cancer that invades adjacent structures such as the pleura, pericardium, azygos vein, 
diaphragm, or peritoneum and T4b which is cancer that invades the major adjacent structures, 
such as the aorta, vertebral body, or trachea. The N stage denotes the nodal status and is 
categorized as N0 which is no regional lymph node metastasis, N1 which is regional lymph node 
metastases involving one to two nodes, N2 which is regional lymph node metastases involving 
three to six nodes and N3 which is regional lymph node metastases involving seven or more 
nodes. The M stage is categorized as M0 which is no distant metastasis and M1 which is the 




Cardio-pulmonary exercise testing (CPEX) is evaluated a patient’s cardiac and pulmonary 
and his or her ability withstand the stress of major surgery. This information provides the 
clinician with an objective assessment of a patient’s fitness (17). 
1.4.2 Curative Treatment  
 
Surgery remains the mainstay for curative treatment of oesophageal cancer (18). However, 
over the last decade, advances in endoscopic technologies have led to the development of 
techniques of limited endoscopic mucosal resection (EMR) of early oesophageal cancer. EMR 
enables the clinician to perform a localised resection of the epithelium and mucosa, as is the case 
for Tis and T1a disease (19, 20). This procedure is performed via the endoscope with the 
patient under sedation and offers a potentially curative resection if the lesion is isolated to the 
mucosal region (20). Extension of the tumour into the submucosa as is the case in T2 and T3 
Figure 1.4.1: TNM staging of oesophageal cancer – American Joint Committee of 
Cancer AJCC 8th Edition 
Illustrates the T stage which denotes the depth of tumour invasion locally. The N stage 
categorises the nodal status. Endoscopic ultrasound in conjunction with computer topography is 
used to the evaluate the T and N stage. The M stage denotes the presence of distant metastases. 
Figure from the publication by Ahmed et al (2010)(16) 
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disease, increases the likelihood of nodal spread and these patients would be considered for an 
oesophagectomy (21, 22). 
Clinical trials have shown survival benefits of peri-operative treatment for patients undergoing 
curative treatment for locally advanced oesophageal cancer (3, 23, 24). At present, patients 
with evidence of nodal disease (N+) and/or tumour stage T3 or greater are considered for peri-
operative treatment. The peri-operative chemotherapy regimens favoured in the UK are based 
on the outcomes of two randomised control trials. Results from the OEO5 trial showed 
improved rates of complete pathological response and a longer interval to disease recurrence in 
patients who received epirubicin, cisplatin and capecitabine (ECX)(25). The previous standard of 
care for patients undergoing peri-operative chemotherapy for oesopahgogastric cancer was the 
ECX regimen, which consists of three peri-operative and three post-operative cycles of the 
chemotherapy. The recently concluded FLOT-4 trial has showed higher complete pathological 
response rates of the primary tumour in patients who received docetaxel, oxaliplatin, 5-
fluorouracil and leucovorin (FLOT) regimen when compared to the ECX regimen(24). As a 
consequence, the new standard of care in patients undergoing peri-operative chemotherapy for 
oesophagogastric cancer is the FLOT regimen which consists of four peri-operative and four 
post-operative cycles of the chemotherapy. The optimum peri-operative treatment modality 
remains unclear. The current Neo-AGIS trial is evaluating the role of chemo-radiotherapy versus 
chemotherapy alone in patients undergoing curative treatment for junctional adenocarcinoma 
(26). Peri-operative treatment is associated with risks. Peri-operative treatment has associated 
an increase in postoperative mortality and morbidity (27, 28). In addition, studies have shown 
that peri-operative chemotherapy has a detrimental effect on cardiovascular and respiratory 
function(17). 
Following peri-operative treatment, patients have a repeat CT scan to evaluate the progression 
of the disease. If the disease remains curative, patients progress to surgery approximately six 
weeks after their last chemotherapy treatment. 
The principles of an oncological resection involve resection of the primary tumour with 
adequate resection margins and a formal lymphadenectomy which involves the resection of 
the local lymph nodes that drain the primary tumour (18). Sub-total oesophagectomy involves 
resection of the mid and distal oesophagus and reconstruction with a gastric conduit. This 
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operation is performed with a midline incision in the abdomen and an incision in the right 
postero-lateral chest wall. Recent advances in technology have led to the development of the 
minimally invasive approach for oesophagectomy (MIO)(29-31). This involves key hole surgery 
in the chest to resect the oesophagus and perform an anastomosis in the chest or the neck, 
a procedure known as thoracoscopic oesophagectomy. The efficacy of the technique and the 
potential benefits are being assessed in randomised control trials(30-32). A potential benefit 
from the reduced handling of the primary tumour with the thoracosopic compare to open 
technique. Wang et al, observed a significant reduction in the number of CTCs in  b lo o d  
samp le  t aken  a f t er  su rgery  in  their thoracoscopic versus the open oesophagectomy 
cohort, thus raising the possibility that tumour cell shedding is reduced in the thoracoscopic 
cohort (33). 
Surgery is associated with a mortality of 2-4% and morbidity of 30-40% (34-36). Furthermore, 
there is a significant negative impact in the quality of life in patients post oesophagectomy 
(37, 38). Recent advances in the enhanced recovery pathway have led to a reduction in 
the recovery time and improved post-operative outcomes (39).  
The response to peri-operative chemotherapy can be evaluated using the Mandard tumour 
regression grading system(40). Table 1.4.2.1 illustrates the tumour regression grade based on 
the response to peri-operative chemotherapy. Tumour regression grade has been shown to be 
an independent prognostic factors in patients who have underwent curative resection 
following peri-operative chemotherapy. 
Grade Definition 
TRG 1 No residual cancer 
TRG 2 Rare residual cancer cells 
TRG 3 Fibrosis outgrowing residual cancer 
TRG 4 Residual cancer outgrowing fibrosis 
Figure 1.4.2.1 Mandard tumour regression Grade 1 to 5  
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TRG 5 Absence of regressive changes 
 
Despite advances in peri-operative treatment and surgical technique, recurrence rate with 
curative intent remain at 46-53% with a median time to recurrence of 11-13 months (41-43). 
As a consequence, five year survival remains poor at 34-46% (44, 45). The prognostic factors that 
predict survival following resection are the final pathological stage of the tumour, the 
presence of nodal disease (N+) and the presence of lymphovascular and peri-neural invasion (44, 
46).  
The pattern of recurrence is classified based on the site of the primary recurrence detected 
radiologically. If the disease recurs at the site of the previous operation either in the chest or 
the abdomen, it is classified as locoregional recurrence. This encompasses both recurrence of 
the disease in the gastric conduit or the native oesophagus and/or the regional lymph nodes 
and/or the pleural/peritoneal cavity. Recurrent disease can present with malignant ascites or 
pleural effusion secondary to transcoeloeimc spread of the disease.  Presence of metastases at 
distant sites, eg liver, brain is classified as distant recurrence and is attributed to 
haematogenous spread of the tumour cells from the primary site.  
Studies that have evaluated the pattern of recurrence following curative treatment report 
varying distributions. Dresner et al, identified a higher rate of locoregional recurrence in 
comparison to distant recurrence in patients who underwent radical oesophagectomy with 
two field lymphadenectomy, 27% versus 18%(41). The majority of the patients in this study did 
not receive peri-operative chemotherapy. Parry et al, evaluated the outcomes of 171 patients 
who developed recurrence following curative treatment for oesophagogastric cancer, of 
whom 59% received peri-operative chemotherapy and/or radiotherapy and surgery (47). In 
their study, 76 patients (44%) developed distant recurrence with the liver and lung being the 
most common sites of metastases. Notably, over 122 patients (71%) had evidence of two or 
more sites of recurrence and 68 patients (40%) had evidence of both locoregional and distant 
recurrence. The study concluded that the presence of distant recurrence and the presence of 
three or more sites of recurrence were independant prognostic factors associated with 
recurrence free survival. Of the patients who relapsed, 62 (37%) received treatment for their 
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recurrence of which the majority had either locoregional (19) or solitary recurrence (24). 
Median post-recurrence survival was higher in the treatment group versus the best supportive 
care group, 9 months versus 2 months. However, the reason that the majority of patients 
received best supportive care was that they were not fit enough for any treatment. Their 
reduced fitness may explain or contribute to their reduced survival. A subgoup of patients 
underwent surgical resection of oligometastases (13), of whom 5 patients had resection of a 
solitary metastases from the brain. Seven of these patients died during the follow up period 
due to disease progression with a median post-recurrence survival of 11 months. Blom et al, 
noted lower rates of locoregional recurrence in patients who received peri-operative 
chemotherapy versus patients who underwent surgery alone for oesophageal cancer, 6 vs 16% 
(p=0.017)(48).  
In all three studies, there was no defined protocol for radiological or endoscopic follow up of 
patients following curative resection for oesophagogastric cancer. Diagnostic imaging occurred 
only if there was clinical suspicion of recurrence based upon the patient’s clinical signs and 
symptoms. Thus, the time between the development of the macroscopic presence of 
recurrence and the subsequent development of patient’s symptoms are unknown. Definitive 
conclusions about the timing and pattern of recurrence following curative resection for 
oesophagogastric cancer remain unclear.  
1.4.3 Palliative Treatment 
Due to the nature of the disease, approximately 50% of patients with oesophageal 
adenocarcinoma present with advanced disease (49). Advanced disease is classified as disease 
that is not amenable to resection, due to the presence of disease invading adjacent organs or 
the presence of disease outside the resection field. The extent of disease can vary from a single 
peritoneal nodule to disseminated disease afflicting distant organs, eg liver. The focus of 
palliative treatment is to treat both the primary tumour and distant metastatic disease. 
Chemotherapy remains the mainstay for treatment of metastatic oesophageal adenocarcinoma 
(50). The monoclonal antibody, trastuzamb has been shown to improve survival in patients 
with HER2 positive adenocarcinomas of the oesophagogastric junction (51). 
Dysphagia a common symptom in patients with locally advanced oesophageal cancer. Primarily 
attributed to the tumour causing either luminal or extraluminal obstruction. Various treatment 
13 
modalities are available to manage these symptoms. Radiotherapy and brachytherapy can be 
used to reduce the tumour burden and provide symptomatic relief(52, 53). Oesophageal stents 
can also be used to preserve the oesophageal lumen and thus allow patients to maintain enteral 
nutrition(53, 54). 
 
1.5 Disseminated and Circulating Tumour Cells 
Dissemination of tumour cells from the primary tumour can occur via four routes. 
Haematogenous dissemination is dissemination directly into the blood stream via the venous 
drainage from the primary tumour and lymphatic dissemination is dissemination via the 
lymphatic drainage channels. Alternatively tumour cells may infiltrate directly into organs 
adjacent to the primary tumour or transcoelomic dissemination by seeding of tumour cells 
within the pleural, pericardial, abdominal or pelvic cavity.  
The reasons how and why cancers metastasise preferentially to specific sites within the body 
remains unclear. The concept of circulating tumour cells (CTCs) was first described by Thomas 
Ashworth in 1869 (55). During an autopsy on a patient with metastatic cancer, he noted that the 
presence of cells in the blood which were morphologically similar to those of the primary 
tumour. In 1889, Paget noted the preferential site of cancer metastases associated with 
different epithelial tumours. During autopsies of patients with breast cancer it was observed 
that metastases were present in the lung and liver (56). In contrast in patients with uterine 
cancer, distant metastases were not present at these sites. Paget concluded that the site of 
metastases was linked to the biological origin of the tumour and proposed the “seed and soil” 
hypothesis. He described the dissemination of cancer cells from the primary tumour as a 
seed which is then deposited at distant sites in the body. Subsequent development of the 
metastases at these sites was thought to be dependent upon the environment, the soil 
which is conducive to the growth. This early observation presaged ideas about the variation in 
the molecular nature of cancer metastases which is thought to be dependent upon the primary 
tumour from which the cells originate. An alternative model based upon anatomical 
dissemination was proposed by Ewing (57). It is accepted that both molecular characteristics and 
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anatomical location of the primary tumour contribute to determine the eventual site of distant 
metastases. 
Our knowledge of tumour dissemination has evolved gradually since this early observation. 
Tumour dissemination and subsequent development of metastases were thought to be late 
occurrences in the evolution of the disease. However, 50% of patients undergoing curative 
resection for oesophageal adenocarcinoma develop recurrence within 5 years, with a median 
time to recurrence of 13 months (43, 58). This observation suggests that tumour dissemination 
to distant sites occurs at a far earlier stage in the development of the primary disease than 
surmised previously. This realisation has led to the development of the evolutionary model of 
tumour growth and dissemination. This model infers that tumour dissemination occurs during 
the initial stage of tumour development, prior to the tumour being detected macroscopically. 
This theory is supported by the detection of micrometastases in lymph nodes of patients 
who have undergone curative resection for oesophageal cancer (59). The presence of these 
metastases was associated with poor prognosis even in patients who had no macroscopic 
disease identified in the lymph nodes following curative resection (44, 60-62).Figure 1.5.1 




1.6 Circulating tumour cells 
Circulating tumour cells (CTCs) were first detected and characterised in peripheral blood by 
Racila et al in 1998 (64). They isolated CTCs based upon the positive expression of epithelial cell 
adhesion molecule (EpCAM) and negative expression of, CD45 a leucocyte marker by 
immmunomagentic separation. Further characterisation of the cells by immunocytochemistry 
with a pan cytokeratin antibody against cytokeratins 5, 6, 8 and 18 indicated that 29 out of 30 
breast cancer patients and all 3 prostate cancer patients had CTCs in the blood. A significantly 
higher number of CTCs were detected in the blood of patients with metastatic than in those 
with localised disease was noted, 122 ± 140 CTCs in patients with distant metastases versus 
15.9 ± 17.4 in patients with disease confined to the organ (P=<0.001)(64). Even in the advanced 
patients, CTCs only accounted for a small proportion of the cellular composition of the blood. 
Presence of CTCs has been associated with poor prognosis in patients with breast, colorectal 
and prostate cancer (65, 66). The number of CTCs deemed to be of prognostic significance is 
variable. Cristofonnalli et al, concluded that >5 CTCs per 7.5 ml of blood was a significant 
prognostic factor in survival in patients with metastatic breast cancer (66). Various methods and 
technologies have been developed to enrich and detect CTCs from peripheral blood. The 
major challenge in this process is that CTCs occur at very low concentrations in the 
peripheral blood, ranging between 1–10 cells per 10 ml blood of most cancer patients in which 
CTCs are detected (67). The half-life of CTCs in the peripheral bloodstream was has been 
estimated to be approximately 1-2 hours (67). Further, there is a lack of a clear definition with 
Figure 1.5.1: Models of tumour dissemination – Stepwise progression and parallel progression 
The figure illustrates the two hypothetical models of tumour dissemination. The first model, parallel 
progression hypothesizes dissemination of the tumour cells during the early development of the primary 
tumour. Early dissemination of the cancer occurs before the primary tumour is detected macroscopically. 
The tumour cells proliferate at the distant sites, eg bone marrow. The disseminated cells are 
hypothesized to be clones that arose from the primary tumour. They may have evolved and hence many 
not be sensitive to the same chemotherapy agents as the primary tumour. 
This model could explain the observed recurrence and relapse of patients who have undergone curative 
resection for cancer. The second model describes stepwise progression. In this model, dissemination of 
the cancer is at a late stage of tumour development. It occurs after the tumour is detectable 
macroscopically. There is clonal diversity between the cells of the primary tumour and tumour deposits 
at metastatic sites. This diversity could explain the varied response of the primary tumour and tumour 
deposits at metastatic sites to chemotherapeutic agents in patients with metastatic oesophageal cancer. 
Figures taken from publication by Maruysk et al (2012) 
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which to define a CTC. The only FDA approved method for the detection of CTCs is the 
CELLSEARCH® system (65). The system classifies a cell in the patients’ blood as a CTC if it 
expresses the epithelial markers, EPCAM and cytokeratins 8, 18 or 19 and does not express 
CD45. However, studies have shown that there is heterogeneity within the CTC population and 
the expression of epithelial markers is variable (68). Of interest are the CTCs that have 
undergone or undergoing EMT within the bloodstream (69-74). These cells express some 
mesenchymal biomarkers and lose expression of epithelial markers. The reliance upon 
epithelial makers alone to detect and isolate CTC may significantly underestimate the population 
as demonstrated by Cristofanailli, who noted that only 50% of patients with metastatic breast 
cancer had CTCs (66). However, mesenchymal markers can also be expressed in cells of 
haematopoeitic lineage which do not disseminate (75). Estimation of the true number of CTCs 
that are undergoing EMT or not is challenging in the absence of a perfect and universal CTC 
biomarker marker is difficult. 
Current enrichment and detection methods rely upon the unique physical and biological 
properties of CTCs to differentiate them from haematopoietic cells (67). CTCs can be isolated 
based upon their larger size, CTCs are typically >8 μm in diameter and that they are less 
deformable than haematopoietic cell ( 6 7 ) . Several methods for the enrichment of CTCs 
based on their physical characteristics have been described (76). Membrane filtration system 
isolate CTCs based on size and CTC chip have been designed to isolate CTCs based upon their 
size and reduced deformability(77). Ficoll hypaque density centrifugation can separate CTCs 
based on the higher density of CTCs in comparison to haematopoietic cells (78). CTCs can also 
be isolated based on their electrical charge via a process called Dielectrophoresis (DEP)(79). A 
spiral CTC chip is used to separate CTCs based on the higher centrifugal forces applied to the 
larger CTCs in comparison to the smaller haematopoietic cells (80, 81). 
Enrichment based upon the biological properties relies upon the biomarker expression of 
CTCs. Positive selection of CTCs has usually been with antibodies specific to epithelial markers 
eg EpCAM, cytokeratins. Of interest is the isolation of CTCs that show epithelial 
mesenchymal plasticity (EMP) and express mesenchymal biomarkers eg: vimentin (82). Unlike 
some other solid epithelial tumours, there is a lack of a tumour specific marker for oesophageal 
cancer. Potential biomarkers evaluated in oesophageal cancer are trefoil proteins, tyrosine 
kinase receptors and chemokine receptors. Trefoil proteins secreted from columnar mucosae of 
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the gastrointestinal tract and play a role in maintaining the integrity of the epithelium. They are 
under investigation as part of the BEST2 and BEST3 trial in the detection of Barrett’s   
oesophagus (83). Human epidermal growth factor receptor 2 (HER2), Fibroblast growth factor 
2 receptor (FGFR2) and tyrosine kinase cell surface protein receptor (c-Met) play a role in 
regulating normal cellular processes. These receptors are now potential therapeutic targets 
for intervention in the treatment for oesophageal carcinoma ( 8 4 - 8 6 ) . Trastuzumab, a 
monoclonal antibody against HER2 in combination with chemotherapy has been shown to 
improve survival in patients with HER2 positive oesophageal junctional and gastric 
adenocarcinoma (51). Chemokine receptors CXCR4 and CCR7 are proposed to play a role in the 
metastatic dissemination of cancers(87). Kaifi et al, detected CXCR4 in 75 out of 136 patients 
who underwent curative resection for oesophageal cancer. CXCR4 expression was 
associated with a significant reduction in overall survival, 25 months in CXCR-4 positive patients 
versus 97 months in CXCR4 negative patients (88). Positive selection of white blood cells based 
upon their expression of leucocyte specific markers eg CD 45 or CD 44 provides an effective 
enrichment of CTCs that does not rely upon expression of any specific biomarkers by the CTCs 
(89, 90). Subsequently analyses of the biomarker expression is possible by 
immunocytochemistry and flow cytometry. 
RNA based technologies, eg reverse transcription quantitative polymerase chain reaction (RT-
qPCR) allows the amplification, detection and quantification of multiple transcripts within a 
sample (91). This method provides a surrogate measure of CTCs in a sample and analysis of small 
numbers of CTCs within a sample. However information about the physical characteristics and 
the specific numbers of CTCs are not available with this approach. 
The EPISPOT technology, CTCs are enriched by positive immune-depletion of blood cells and 
placed on a membrane coated with an antibody for a tumour specific protein that is anticipated 
to be secreted or release by the CTCs (77)(92).  Any tumour specific protein capture by the 
antibody with which the membrane was coated is detected with a second fluorescence 
conjugated antibody against the tumour specific protein. The fluorescence is detected by 
fluorescent microscopy. The viability of CTCs and their metastatic potential has been evaluated 
with xenotransplantation models, which involves the injection of CTCs(67).  
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The ideal method for detection and characterisation of CTCs would be one that is sensit ive, 
reliable, reproducible and cost-effective. The lack of tumour specific markers for oesophageal 
cancer and the presence of heterogeneity within the CTC population remains a challenge. 
Analyses of a wide range of biomarkers should maximise the detection and characterisation of 
CTCs in oesophageal carcinoma patients. 
1.7 Epithelial to mesenchymal plasiticity in oesophageal cancer 
A current theory is that CTCs originate from a subpopulation of cancer stem cells within the 
primary tumour (93). The cancer stem cells are non-proliferative and thus resistant to the 
effects of chemotherapeutic agents (93, 94). The cancer stem cells undergo a transition from an 
epithelial to a more mesenchymal phenotype which allows the cells to enter the systemic 
circulation and travel to distant sites within the body. Figure 1.7.1 illustrates the factors that 





Studies have shown that increased expression of the regulators of EMT, such as Twist 1, Zeb1, 
Zeb2, Snail1 and Snail2/Slug, in primary tumours is associated with an increased risk of 
metastatic relapse (96). Increased expression of these factors has been associated with poor 
prognosis in patients with oesophageal cancer (74). The presence of CTCs with mesenchymal 
phenotypes has been associated with poor prognosis in patients with breast and prostate cancer 
(97, 98). 
Figure 1.7.2 illustrates the prognostic significance of epidermal growth factor (EGFR) expression 










Fig 1.7.1: Interaction between epithelial markers, mesenchymal markers and transcription factors 
during epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial transition (MET) 
Epithelial cells lose their adherence to adjacent cells and basement membrane and undergoes a 
transition to a mesenchymal cell which is then able to enter the systemic circulation. Complex 
interaction between growth factors, cytokines and the extracellular matrix plays a role in this process. 




During the initial transition from an epithelial phenotype to a more mesenchymal phenotype, it 
is thought that the cells lose their adherence to surrounding cells and the basement 
membrane. E-cadherin and β-catenin are proteins that play a role in cell adhesion. It has been 
shown that the loss of E-cadherin expression in the primary tumours is associated with poor 
prognosis in patients undergoing curative surgery for oesophageal cancer (99). Epidermal 
growth factor receptor (EGFR) is a transmembrane protein that plays a role in regulating DNA 
synthesis and cell proliferation. Overexpression of EGFR has been associated with 
significantly worse prognosis in patients following curative resection for oesophageal 
adenocarcinoma (72). 
During EMT, cells lose expression of epithelial markers. As a consequence, detection of 
these cells after this period of transition requires other biomarkers such as mesenchymal 
markers. Vimentin is a protein present in the cystoskeleton of mesenchymal cells. The 
presence of vimentin in the primary tumour of patients undergoing curative treatment for 
oesophageal cancer has been shown to be associated with poor prognosis (100). 
1.8 Disseminated tumour cells in oesophageal adenocarcinoma 
Bone marrow consists primarily of  stroma, fibroblasts, macrophages and osteoblasts which 
form the framework and structure of the marrow. The cellular component comprises cells of 
haematopoietic origin, myelopoietic origin and erythropoietic origin that are interspersed 
within the stroma. Abundant blood supply and favourable microenvironment are thought to 
be among the reasons why tumour cells migrate to and reside in the bone marrow (101). The 
bone marrow has been proposed to act as a reservoir for metastatic tumour cells that can 
recirculate into the bloodstream and then to distant sites within the body (101). The presence of 
disseminated tumour cells within the bone marrow (BMTCs) has been associated with 
Figure 1.7.2: The prognostic significance of epidermal growth factor receptor (EGFR) expression in 
resected oesophageal cancer specimens 
Higher EGFR expression was associated with a significant reduction in survival. Median survival was 
59.5 months in patients with low EGFR expression and 20.8 months in patients with high EGFR 
expression (p<0.001, log rank). Figure taken from the following reference, Prins et al (2015) (68)  
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poor prognosis in patients with breast, prostate and colorectal cancer (102-105). The 
presence of BMTCs has been linked to an increased risk of metastatic relapse in patients 
who have undergone curative treatment for breast cancer (106). 
Fifteen studies have evaluated the role of BMTCs in patients undergoing curative 
treatment for oesophageal cancer (58, 107-120). The detection rates varied significantly 
between the studies and ranged from 32% to 88%. The majority of the studies were 
focused on patients with squamous cell carcinomas and only five of the studies included 
patients with oesophageal adenocarcinoma. Furthermore, the site of bone marrow sampling 
and the volumes of bone marrow obtained varied. Bone marrow was sampled from two 
primary sites. Bone marrow was extracted directly from the rib portion which is excised as 
part of thoracotomy during the oesophagectomy or from a bone marrow aspirate taken 
during surgery. The other site of bone marrow aspiration was the iliac crest. One study that 
compared sampling sites, noted t h a t  a  significantly higher volume of bone marrow 
w a s  obtained from the rib section compared to bone marrow aspirates from the iliac 
crest (114). The tumour cell detection rate in the rib section was noted to be 88% in 
comparison to 15% in the iliac crest(114). Methods for detecting BMTCs varied. The majority 
of studies placed bone marrow extracts onto glass plates and analysed expression of 
epithelial biomarkers by BMTCs, primarily EpCAM and/or cytokeratins.   
Only a small proportion of the studies evaluated the role of peri-operative treatment on 
disseminated tumour cells. Ryan et al, detected significantly fewer BMTCs in patients who 
underwent neoadjuvant chemoradiotherapy in 12 out of 47 patients (39%) versus surgery 
alone in 27 out of 41 patients (61%) for oesophageal adenocarcinoma (116). There was no 
significant difference in patients who underwent peri- operative treatment for squamous 
cell cancer versus surgery alone. In contrast, O’sullivan et al showed no difference in the 
number of BMTCs in patients who underwent neo-adjuvant treatment and surgery versus 
surgery alone for oesophageal adenocarcinoma, however only 5 out of the 31 patients with 
adenocarcinoma underwent neo-adjuvant chemotherapy in this study (114). The authors 
concluded that there were chemoresistant cells within the population of BMTCs. The small 
subset of patients within the studies makes it difficult to assess confidently the impact of 
neo-adjuvant treatment on BMTCs in oesophageal cancer. The prognostic significance of 
disseminated tumour cells in oesophageal adenocarcinoma remains unclear. The follow up 
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times for the studies ranged from 20-60 months. The studies concluded that the presence of 
BMTCs was an independent prognostic factor in poor survival but there was a lack of 
consensus on the number of BMTCs deemed to be of prognostic significance. The primary 
reason for this issue maybe the significant variation between the methods for detecting 
BMTCs. 
Two studies which followed patients over a 10 year period had different conclusions on the 
prognostic significance of BMTCs (110, 116). Gray et al, concluded that the presence of 
BMTCs was associated with adverse tumour characteristics but did not impact on long 
term survival or recurrence ( 1 1 0 ) . Ryan et al, established that the presence of BMTCs 
was associated with increased risk of cancer-related death and was an independent 
prognostic factor in patients undergoing surgery alone for oesophageal cancer (116). 
1.9 Circulating tumour cells in oesophageal adenocarcinoma 
The prognostic significance of CTCs in oesophageal adenocarcinoma remains unknown. The 
majority of studies that have evaluated the role of CTCs in oesophageal cancer have focused 
on patients with squamous cell carcinomas ( 1 2 1 - 1 2 7 ) . They conclude that the presence 
of CTCs had a significant association with poor survival and suggested that the presence of 
CTCs has a negative effect on prognosis. Direct comparisons between the studies is difficult 
due to variations in the patient cohorts and the methods used in the detection and 
enumeration of CTCs. Detection rates of CTCs in peripheral blood of patients with squamous 
cell carcinomas varied between 18%-45% ( 1 2 1 - 1 2 6 ) . In three studies with a total of 90 
patients with locally advanced oesophageal adenocarcinoma, CTCs were evaluated by RT-
qPCR (121, 125, 126). The studies are limited therefore because individual CTCs were not 
identified but rather survivin mRNA, ERCC1 mRNA and CEA mRNA were quantified. 
Detection rates varied between 59.7% to 61%  (121, 125, 126). Investigators concluded that 
ERCC1 mRNA levels correlated positively with response to peri-operative chemoradiation and 
that a fall in survivn mRNA levels following resection was an indicator of completeness of 
surgical resection (121, 125, 126). 
Five studies have evaluated the presence of CTCs in patients undergoing curative treatment 
oesophageal adenocarcinoma based on the expression of  epithelial markers by CTCs 
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(128-132). Reeh et al, noted the presence of CTCs in 14 out of 68 patients undergoing 
curative resection for oesophageal adenocarcinoma. CTCs were detected with CellSearchR  
system.  The  criteria  for  CTC  identification  after positive selection of EpCAM expression 
was  the  presence  of  a  nucleus,  positive cytokeratin expression, round or oval cell 
morphology and absence of CD45 expression. The investigators concluded that in patients 
with adenocarcinoma, large tumour size and an advanced pathological stage of the tumour 
were associated with a higher number of CTCs in the blood (p=0.0027)(129). The number of 
patients in which CTCs were detected was lower in the cohort with squamous carcinomas,  
10% (3/29 patients) than in the adenocarcinoma cohort, 20.6% (14/68) (129). The 
investigators had a lower threshold for the detection of CTCs than in previous studies using 
the CellSearchR system. One or more CTCs detected per 7.5 ml of blood was taken to be 
significant. Two year follow up indicated that the presence of CTCs was an independent 
and strong prognostic factor for overall and recurrence-free survival in patients with 
oesophageal adenocarcinoma (129). The study is limited by the number of markers employed 
to characterise CTCs and dependence upon positive selection for EpCAM expression which 
means that the actual number of CTCs may be underestimated. Konzaella et al, evaluated the 
prognostic significance of CTCs and DTCs in the bone marrow in patients undergoing curative 
treatment for oesophageal adenocarcinoma. Bone marrow was aspirated from the iliac crest 
and cells were enriched by Ficoll density centrifugation and stained with pan-cytokeratin 
antibody(128). CTCs were enumerated from the blood using the CellSearchR  system. CTCs 
were detected in 20% (15/76) patients and DTCs in 17% (13/76) patients. Only three patients 
had both CTCs in the blood and DTCs in the bone marrow. The study concluded that CTCs 
were the only independent prognostic factor in relapse free and overall survival in patients 
undergoing curative oesophageal adenocarcinoma(128). Two other studies enriched CTCs 
from blood using filters which separated cells based on the size. Cells greater than 8 microns 
in diameter were isolated. Bobek et al, detected CTCs in 75% (12/20) patients using the 
MetaCellR filter (130). Post enrichment, cells were identified based on a positive nuclear 
(NucBlueTM) and cytoplasmic stain (CellTrackerTM). Kuvendjiska et al, reported on the 
sequential measurements of CTCs during the course of neo-adjuvant chemoradiotherpay and 
neo-adjuvant chemotherapy followed by surgery in patients undergoing curative treatment 
for oesophageal adenocarcinoma(132). CTCs were enriched from blood with the ScreenCellR 
device which isolated cells based on side. Post enrichment, cells were labelled with pan-
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cyokeratin and vimentin. Cells that expressed both biomarkers were classified as CTCs. In this 
study, CTCs were detected in 30% (6/20) patients prior to the start of treatment and the 
number of CTCs detected varied between 1-330 cells per 7ml of blood. Of the 20 patients in 
the study, 13 patients completed neo-adjuvant treatment and underwent surgery of which 5 
patients had CTCs in the pre-treatment blood sample. The study reported that there was 
increase in the number of CTCs per ml of blood after neo-adjuvant therapy in these 5 
patients. After completion of neo-adjuvant treatment and surgery, CTCs were detected in 
62% (8/13) patients. The authors reported that 55% (5/9) patients who had CTCs at some 
time point during the course of treatment relapsed over a two year follow up period.  
Dent et al, detected and characterised CTCs in patients with epithelial tumours by high 
resolution imaging flow cytometry ( 1 3 1 ) . The criteria for CTC selection were on the 
presence of EpCAM expression and/or cytokeratins, presence of a nucleus and negative 
expression of CD 45. Two out of six patients (33%) with locally advanced oesophageal 
adenocarcinoma had CTCs and the numbers of CTCs ranged from 0 to 64 CTCs per 7.5 ml of 
blood. 
 
1.10 Novel Biomarkers 
In previous studies, CTCs were identified in patients with oesophageal adenocarcinoma based 
upon the presence of the epithelial biomarkers, EpCAM and/or cytokeratins. CTCs undergoing 
EMP may not express epithelial biomarkers. Incorporation of mesenchymal biomarkers, eg 
vimentin, could help identify this subgroup population of CTCs. Cadherins are types of cell 
adhesion molecules that regulate cell differentiation and maintains the structural integrity of 
epithelial cells. A feature of EMP is loss of E-cadherin expression and gain of N-cadherin 
expression(133). Reduced E-cadherin expression is hypothesised to play a role in loss of 
cellular adhesion and subsequent invasion and proliferation of tumour cells at distant sites. 
Reduced expression of E-cadherin in the primary tumour was associated with poor prognosis 
in patients with oesophageal cancer(134). Increased N-cadherin expression in oesophageal 
cancer is associated with an increase in the migratory and invasive capacity of the tumour cells 
present(135).  
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Identification of patients whose tumour cells are resistant to the chemotherapy regimes 
available before the onset of treatment would ensure that these patients proceed 
immediately to surgery. They would be spared the morbidity associated with peri-operative 
chemotherapy that would be in their case ineffective and the associated delay in their curative 
treatment. Platinum-based chemotherapeutic agents, eg cisplatin cause crosslinking of DNA 
strands, which leads to cell death. As part of DNA repair, the excision repair cross-
complementing 1 (ERCC1) enzyme, which is involved in nucleotide excision repair pathway, 
excises platinum based adducts from the DNA strands. Studies have shown that high levels of 
ERCC1 expression in gastric and oesophageal cancer are associated with clinical resistance to 
platinum based chemotherapy agents(136). Fluorouracil (5-FU) or equivalent drugs are part of 
chemotherapy regimens for the treatment of oesophagogastric cancer. Their primary 
mechanism of action is to impair DNA replication by inhibition of thymidylate synthase. 
Thymidylate synthase is an enzyme responsible for the reductive methylation of deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) which is required for the 
synthesis of DNA and concomitant conversion of 5,10-methylenetetrahydrofolate to 
dihydrofolate. Increased expression of thymidylate synthase in the primary tumour has been 
associated with shorter disease free survival, poor tumour differentiation and resistance to 
chemotherapy in patients with gastric cancer(137).  
HER 2 and cMET have been identified as potential therapeutic targets in patients with 
oesophagogastric cancer(51, 138). Trastuzumab, a monoclonal antibody that inhibits HER 2 
activity improves survival in patients undergoing palliative treatment for gastric and 
oesophagogastric junctional tumours that express HER 2(51). Identification of CTCs which 
express these biomarkers in patients undergoing curative treatment could potentially indicate 
that these are appropriate therapeutic targets in the peri-operative and/or adjuvant setting.  
The trefoil factor family of proteins are involved in mucosal protection and repair of mucosae 
of the gastrointestinal tract. Trefoil proteins are found in the malignant progression from 
Barret’s oesophagus to adenocarcinoma(139). TFF3 is a trefoil protein that has been 
investigated as a potential diagnostic biomarker in Barret’s metaplasia of the oesophagus(83).  
As stated earlier, the tumour microenvironment consists of a heterogenous population of 
cells. Incorporation of a wide range of biomarkers, which includes epithelial, mesenchymal 
and therapeutic targets in the detection of CTCs will help characterise the heterogeneity of the 
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disseminated tumour cells and allow comparison with the primary tumour.  These studies will 
help improve our understanding of molecular complexities of tumour metastasis, and could 
identify potential targets for therapeutic strategies or provide prognostic information.
Chapter 2: Materials and Methods 
2.1 Laboratory Practice 
Laboratory induction was completed as per the Newcastle University guidelines prior to 
commencement of the research at the Northern Institute of Cancer Research. Attendance at 
control of substance hazardous to health (COSHH) and biological safety risks assessment 
(BIOCOSHH) training was completed during the first month of the research study. The risk for 
each individual experiment was assessed and the summaries stored in the laboratory file. 
Laboratory coat and gloves were worn at all times during laboratory experiments.   
2.2 Cell Culture 
2.2.1 Culture of Oesophageal and gastric cancer cell lines 
SK-GT-4, OE19, OE33, FLO-1 and ESO51 were cultured aseptically in a class II BioMat-2 
microbiology safety cabinet (Medical Air Technology). Plates, flasks and pipettes for tissue 
culture were obtained from Corning. Cells were cultures in two different medium, Roswell 
Park Memorial Institute (RPMI) medium and Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Table 2.2.1). To each 10% foetal calf serum (FCS) was added. Cells were incubated at 37oC in a 
humidified environment with 5% CO2 (Hereaus equipment). Cells were tested regularly to 
confirm the absence of mycoplasma and authenticity confirmed by Short Tandem analysis.   
 
 
Cell Line Origin Catalogue Number  Medium* 





Table 2.2.1:  Oesophageal adenocarcinoma cell lines and the corresponding culture 
medium 
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ESO51 Distal oesophageal 
adenocarcinoma  
11012010 RPMI 
OE33 Distal oesophageal 
adenocarcinoma 
96070808 RPMI 
* Roswell Park Memorial Institute (RPMI) medium and Dulbecco’s Modified Eagle’s Medium (DMEM) 
Cells were analysed below passage number 50. Cell lines were thawed to room temperature 
and added to the appropriate media with 10% FCS. The cell suspension was transferred to a 
25cm3 Corning® flask that contained 20ml of media and placed in the incubator. Cells were 
divided once they had achieved 80% confluency into either a 75cm3 flask or 125cm3 flask 
dependent upon the number of cells required for the subsequent experiments.  
2.2.1.1 Trypsinisation of cell lines for culture 
Sterile phosphate buffered saline (PBS) (137 nM NaCl, 83 mM KCL, 10 nM Na2HPO4, ph 7.2) 
was prepared. Trypsin (Sigma Aldrich) was diluted to 10% with sterile PBS and stored at 4oC.  
The procedure for tyspsinisation of cell lines for culture was dependent upon the cell lines and 
the culture medium. ESO51 cell line were cultured in suspension with RPMI medium 
containing 10% FCS and 20mM L-glutamine. The cell suspension was aspirated into 20 ml 
sterile Falcon tube and centrifuged at 500g for 5 min. The cell pellet was resuspended in 5 ml 
RPMI containing 10% FCS. The cell suspension was then split into either a 75cm3 Corning® 
flask or 125 cm3 Corning® flask dependent upon the number of cells required for the 
subsequent experiments. For the remainder of the cell lines which grow as adherent cells, the 
medium was aspirated and discarded. The cells were washed twice with sterile PBS. Diluted 
trypsin was added to the flask, the volume was dependent upon the size of the flask. Cells 
were placed in trypsin for five minutes. After which an equivalent volume of full media was 
added to the flask. The cell suspension was aspirated and collected in a 15 ml Falcon 
centrifuge tube. The cell suspension was centrifuged at 500g for five minutes. The supernatant 
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was aspirated and discarded. If the cells were required for further culture they were 
resuspended in 5 ml of full media and divided into either a 75 cm3 Corning® flask or 125 cm3 
Corning® flask.  
Cell lines were fixed with 4% paraformaldehyde prior to use in the laboratory experiments. 
The cell pellet post trypsinisation was resuspended in 1 ml of 4% paraformaldehyde and 
incubated for 20 minutes to fix the cells prior to their use for laboratory. After 20 minutes, 10 
ml of sterile PBS was added to the cell suspension and centrifuged at 500g for 5 minutes. The 
supernatant post centrifugation was discarded and the cell pellet resuspended in sterile PBS.  
2.2.1.2 Freezing cell lines and bone marrow cells from the rib 
Freezing media was prepared with the following constituents, 2.5 ml of sterile full media, 
2.5ml of 20% FCS and 0.5 ml of 10% dimethylsulfoxide (DMSO).  For cell lines in culture, the 
cell pellet post trypsination was resuspended in 2 ml of sterile freezing media. The cell 
suspension was transferred to a sterile cryovial and labelled with the details of the cell line, 
the passage and the date placed in storage. The cryovials were stored at - 800C.  
Bone marrow solution was passed through a 70 micron filter and transferred to a sterile 20 ml 
Falcon tube. The solution was centrifuged at 500 g for 10 minutes. The cell pellet post 
centrifugation was resuspended in 2 ml of sterile freezing media. The cell suspension was 
transferred to a 2 ml sterile cryovial and stored at - 800C. 
2.2.2 Culture of tumour cells from the exudates in patients with metastatic oesophagogastric 
cancer 
Ascitic and/or pleural fluid samples were passed through a 70 micron filter. Post filtration, 50 
ml of filtrate was transferred equally into two 50 ml Falcon tubes. The samples were 
centrifuged at 500g for 10 minutes. The supernatants were discarded. Twenty millilitres of the 
RPMI culture media listed in Table 2.2.2.1 were added to cell pellet in one of the 50 ml Falcon 
tubes. Twenty ml of the DMEM culture media listed in Table 2.2.2.1 was added to cell pellet in 
the other 50 ml Falcon tube.  




Patient Volume of 
Ascites post 
filtration (ml) 
Culture Medium * 
P10 50  RPMI + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)  
DMEM + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)   
JR 30 RPMI + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)  
SH1 50 RPMI + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)  
DMEM + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)  
BB1 50 RPMI + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)  
DMEM + 20% FCS + 1% Pencillin-Streptomycin (10 000 U/ml)  
*RPMI (Rosewell Park Memorial Institute) (Herpes modification)(Sigma Aldrich), DMEM (Dulbecco’s Modified Eagle 
medium)(Sigma Aldrich), FCS (foetal calf serum), Pencillin-Streptomycin (10 000 U/ml)(Gibco),  
 
The cell pellets were resuspended in the culture media and placed directly into two individual 
75 cm2 Corning® flasks containing 20 ml of the corresponding culture medium. Cells were 
incubated at 37oC in humidified environment with 5% CO2 (Hereaus Incubator). The culture 
media was changed at 24, 72 and 96 hours or until the cells reached 80% confluence. Cells 
were trypsinised as per the method described in Section 2.2.1.1. 
2.2.3 Culture of oesophageal adenocarcinoma cells isolated from blood  
Oesophageal adenocarcinoma cells were added to healthy volunteer blood to simulate the 
presence of circulating tumour cells in the blood. The following method describes the isolation 
of the oesophageal adenocarcinoma cells from blood directly into culture. The aim of the 
following experiment was to develop a protocol for isolating circulating tumour cells from the 
blood and disseminated tumour cells from the bone marrow directly into culture. 
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Two ml of blood obtained from a healthy volunteer. One hundred thousand SKGT-4 cells were 
added to the blood sample and placed in a 5 ml round bottomed polystyrene Falcon tube pre-
blocked with 3% BSA solution. One hundred microlitres of Easy SepTM Direct CTC enrichment 
cocktail (Catalog #19657) (50 µl/ml) was added to the blood sample and mixed gently. The 
suspension was incubated at room temperature for 5 minutes. The aliquot of Easy SepTM 
RapidSpheresTM was vortexed gently. One hundred microliters of Easy SepTM RapidSpheresTM 
was added to the cell suspension and mixed gently. The cell suspension with the Easy SepTM 
RapidSpheresTM was incubated at room temperature for 10 minutes. The cell suspension was 
adjusted to a total volume of 5 ml with the addition of 3 ml of 3% BSA solution and placed in 
the Easy SepTM magnet without a top at room temperature for 10 minutes. With the first 
polystyrene 5 ml Falcon tube still in the magnet, the magnet was inverted in one smooth clean 
movement over the second pre-blocked round bottomed polystyrene 5 ml Falcon tube for 2-3 
seconds to decant the cell suspension. An additional 100 µl of Easy SepTM RapidSpheresTM was 
added to the cell suspension and mixed gently. The cell suspension with the Easy SepTM 
RapidSpheresTM was incubated at room temperature for 10 minutes. The cell suspension in the 
second tube was adjusted to a total volume of 5 ml with the addition of 3 ml of 3% BSA 
solution and placed in the Easy SepTM magnet without a top at room temperature for 10 
minutes. With the second polystyrene 5 ml Falcon tube still in the magnet, the magnet was 
inverted in one smooth clean movement over the third pre-blocked round bottomed 
polystyrene 5 ml Falcon tube for 2-3 seconds to decant the cell suspension. 
The cell suspension post enrichment was resuspended in 20 ml of (RPMI and 20% FCS) and 
placed divided equally into two T75 cm3 Corning® flasks. Cells were incubated at 37oC in 
humidified environment with 5% CO2 (Hereaus incubator). The culture media was replaced at 




2.3 Method for collection, storage and processing of volunteer and patient blood samples in 
preparation for imaging on the high resolution imaging flow cytometer and/or Fluorescence 
activated cell sorting (FACS) 
2.3.1 Collection and storage of blood samples  
Volunteer blood samples were obtained from the staff and students at the Northern Institute 
of Cancer Research (NICR) in accordance with the Ethics. Informed consent was obtained and 
a consent form was completed.  
Patients were recruited into the study IRAS ID: 185350 in accordance with the NRES 
committee North East – Newcastle and North Tyneside 1 Ethics committee. Patients were 
recruited at two sites within the Newcastle Hospital NHS Trust: Royal Victoria Infirmary and 
Norther Centre for Cancer Care. Consent form (Appendix A) was completed. Blood samples 
were taken under aseptic conditions and collected in 6 ml tubes containing postassium 
ethylene-diaminetetraccetic acid (K2EDTA) (BD Biosciences). The tubes were labelled with the 
corresponding patient identifier number. Samples taken within the Newcastle Hospital NHS 
Trust were transported to the NICR in a bag marked with the UN 3373 label (certified for 
transport of diagnostic human specimens) at room temperature. Blood sample were 
processed within four hours of collection.  
2.3.2 Red cell lysis in blood 
Five ml of 1.5 g bovine serum albumin diluted in sterile PBS (3% BSA:PBS) was added to three 
50 ml Falcon tubes that were placed onto a bench-top roller at room temperature for 20 
minutes. After 20 minutes, the 3% BSA solution was removed from the Falcon tubes and 
stored in a 14 ml Falcon tube for use later in the protocol. Two millilitres of blood was added 
to each of the three 50 ml Falcon tubes. Stock 20% PhospholysefixTM buffer solution was 
prepared in accordance with the manufacturer protocol. Two hundred millilitres of the 
solution was prepared with the addition of 128 ml of distilled water to 32 ml of the 
concentrated PhospholysefixTM solution at room temperature. The stock solution could be 
stored for up to one month at room temperature. The stock PhospholysefixTM buffer solution 
was placed in a water bath at 37oC for 30 minutes prior to red cell lysis. Forty millilitres of the 
stock PhospholysefixTM buffer solution pre-warmed at 37oC was added to each of the 50 ml 
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Falcon tubes. Each tube was inverted ten times to ensure adequate mixing of the 
PhospholysefixTM buffer solution with the blood. The samples were placed in a water bath at 
37oC for 15 minutes. After 15 minutes, the samples were centrifuged at 500g for 10 minutes. 
The supernatant was poured off into a waste container in one smooth movement. Any excess 
lysis buffer was removed with a Pasteur pipette. One millilitre of 3% BSA was added to the cell 
pellet. Three 15 ml round-bottomed polystyrene Falcon tubes were pre-blocked with the 
addition of 2 ml of 3% BSA and placed on a bench-top roller for 20 minutes at room 
temperature. The 3% BSA solution was removed and discarded after this stage. One millilitre 
of 3% BSA was added to the cell pellet and the suspension was transferred into one 15 ml 
Falcon tube with a siliconised tip, 200 µl at a time. This process was repeated three times for 
each tube with 1 ml of 3% BSA to ensure the transfer of any residual cells into the one 15 ml 
Falcon tube. The cell pellet could be stored overnight at 4oC at this point.   
2.3.3 Depletion of white blood cells 
The cell suspension in the 15 ml round-bottomed polystyrene Falcon tubes was centrifuged at 
500 g for 8 minutes. The supernatant is discarded post centrifugation. The next stage was the 
addition of 500 µl of 3% BSA solution using a siliconised pipette without resuspending the cell 
pellet. Twenty-five microliters of EasySepTM depletion cocktail (50 µl/ml) was added to the cell 
pellet and mixed gently with a siliconised pipette. The cell suspension was incubated at room 
temperature for 15 minutes. The aliquot with the EasySepTM magnetic beads was agitated 
gently and 50 µl of EasySepTM magnetic beads solution (100 µl/ml) was added. The cell 
suspension was incubated for 10 minutes at room temperature. The cell suspension was re-
constituted to a total volume of 5 ml with the addition of 4.5 ml of 3% BSA solution. The cell 
suspension was mixed gently to prevent the magnetic beads from coalescing at the bottom of 
the tube. Five microliters was aspirated from the cell suspension and diluted 1 in 10 in PBS. 
The cells were counted with a haemocytometer.  
The round bottomed 15 ml polystyrene Falcon tube containing the cell suspension was placed 
into the EasySepTM magnet without its cap and incubated for 10 minutes. With the first 
polystyrene 15 ml Falcon tube still in the magnet, the magnet was inverted in one smooth 
clean movement over the second pre-blocked round bottomed polystyrene 15 ml Falcon tube 
for 2-3 seconds to decant the cell suspension. The second tube was placed in the EasySepTM 
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magnet and incubated at room temperature for 10 minutes. With the second polystyrene 15 
ml falcon tube still in the magnet, the magnet was inverted in one smooth clean movement 
over the third pre-blocked round bottomed polystyrene 15 ml Falcon tube for 2-3 seconds to 
decant the cell suspension. The following additional step was included to improve the 
recovery of CD 45 negative cells. Five millilitres of 3% BSA:PBS solution was added to the first 
polystyrene 15 ml Falcon tube and re-inserted into the EasySepTM magnet 10 minutes at room 
temperature.  With the first polystyrene 15 ml Falcon tube still in the magnet, the magnet was 
inverted in one smooth clean movement over the third Falcon tube containing the CD 45-
depleted cell suspension.  
2.3.4 Permeabilisation of cells  
Permeabilisation solution was constituted with the addition of 5 ml of BD Perm/washTM to 45 
ml of sterile water. The BD Perm/washTM solution was stored at 4oC. The solution was warmed 
to room temperature for 15 minutes prior to use.  
The CD 45 depleted cell suspension in the 15 ml Falcon tube was centrifuged at 500g for 5 
minutes. The supernatant was discarded. Two hundred microliters of the BD Perm/washTM 
solution was added to the cell pellet and the cells were transferred into a 1.5 ml Eppendorf 
tube with a clean siliconized pipette. This process was repeated four times to ensure that all 
the cells have been transferred from the 15 ml  Falcon tube into the Eppendorf. The cells were 
incubated at room temperature for 1 hour or overnight at 4oC.  
 
2.3.5 Antibody labelling 
The cell suspension with the BD Perm/washTM solution post permeablisation was centrifuged 
at 500g for 5 minutes. The supernatant was removed and discarded. Three hundred 
microliters of the BD Perm/washTM solution was added to the cell pellet in the Eppendorf and 
gently mixed with a siliconized pipette. The cell suspension was divided equally into three 1.5 
ml Eppendorf tubes each containing 100 µl. Each Eppendorf tube is labelled with the 
corresponding antibody bodies in the three panels listed in Table 2.3.5.1, 2.3.5.2 and 2.3.5.3.. 
 
Table 2.3.5.1: Antibodies and the corresponding fluorochromes in panel A 
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Antigen 1o antibody Fluorochrome Volume in 100 µl 
of cell suspension 
E-cadherin CD 324 Anti-human 
Biolegend #324110 
Alexa Fluor® 488 
conjugated 
1 µl 
Pan cytokeratin  
(clone C-11)  
Cayman Chemical 
#10478  
PE conjugated 3 µl 
N-cadherin CD325 Anti-human  
Biolegend #350816 
Alexa Fluor® 568 
conjugated 
1 µl 





PE-Cy5.5 conjugated 2 µl 
CD45  
(clone H130) 
Mouse   
BioLegend 
#304016 
PE-Cy7 conjugated 1 µl 
DAPI Bioloegend 
#422801  
1 µl of 10 µg/ml 
 
1 µl 
Vimentin (V9) Santa Cruz 
#sc-6260 
Alexa Fluor® 647 
conjugated 
0.5 µl  
 
Antigen 1o antibody Fluorochrome Volume in 100 µl 




Rabbit  #8741S  
Alexa Fluor® 488 
conjugated 
1 µl 
Pan cytokeratin  
(clone C-11)  
Cayman Chemical 
#10478  
PE conjugated 3 µl 
EpCAM CD326   
(clone 9C4) 
Mouse   
BioLegend 
#324214 
PE-Cy5.5 conjugated 2 µl 
Table 2.3.5.2: Antibodies and the corresponding fluorochromes in panel B 
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PE-Cy7 conjugated 1 µl 
DAPI Bioloegend 
#422801  
1 µl of 10 µg/ml 1 µl 








Antigen 1o antibody 2o antibody 
 
Fluorochrome Volume in 100 µl 









Alexa Fluor® 488 1 µl 
Pan cytokeratin 




 PE conjugated 3 µl 
ERCC1  
(clone 4F9) 
Mouse    
Dako #364829-
2 
– 1 ul 
Anti-mouse AF 
568 





















  1 µl 
TFF 3 2mg/ml  AF 647 1 µl 
 
All of the antibodies in panels A and B were conjugated and did not require the addition of a 
secondary, conjugated antibody for detection. Conjugated antibodies listed in Tables 2.3.5.1 
and 2.3.5.2 and 1 µl of DAPI at the following concentration 10 µg/ml were added to cells in the 
corresponding Eppendorf tubes. The antibodies were incubated for 30 minutes at room 
temperature in the dark. One millilitre of PBS was added to the cells in each Eppendorf tube 
and mixed gently. The cell suspension in each Eppendorf tube was centrifuged at 500 g for 5 
minutes and the supernatant was discarded. The cell pellet in each Eppendorf tube was 
resuspended in 100-150 µl of PBS and the sample was ready for analysis on the high resolution 
imaging flow cytometer or by FACS.  
Panel C contains two primary antibodies that were not conjugated. For Panel C, cells were 
incubated sequentially with these two primary antibodies and the with their secondary 
conjugated detection antibodies prior to the incubation of the other antibodies in the panel. 
The primary antibodies listed in Table 2.3.5.3 were added to the cell suspension at the 
required concentration to the Eppendorf labelled panel C and incubated at room temperature 
in the dark for 30 minutes. One millilitre of PBS was added to the Eppendorf and mixed gently. 
The cell suspension was centrifuged at 500 g for 5 minutes and the supernatant was discarded. 
The cell pellet was resuspended in 100 µl Perm/washTM solution. The secondary conjugated 
antibodies listed in table 2.3.5.3 were added to the cell suspension in the Eppendorf tube 
labelled panel C at the required concentration and incubated at room temperature in the dark 
for 30 minutes. One millilitre of PBS was added to the Eppendorf and mixed gently. The cell 
suspension was centrifuged at 500g for 5 minutes and the supernatant was discarded. The cell 
pellet was resuspended in 100 µl Perm/washTM solution. The conjugated antibodies listed in 
Table 2.3.5.3 and DAPI were added at the required concentration to the cells in the Eppendorf 
tube labelled panel C.  Conjugated antibodies and DAPI listed in tables 2.3.5.1 and 2.3.5.2 are 
added to the corresponding Eppendorf tubes.  
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Figure 2.3.5.4 illustrates a flowchart of the protocol described above and a brief description of 






Addition of 46 ml of BD Phospholyse fix buffer ™. Sample inverted eight times and placed in water bath at 37oC 
for 15 minutes. Sample centrifuged at 500g for 10 minutes  
Supernatant discarded post centrifuge. Cell pellet resuspended in 1 ml of 3% BSA:PBS. Transfer of cell pellet 
with 200 µl polythene pipette tip into a pre-blocked 14 ml Falcon tube with 3% BSA. Additional 1ml of 3% 
BSA:PBS added to 50 ml Falcon tube and cell suspension transferred into 14 ml Falcon tube.  
Cell suspension in 14ml falcon tube centrifuged at 500 g for 5 minutes. Supernatant discarded. Addition of 25 µl 
of EasySep™ Human CD45 Depletion Cocktail with a 200 µl polythene pipette tip to the cell pellet and incubation 
at room temperature for 5 minutes.  
Addition of 50 µl EasySep™ Dextran RapidSpheres™ to the cell suspension and incubation at room temperature 
for 5 minutes.  
Addition of 4.5ml 3% BSA:PBS to the cell suspension.   
Cell suspension placed into EasySep™ magnet for 10 minutes. The 14 ml Falcon tube with the cell suspension 
in the EasySep™ magnet are held together and the cell suspension in transferred into a 14 ml Falcon tube pre-
blocked with 3% BSA:PBS. The cell suspension in the 14 ml Falcon tube post immunomagnetic separation is 
placed into the EasySep™ magnet for 10 minutes. The process is repeated. The cell suspension post 
immunomagnetic separation is transferred into a 14 ml Falcon tube pre-blocked with 3% BSA:PBS 
EasySep™ Human CD45 Depletion Cocktail contains antibody complexes which bind to CD45 positive 
cells within the suspension. A secondary part of the antibody complex is a site specific to the magnetic 
particles present in the EasySep™ Dextran RapidSpheres™ 
EasySep™ Dextran RapidSpheres™ are magnetic particles that bind the antibody complexes present in the 
EasySep™ Human CD45 Depletion Cocktail which are by now bound to the CD-45 positive cells in the suspension.  
EasySep™ Dextran RapidSpheres™ magnetic particles which are indirectly bound to CD45 positive 
cells are separated from the cell suspension during this stage and become adherent to the sides of the 
Falcon tube.  
Four millilitres of blood added to pre-blocked 50 ml Falcon tube with 3% BSA:PBS 
BD Phospholyse fix buffer ™ is an aqueous buffered solution that contains 
formaldehyde and proprietary ingredients.  The solution lyses red cells and fixes 
the remainder of the cells in whole blood 
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2.4 Method for collection, storage and processing of bone marrow from discarded rib section 
in preparation for analysis by high resolution imaging flow cytometer 
2.4.1 Collection and storage of bone marrow from the rib section 
Patients were recruited into the study IRAS ID: 185350 in accordance with the NRES 
committee North East–Newcastle and North Tyneside 1 Ethics committee. Patients were 
recruited at the Royal Victoria Infirmary and consent form (Appendix B) was completed prior 
to surgery. The rib section was excised as part of a routine open thoracotomy during a two 
stage oesophagectomy. The excised rib section was collected in a sterile universal container 
and transferred to the NICR in a bag marked with the UN 3373 label (certified for transport of 
diagnostic human specimens) at room temperature. Samples were processed within four 
hours of collection. The rib section was broken in half with a bone cutter. The marrow was 
The cell suspension in the 14 ml Falcon tube post-immunomagnetic separation is centrifuged at 500 g for 
five minutes. The supernatant is discarded post centrifugation. The cell pellet is resuspended in 1 ml 3% 
BSA:PBS and transferred into a 1.5ml Eppendorf tube with a 200 µl polythene pipette tip.  
Addition of antibodies raised against intracellular proteins conjugated to fluorophores at required 
concentration. Eppendorf tube covered in foil and placed on rollers for 30 minutes. 
Addition of antibodies specific to cell membrane  proteins conjugated to fluorophores and the nuclear dye 
at required concentrations. Incubation of the antibodies for 30 minutes with the Eppendorf tube covered 
Post incubation, 1 ml PBS added to cell suspension and sample centrifuged at 500 g for 5 minutes. 
Supernatant aspirated and discarded. Cell pellet resuspended in 100 µl PBS. Sample is ready to be 
analysed by imaging flow cytometry or can be kept covered in foil overnight at 4oC 
Cell suspension in Eppendorf tube centrifuged at 500 g for 5 minutes. Supernatant discarded. Addition of 
100 µl 10% Permwash™ buffer. Sample incubated at room temperature for 30 minutes or overnight at 
4oC. Addition of 1 ml PBS and sample centrifuged at 500 g for 5 minutes. Supernatant aspirated and 
discarded. Cell suspension resuspended in 100 µl 10% Permwash™ buffer.  
Permwash™ contain feotal bovine serum and saponin. The solution acts to maintain the cells’ structure, 
permeabilise the plasma membrane to allow antibodies to enter the cell for detection of intracellular 
       
Figure 2.3.5.4: Protocol for collection, storage and processing of volunteer and patient blood 
samples in preparation for high resolution imaging flow cytometry 
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recovered from the rib with toothed forceps and placed in 10 ml of sterile PBS. The solution 
was passed through a 70 micron filter into a pre-blocked 50 ml Falcon tube. Forty millilitres of 
the PhospholysefixTM buffer solution pre-warmed at 37oC was added. The tube was inverted 
ten times to ensure adequate mixing of the PhospholysefixTM buffer solution with the bone 
marrow. The samples were placed in a water bath at 37oC for 15 minutes. After 15 minutes, 
the samples were centrifuged at 500 g for 10 minutes. The supernatant was poured off into a 
waste container in one smooth movement. Any excess lysis buffer was removed with a 
Pasteur pipette. One millilitre of 3% BSA is added to the cell pellet. 
For the first ten patients, twenty ml of the bone marrow suspension post filtration was 
obtained and divided into two 50 ml Falcon tubes. Cells from Ten ml of the bone marrow 
suspension were processed for CD 45 depletion and incubated with antibodies prior to 
analysis on high resolution imaging flow cytometer. The cell pellet from the second 10 ml of 
the bone marrow solution post red cell lysis was stored at -80oC described in section 2.2.1.2.  
2.4.2 CD 45 depletion and antibody labelling of cells in the rib bone marrow  
The cells suspension isolated from the bone marrow solution processed for CD 45 depletion as 
described in section 2.3.3. The method for permeabilisation and incubation with antibodies 
was described in Sections 2.3.4 and 2.3.5. Post CD 45 depletion, the cell suspension in the 
bone marrow was labelled with the antibodies in the three panels listed in Tables 2.3.5.1, 
2.3.5.2 and 2.3.5.3. 
2.5 Analysing cells on the high resolution imaging flow cytometer 
2.5.1 Developing the compensation matrix 
The ImagestreamTM imaging flow cytometer available in the NICR contains two high resolution 
cameras and four excitation lasers with wavelengths of 405 nm, 488 nm, 561 nm and 642 nm. 
There are 12 channels for detection of individual cells, two of which are the bright field 
channels that capture high resolution images of individual objects. The bright field images 
were captured routinely with a 40x objective. The remaining 10 channels are set at defined 
wavelengths and are available to detect fluorescence from fluorochromes conjugated to 
invidual antibodies following excitation by the lasers. The lasers were set at their maximum 
intensity. Each fluorochrome is assigned for detection in a specific channel based upon its 
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individual excitation and emission spectra. Figure 2.5.1.1 illustrates the excitation and the 
emission spectra of fluorochromes recommended by the suppliers of the ImagestreamTM 
imaging flow cytometer (140).   
 
 
Figure 2.5.1.1: Excitation and emission spectra of fluorochromes on the ImagestreamTM 
machine (129) 
Figure taken from https://ysm-websites4-live-
prod.azureedge.net/immuno/flowcore/instrumentation/TACamnis_311819_39211_v2.jpg 
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UltraComp eBeads™ contain two population of spherical particles, one population can be 
coated with antibodies conjugated to individual fluorophores and the second population that 
will not bind to antibodies. Both populations were present when the UltraComp eBeads™ are 
used as single colour compensation controls. Twenty microliters of the beads were incubated 
with each conjugated antibody at the concentrations listed in Tables 2.3.5.1, 2.3.5.2 and 
2.3.5.3. The brightfield channel was turned off and the laser settings were set at the maximum 
intensity. The machine was calibrated to calculate spectral overlap for each fluorochrome 
analysed. A compensation matrix (cif) which calculates the spectral overlap between the 
flurochromes was created for each panel of antibodies listed in 2.3.5.1, 2.3.5.2 and 2.3.5.3. 
The single colour controls and the compensation matrix (cif) was recalibrated each time when 
a new aliquot of antibody was purchased.  
2.5.2 Gating template 
The ability of the machine to capture high resolution images of individual cells means that 
large image files are generated which leads to an increase in the time taken to process an 
individual clinical sample. Consequently, further downstream processing and analysis of the 
image files was difficult. Inclusion of a gating strategy ensures that only cells of interest are 
captured which reduces the file sizes generate and allows more of clinical sample to be 
collected for analysis in each file.   
Oesophageal cancer cell lines described in Table 2.2.1 were labelled with epithelial biomarkers 
(EpCAM and cytokeratins) and the therapeutic predictive biomarkers (HER2) and mixed with 
white blood cells from healthy human volunteer blood. Cells were labelled with antibodies as 
listed in Tables 2.3.5.1, 2.3.5.2 and 2.3.5.3. The cell lines and white blood cells were analysed 
by the high resolution imaging flow cytometry. The morphological characteristics of the 
oesophageal cancer cells and white blood cells, eg size, nuclear density, intensity of CD45 
biomarker immunoreaction and a threshold value for each criteria was determined based on 
the data. The smallest oesophageal cancer cell line was OE19, individual OE19 cells were 10 
µm in diameter. The smallest white blood cell was 8 µm in diameter. Based on previous 
studies, the smallest CTCs detected previously were 10 µm in diameter. The following gating 
template was applied to identify CTCs in the blood: diameter ≥ 10 µm and presence of a 
nucleus based on the intensity of DAPI. The same gating template was adapted for imaging 
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DTCs in the bone marrow. Bone marrow contained a large amount of white blood cells thus 
the gating template was as follows: diameter ≥ 10 µm, presence of a nucleus based on the 
intensity of DAPI and CD45 negative cells.  
2.5.3 Analysis of image files 
Each sample processed on the high resolution imaging flow cytometer was stored as a raw 
image file (rif). The IDEAS software combines the raw image file (rif) with the corresponding 
compensation matrix (cif), eg images of CTCs labelled with antibodies listed in panel A 
captured as raw image files were combined with the compensation matrix for the antibodies 
conjugated with the fluorophores in panel A. The software generated a data analysis file (daf). 
IDEAS software allowed further analysis of the data. Statistical analysis of the cell counts and 
data generated as described in Chapter 5 and 6 was with Prism Graph pad (version 8).  
2.6 Fluorescence activated single cell sorting (FACS) 
Cells were analysed by Fluorescence activated single cell sorting (FACS) with a BD FACSAria™ 
Fusion. This is a high speed flow cytometer that allows single cells to be isolated. Details of the 
machine are described in Chapter 4.  
2.6.1 Sample analysis by high resolution imaging cytometry and confocal microscopy post 
Fluorescence activated single cell sorting (FACS) 
Oesophageal cancer cell lines listed in section 2.2.1, OE19 and SK-GT-4 fixed in 4% 
paraformaldehyde and added to blood obtained from healthy human volunteer under the 
NICR ethics. Details of the experiments are described in Chapter 4. Red blood cells were lysed 
with PhospholysefixTM buffer as described in Section 2.3.2. The cells were centrifuged and the 
cell pellet was resuspended in 1 ml PBS and transferred to a 6 ml FACS tube with a siliconized 
pipette. The cell suspension was incubated with the antibodies described in Chapter 4, Section 
4.2 for 30 minutes. Two millilitres of PBS was added to the cell suspension in preparation for 
the FACS single sorting. The sample was covered in foil and transferred to the flow cytometry 
centre for sorting.  
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2.6.1 Culture of cells sorted by FACS  
Oesophageal cancer cell lines were cultured as described in Section 2.2.3. Following 
trypsinisation, the cell suspension was counted with a haemocytometer. Blood obtained from 
healthy human volunteer under the NICR ethics and collected in an EDTA tube was transferred 
under aseptic conditions into a 15 ml Falcon tube. The required number of cells for the 
experiment was added directly under sterile conditions into the Falcon tube with the blood 
sample. BD Pharm Lyse™ stock solution was diluted with sterile water at a ratio of 1:10 to 
create a BD Pharm Lyse™ buffer. The BD Pharm Lyse™ solution lysed red blood cells without 
fixing the cells. BD Pharm Lyse™ buffer solution was warmed to room temperature was added 
to the blood at the following ratio: 10 ml of BD Pharm Lyse™ buffer solution per 1 ml of blood. 
The cells were vortexed gently for 30 seconds and incubated in the dark at room temperature 
for 15 minutes and centrifuged at 300 g for five minutes. The supernatant was aspirated and 
discarded. The cell pellet post red blood cell lysis was resuspended in 100 µl of sterile PBS and 
incubated with the antibodies listed in Section 4.4, (EpCAM, HER2, CD45) for 30 minutes in the 
dark. One millilitre of sterile PBS was added to the 15 ml Falcon tube and the cell suspension 
was transferred under sterile conditions into a 6 ml FACS tube with a siliconized pipette tip. 
The process was repeated with an additional two ml of sterile PBS. The sample was covered in 
foil and transferred to the flow cytometry centre for sorting.  
2.6.2 Creation of a gating template 
The staff at the single cell laboratory assisted in the processing of samples on the BD 
FACSAria™ Fusion cell sorter. UltraComp eBeads™ were used to create single cell controls for 
each fluropohore. The single colour controls were used to optimise the voltage settings of the 
lasers used in the FACS machine. Oesophageal cancer cell lines and white blood cells provided 
guides to create the gating template which would identify the single cells with a nucleus. The 
template ensured that only cells of interest would be captured.  
2.6.3 Sorting single cells for culture by FACS 
The compensation matrix was created based on the relevant fluorophores and the gating 
template was created. The sample was loaded into the machine. The nozzle size for the sorter 
was set at 100 µm. An initial 100 µl of the sample was processed in the machine. The gating 
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template as described in Section 2.6.2 was used to identify the populations of cells of interest 
which are then selected for collection. The cells were sorted into individual six well plates 
containing 2 ml of RPMI with 20% FCS.  
2.6.4 Sorting single cells for imaging on the high resolution imaging flow cytometer by FACS  
As described in Section 2.6.3, the compensation matrix and gating template were created for 
each experiment. Cells of interest were isolated and sorted into 1.5 ml Eppendorf tube. The 
Eppendorf tubes were covered in foil and were ready for processing on the high resolution 
imaging flow cytometer.  
2.6.5 Sorting single cells for imaging on the confocal microscope with the FACS machine 
As described in Section 2.6.3, a compensation matrix and gating template were created for 
each experiment. Cells of interest were isolated and sorted and placed directly onto a 
microscope slide. After the sorting process, the cells were secured with a cover slide. The cells 
were imaged by confocal microscopy.  
2.7 Imaging cells on the confocal microscope 
Images of cells post single cell sorting were captured with a Leica TCS SP2 UV AOBS point 
scanning confocal microscope.  Confocal analyses were with assistance of the support staff 
Bioimaging unit, Faculty of Medical Sciences, Newcastle University.  
2.7.1 Setting up the confocal microscope 
Standard operating protocol for the Leica TCS SP2 UV AOBS confocal microscope was followed 
in preparation for imaging a sample.  
2.7.2 Capturing images on the confocal microscope 
The microscope slide was placed onto the microscope. A wide angle image of the slide was 
taken. The imaging software divides the image into 16 equal quadrants. Cells were identified 
based upon their nuclear stain and are marked in each quadrant. The lasers and filters are 
were calibrated for each individual fluorophore and an image of the cells at 40 x objective was 
taken. The image files were analysed on the Leica software. The software allows the merging 
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of multiple images and automatically performs a count on the total number of cells present on 
each slide.  
2.8 ParsortixTM 
The ParsortixTM (Angle) separates CTCs from the blood based on their difference in size and 
compressibility compared to white blood cells. Details of the process are described in section 
3.3.1. 
2.8.1 Collection of samples 
Blood samples were collected in a 10 ml CellSaveTM tube as per the manufactures instructions. 
2.8.2 Processing sample 
The machine consists of a disposable cassette which filters the blood and captures the CTCs 
within the cassette. Figure 2.7.2.1 illustrates key components of the machine (141). 
 
Figure 2.8.2.1: ParsortixTM PR1 Cell separation system  
Components of the ParsortixTM cell separation system which consists of the blood sample tube 
mount, separation cassette holder, harvest line and waste collection tube and the buffer solution 
for cleaning and priming the machine.  
Figure taken from (130)  
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A sample cassette was placed in the clamp and was flushed with PBS which was used as the 
buffer, this process takes approximately 60-90 minutes. The ParsortixTM  has individual 
programmes for each step. The machine automatically determines the length of each 
programme. A new cassette was placed into the holder as shown in Figure 2.7.2.1. The first 
programme PX2_P was selected. This programme primes the new cassette with the buffer. 
The second programme was PX2_S99F. A 10 ml CellSaveTM tube or 10 ml EDTA tube containing 
the blood sample at room temperature was loaded into the machine following the prompt. 
The blood was drawn into the machine and circulated into the cassette. This process took 
between 2-3 hours dependent upon the volume of blood processed. The waste was discarded 
into a separate bottle. Following completion of the second programme, the cells captured in 
the cassette can either be labelled within the cassette or be harvested into a separate 
container. Programme PX2_H was selected to harvest the cells. A 1.5 ml Eppendorf tube was 
placed under the harvest line and secured. The manual harvest valve was turned into the anti-
clockwise position and cassette was flushed with 200 µl of PBS. The cell suspension is collected 
in the Eppendorf tube. The line was flushed with a further 1 ml of PBS to maximise cell 
recovery. The cells suspension was ready for downstream analysis. The machine was covered 
in foil and protected from light when cells conjugated with fluorescence antibodies were 
separated.  
The machine was cleaned using the programme PTXC_2 in preparation for the next sample or 
user. 
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Chapter 3: Development and optimization of the protocol for isolating 
disseminated tumour cells from the blood and bone marrow 
3.1 Introduction 
The chapter focuses on the development and optimisation of the protocols for the isolation of 
circulating tumour cells from the blood and disseminated tumour cells from the bone marrow.  
A protocol for the isolation of circulating tumour cells from peripheral blood with red cell lysis 
and immunomagnetic separation had been previously published(131). The enrichment and 
recovery using this method was reported at 50%. When the protocol was trialled with 
oesophageal cancer cell lines added to blood samples obtained from healthy volunteers, the 
enrichment and recovery of the oesophageal cancer cells was poor. The recovery was 
approximately 10-15%. In addition, the time for processing individual blood samples was over 
three hours. The focus on the initial experiments was to identify areas within this protocol 
which could be optimised to improve the enrichment and recovery of circulating tumour cells 
in the blood. The main areas of interest were the following: Collection and storage of the blood 
samples, red cell lysis using the BD PhosflowTM Lyse/Fix buffer and reducing the time period 
for processing the blood sample 
Bone marrow consists of cellular and non cellular components and present in the spongy part 
of the bone beneath the cortex. The main sites of bone marrow are the ribs, vertebrae, 
sternum and bones of the pelvis. It consists of stromal tissues, adipose tissue and 
haematopoietic progenitor cells. The haematopoietic progenitor cells develop into three main 
types of cells: white blood cells, red blood cells and platelets. Previous studies have 
demonstrated the successful isolation of disseminated tumour cells in the bone marrow from 
the rib in patients with oesophageal cancer using Ficoll-Hypaque density centrifugation ((112). 
This method relies upon the difference in size between the disseminated tumour cells and the 
other mononuclear cell within the bone marrow. The reported rates of detection using this 
method varied from 18-88%. The aim was to compare different methods and develop a 
protocol to enrich and isolate disseminated tumour cells from the bone marrow.  
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Another focus on this chapter is the evaluation of other methods used to isolate circulating 
tumour cells from the blood. Two methods were compared. ParsortixTM separates CTCs directly 
from blood based on their increased size in comparison to other monoculear cells within the 
blood. Easy SepTM Direct human CTC enrichment which uses immunomagnetic beads to isolate 
CTCs from blood directly without the addition of fixative agents and with the potential to 
isolate CTCs directly into culture.  
3.2 Validation and optimisation of the protocol for enumerating circulating tumour cells in 
peripheral blood 
3.2.1 Optimisation of the red cell lysis in the protocol for enumerating circulating tumour 
cells in peripheral blood 
Several experiments were designed to improve the CTC recovery rate and minimize the time 
for processing. Initial experiment was to evaluate the maximum volume of blood that could 
be processed per fixed volume of the BD PhosflowTM Lyse/Fix buffer. Four different ratios of 
blood :  BD BD PhosflowTM Lyse/Fix buffer (1:5, 1:10, 1:20, 1:30) were tested for a fixed volume 
of 1 ml of blood per sample. Cells were counted following the red cell lysis and centrifugation 


















The optimal ratio of blood : BD phosphor/lyse fix buffer was 1:20. A lower ratio led to a 
significant loss of the cellular component of the blood. Although a higher ratio led to an increase 
in the number of white blood cells recovered, the large volume of buffer required was not 
justifiable.  
Figure 3.2.1.1: Mononuclear cell recovery with different ratios of blood : BD PhosflowTM Lyse/Fix 
buffer 
Four pre-blocked (3% BSA) 50 ml Falcon tubes each with 1 ml of healthy volunteer blood were 
prepared. Diluted BD Phosflow Lys/Fix buffer pre-warmed at 37oC was added to the blood at the 
following ratios to each individual tube, 1:5, 1:10, 1:20 and 1: 30. Each sample was incubated at 370C 
for 15 minutes. Then centrifuged at 500 g for 10 minutes. The supernatant was discarded and the 
cells in the pellet were counted with a haemacytometer. The experiment was repeated with another 
healthy volunteer sample. The approximated number of cells in the blood sample prior to red cell 
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3.2.2 Comparing the collection and storage of peripheral blood sample with BD Vacutainer 
tube (EDTA) and CellSaveTM 
 
The collection and storage of the peripheral blood was previously carried out using the 
CellSaveTM tube which contains 300 µL of Na2EDTA for clotting prevention and a cell surface 
preservative to maintain the morphology and cell surface antigen expression for phenotyping 
(ref manufacturer). The manufacturer specification stated that cells can be preserved in the 
CellSaveTM tube for up to 96 hours at room temperature. BD VacutainerTM tube contains EDTA 
and preserve cells up to 4 hours at room temperature. Initial experiments evaluating recovery 
of oesophageal cancer cell lines added to volunteer blood samples with the CellSaveTM tube was 
poor, less than 15% of the mononuclear cells were recovered post red cell lysis. In addition, 
majority of the cells recovered were not healthy.  
An experiment was designed to evaluate the recovery of the mononuclear cellular component 
from peripheral blood using the two different methods of collection and storage. Twelve ml of 
blood was obtained from a healthy volunteer, 4 ml was collected in a BD vacutainer EDTA tube 
and the other 8 ml of blood was collected and divided equally into four CellSaveTM tubes. The 
samples were stored at room temperature. At two and four hours post collection, the blood 
sample in the BD vacutainer tube underwent red cell lysis with the BD PhosflowTM Lyse/Fix 
buffer. Post red cell lysis, a haemocytometer was used to perform a cell count and evaluate the 
enrichment of the mononuclear samples from the sample. Blood samples in the CellSaveTM 
tubes underwent red cell lysis with the PhosflowTM Lyse/Fix buffer at the following intervals: 2, 
12, 24 and 48 hours. Figure 3.2.2.1 illustrates the difference in the enrichment of the 
mononuclear component of the blood between the BD Vacutainer EDTA tube and CellSaveTM 
tubes.  
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 There was a significant drop in the number of viable mononuclear cells present in the sample 
collected and stored in the CellSaveTM tube after 12 hours. As indicated in the Figure 3.2.2.1, at 
24 hours following red cell lysis only a small fraction of the mononuclear cells were recovered 
and majority of the sample contained cellular debris. In addition, the enrichment of the 
mononuclear cellular component was superior with the blood samples collected and stored in 
the BD vacutainer EDTA tube at two hours when compared to the CellSaveTM tube. Figure 3.2.2.2 
illustrates the difference in the cell viability post red lysis between the two methods of storage.  
Figure 3.2.2.1: Comparison of the mononuclear cell recovery with two different methods of 
peripheral blood collection and storage 
Two ml of blood collected and stored in BD Vacutainer EDTA tube for two hours was added to a pre-
blocked (3% BSA) 50 ml Falcon tubes. Diluted BD Phosflow Lys/Fix buffer pre-warmed at 37oC was 
added to the blood at the following ratio 1:20. The sample was incubated at 370C for 15 minutes. Then 
centrifuged at 500 g for 10 minutes. The supernatant was discarded and the cells in the pellet were 
counted with a haemocytometer.  
 The experiment was repeated with blood stored in the CellSaveTM tubes at the following time intervals 
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Figure 3.2.2.2: Comparison of the mononuclear cell recovery with two different methods of 
peripheral blood collection and storage on the high resolution imaging flow cytometer 
Two milliliters of blood collected and stored in BD Vacutainer EDTA tube for two hours was added 
to a pre-blocked (3% BSA) 50 ml Falcon tubes. Diluted BD Phosflow Lys/Fix buffer pre-warmed at 
37oC was added to the blood at the following ratio 1:20. The sample was incubated at 370C for 15 
minutes. Then centrifuged at 500 g for 10 minutes. The cell pellet was incubated with the following 
anti-bodies in 100 µl PermwashTM for 30 minutes: PE/Cy7 conjugated anti-human (CD 45) antibody 
(Cat# 324414) at 1 in 100 dilution and DAPI (10 µg/ml) at 1 in 100 dilution. The cells were visualised 
on the high resolution imaging flow cytometer and analysis was performed on the IDEAS software.  
The process was repeated with 2 ml of blood collected and stored in CellSaveTM tube 
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Cells stored in the CellSaveTM tube had evidence of degradation and there was a higher amount 
of cellular debris as illustrated in Figure 3.2.2.2. This raises concerns regarding the viability of 
CTCs collected and stored in CellSaveTM tube when compared to the BD vacutainer EDTA tube.   
3.2.3 Excluding the FcR blocking reagent from the protocol for enumerating circulating 
tumour cells in peripheral blood 
The first step of the protocol involved incubating the blood with the FcR blocking reagent 
human (Cat no 135-059-901 Miltenyl Biotec) for twenty minutes at 4oC prior to red cell lysis. 
The primary function of the FcR blocking reagent human (Cat no 135-059-901 Miltenyl Biotec) 
is to prevent non specific binding of anti-bodies to cells expressing the human Fc receptor, eg 
plasma B cells, monocytes and macrophages. It also increases the specificity of antibody 
labelling of rare target cells within the blood, eg circulating tumour cell, haematopoietic 
progenitor cells. The efficacy and function of the reagent was evaluated with the following 
experiment. Ten thousand OE19 cells cultured in RPMI were added to 1 ml of peripheral blood 
from a healthy volunteer. The volume of the FcR blocking reagent human (Cat no 135-059-901 
Miltenyl Biotec) required for the experiment was determined as per the manufacturer’s 
datasheet. The sample was then incubated at 4oC for 20 minutes with 80 µl FcR blocking 
reagent human (Cat no 135-059-901 Miltenyl Biotec). The sample underwent red cell lysis. The 
cell pellet obtained post red cell lysis was incubated with the following antibodies for 30 
minutes at room temperature: Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) 
antibody (Cat # 324210) at 1 in 100 dilution, PE/Cy7 conjugated anti-human (HER-2) antibody 
(Cat# 324414) at 1 in 100 dilution, Alexa Fluor 647 anti-human CD45 antibody (Cat # 30406) at 
1 in 100 dilution and DAPI (10ug/ml) at 1 in 100 dilution. The sample was then analysed on the 
high resolution imaging flow cytometer. The experiment was repeated without the addition of 
the FcR blocking reagent human (Cat no 135-059-901 Miltenyl Biotec). Figure 3.2.3.1 illustrates 
the comparison between the two samples. The addition of the FcR reagent had no impact on 
the antibody binding. There was no evidence of non-specific binding of the anti-bodies in both 

















Figure 3.2.3.1: Comparison of the efficacy of the FcR block reagent  
Ten thousand OE19 cells cultured in RPMI were trypsinised and added to 1 ml of blood. FcR blocking reagent 
human (Cat no 135-059-901 Miltenyl Biotec) 80 µl was added to the sample as per the standard protcol and 
incubated at 40C for 20 min. Red blood cells were lysed with BD phosphlo/lyse fix buffer. The cell suspension 
was incubated with the following antibodies for 30 minutes: Alexa Fluor 488 conjugated anti-human CD326 
(EpCAM) antibody (Cat # 324210) at 1 in 100 dilution, PE/Cy7 conjugated anti-human (HER-2) antibody (Cat# 
324414) at 1 in 100 dilution, Alexa Fluor 647 anti-human CD45 antibody (Cat # 30406) at 1 in 100 dilution and 
DAPI (10 µg/ml) at 1 in 100 dilution. This was labelled Sample A.  
The experiment was repeated without FcR blocking reagent human (Cat no 135-059-901 Miltenyl Biotec) and 
labelled Sample B. The cells were visualised on the high resolution image flow cytometer. Comparison of the 
data was performed with IDEAS software 
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The addition of the FcR blocking reagent human (Cat no 135-059-901 Miltenyl Biotec) 
increased the time taken for the protocol and the potential for a decrease in the recovery of 
the CTCs for no observable benefit as illustrated in the results. As a consequence, the FcR 
blocking reagent human (Cat no 135-059-901 Miltenyl Biotec) was excluded from the protocol.  
3.3 Validation and optimisation of the protocol for enumerating disseminated tumour cells 
from the bone marrow 
3.3.1 Identifying cells within control bone marrow samples 
Prior to the density centrifugation, filtration of the bone marrow is required to exclude the 
stromal components. The size of the filter used in the studies for this purpose varied from 70 
to 100 microns. The initial experiment focused on developing a protocol for enumerating 
disseminated tumour cells from the bone marrow and characterising the cellular population 
present in the bone marrow using the high resolution imaging flow cytometer. 
Bone marrow from the femur was obtained from a patient undergoing an orthopaedic 
procedure. The marrow was excised from the section of bone and placed in 20 ml of sterile 
PBS. Two millilters of the solution was placed through a 70 micron filter and the filtrate was 
centrifuged at 500g for five minutes. The cell pellet post centrifugation was fixed in 4% 
paraformaldehyde for 10 minutes. The sample was centrifuged at 500g for 5 minutes. The 
supernatant was aspirated and discarded. The cell pellet was resuspended in 100 µl of PBS and 
incubated with the following primary and secondary antibodies listed in Section 2.3.5. The 
sample was analysed on the high resolution imaging flow cytometer as illustrated in Figure 
3.3.1.1 
Figure 3.2.3.2: Images of OE 19 cells and CD45 positive cells from the high resolution imaging flow 
cytometer with and without the addition of the FcR blocking reagent human (Cat no 135-059-901 
Miltenyl Biotec) 
OE 19 cells express the epithelial markers: EpCAM, cytokeratin and human epidermal growth factor 
receptor (HER 2). In both samples there is clear differentiation between the white blood cells expressing 
the CD45 biomarker and the OE19 cells expressing the epithelial markers. There is no difference in the non 
specific antibody binding between the samples.  
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Figure 3.3.1.1: Images of cells present in the bone marrow of a healthy patient with the high resolution 
imaging flow cytometer 
There were two distinct populations of cells identified based on the expression of the CD 45 biomarker. 
Population A consisted of cells that did not express any of the epithelial, mesenchymal and CD 45 
biomarkers. These are likely the haematopoietic progenitor cells. Population B consisted of the white blood 
cells which expressed the CD 45 biomarker. There were no cells identified in the bone marrow which 
expressed either an epithelial and/or mesenchymal biomarker.   
 
Figure 3.3.1.2: Two population of cells within 
the control bone marrow sample 
Population A consists of white blood cells and 
accounts for approximately 50% of the cellular 
population.  
Population B consists of cells which did not 
express any of the epithelial, mesenchymal and 
CD 45 biomarkers. They account for the 
remainder of the population of cells within the 
bone marrow.  
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3.3.2 Development of a protocol for isolating disseminated tumour cells from the bone 
marrow 
The next experiment focused on the isolation of the mononuclear component from the bone 
marrow. The remainder of the bone marrow solution approximately 18 ml post filtration was 
separated into four 20 ml Falcon tubes.  
Two methods of enrichment were compared, density centrifugation using the LymphoprepTM 
density gradient medium and red cell lysis with BD PhosflowTM Lyse/Fix buffer. LymphoprepTM 
density gradient medium separates the components of the bone marrow into three distinct 
layer by centrifugation. The mononuclear component of the bone marrow is isolated from the 
plasma and red blood cells with a pipette. Four ml of the bone marrow was added to four ml of 
PBS containing 2% fetal bovine serum (FBS) into a 14 ml Falcon tube. Four ml of the 
LymphoprepTM was carefully layered on top of the solution. The sample was centrifuged at 800g 
for 20 minutes at room temperature (15oC-25oC). The components of the bone marrow had 
separated into three layers: plasma, mononuclear cells and red cells. The mononuclear 
component was aspirated and placed in 5 ml of sterile PBS. A cell count was obtained using a 
haemacytometer. BD PhosflowTM Lyse/Fix buffer was used to lyse red cells and isolate the 
mononuclear component in four ml of the bone marrow solution using the standard protocol. 
Cell count post red cell lysis was obtained using a haemacytometer. Table 3.2.1 illustrates the 
efficacy of enrichment of the two methods. 
 LymphoprepTM density 
gradient 
BD PhosflowTM Lyse/Fix 
Sample A 1.8 x 105 2.5 x 106 
Sample B 1.7 x 105 2 x 106 
Enrichment of the mononuclear component of the bone marrow was higher with the BD 
PhosflowTM Lyse/Fix compared to the LymphoprepTM density gradient. The next experiment 
focused on comparing the efficacy of enrichment and recovery of oesophageal cancer cell lines 
added to the bone marrow between the two methods. Twenty ml of bone marrow solution from 
Table 3.3.2.1 Comparison of enrichment of monocnuclear cells from the bone marrow using the 
LymphoprepTM density gradient medium and BD PhosflowTM Lyse/Fix 
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No of SK-GT-4 cells recovered from 100 000 cells added 
 
No of SK-GT-4 cells recovered from 10 000 cells added 
 4050 46000 
20500 1518 
the femur of a patient undergoing an elective hip replacement was obtained. The sample was 
divided into four 20 ml falcon tubes containing 5 ml of bone marrow solution. SK-GT-4 cells 
cultured In RPMI were added at the following concentrations, 100 000 and 10000 cells in to the 
bone marrow prior to filtration. Figure 3.3.2.2 illustrates the difference in enrichment and 
recovery of SK-GT-4 cells added to the bone marrow between the two methods. 
The recovery of the SK-GT-4 cells with the LymphoprepTM density centrifugation medium was 
lower when compared to the BD PhosflowTM Lyse/Fix buffer, 15% and 20.5% compared to 46% 
Figure 3.3.2.2 Comparison of enrichment and recovery of SK-GT-4 cells from the bone marrow using the 
LymphoprepTM density gradient medium and BD PhosflowTM Lyse/Fix 
One hundred thousand SK-GT-4 cells cultured in RPMI medium and fixed in 4% paraformaldehyde was added 
to five ml of bone marrow. The bone marrow was placed through a 70 micron filter. The filtrate was added 
to five ml of PBS containing 2% fetal bovine serum into a 20 ml Falcon tube. Five millitres of the 
LymphoprepTM was carefully layered on top of the solution. The sample was centrifuged at 800g for 20 
minutes at room temperature (15oC-25oC). The components of the bone marrow had separated into three 
layers: plasma, mononuclear cells and red cells. The mononuclear component was aspirated and centrifuged 
at 500g for 5 minutes. Immunomagnetic separation of the white blood cells was performed using EasySep™ 
Human CD45 Depletion (StemCell technologies). Post enrichment the cells were incubated with the following 
antibodies for 30 minutes: Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) (Cat 324214 BioLegend) 
at 1 in 100 dilution, DAPI (10 µg/ml) at 1in 100 dilution and PE/Cy7 anti-human CD45. The sample was imaged 
on the high resolution imaging flow cytometer and analysed using the IDEAS software. The experiment was 
repeated with 10 000 SK-GT-4 cells. 
100 000 SK-GT-4 cells cultured in RPMI medium and fixed in 4% paraformaldehyde was added to five ml of 
bone marrow. The bone marrow was placed through a 70 micron filter. Red cells were lysed with BD 
PhosflowTM Lyse/Fix buffer. The cell pellet post lysis underwent immunomagnetic separation with EasySep™ 
Human CD45 Depletion (StemCell technologies) and labelling with the anti-bodies as described above. The 
experiment was repeated with 10 000 SK-GT-4 cells. 








































and 40%.  The proportion of the SK-GT-4 cells recovered was dependant upon the number of 
cells present initially in the bone marrow solution, 46% and 20.5% recovery with 100 000 cells 
versus 40% and 15% recovery with 10 000 cells. The experiment was repeated with OE19 cells 
with 20mls of bone marrow obtained from the femur of a patient undergoing an elective 
orthopaedic hip replacement. Figure 3.3.2.3 illustrates the difference in enrichment and 
recovery of OE19 cells added to the bone marrow between the two methods.  
 
 
No of OE19 cells recovered from 10 000 
Figure 3.3.2.3 Comparison of enrichment and recovery of OE19 cells from the bone marrow using the 
LymphoprepTM density gradient medium and BD PhosflowTM Lyse/Fix 
One hundred thousand OE19 cells cultured in RPMI medium and fixed in 4% paraformaldehyde was added 
to 5 ml of bone marrow. The bone marrow was placed through a 70 micron filter. The filtrate was added to 
5 ml of PBS containing 2% fetal bovine serum into a 20 ml Falcon tube. Five ml of the LymphoprepTM was 
carefully layered on top of the solution. The sample was centrifuged at 800 g for 20 minutes at room 
temperature (15oC-25oC). The components of the bone marrow had separated into three layers: plasma, 
mononuclear cells and red cells. The mononuclear component was aspirated and centrifuged at 500 g for 5 
minutes. Immunomagnetic separation of the white blood cells was performed using EasySep™ Human CD45 
Depletion (StemCell technologies). Post enrichment the cells were incubated with the following antibodies 
for 30 minutes: Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) (Cat 324214 BioLegend) at 1 in 100 
dilution, PE/Cy7 conjugated anti-human (CD 45) antibody (Cat# 324414) at 1 in 100 dilution and DAPI (10 
µg/ml) at 1 in 100 dilution. The sample was imaged on the high resolution imaging flow cytometer and 
analysed using the IDEAS software. The experiment was repeated with 10 000 OE19 cells. 
100 000 OE19 cells cultured in RPMI medium and fixed in 4% paraformaldehyde was added to 5 ml of bone 
marrow. The bone marrow was placed through a 70 micron filter. Red cells were lysed with BD PhosflowTM 
Lyse/Fix buffer. The cell pellet post lysis underwent immunomagnetic separation with EasySep™ Human 
CD45 Depletion (StemCell technologies) and labelling with the anti-bodies as described above. The 
experiment was repeated with 10 000 OE19 cells 
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Enrichment and recovery of the OE19 cells was lower with the LymphoprepTM density gradient 
medium in comparison to the BD PhosflowTM Lyse/Fix buffer, 24.5% and 18.9% versus 51% and 
47.5%. The difference in recovery in both experiment is attributed to a number of reasons. The 
successful isolation of the mononuclear cell component from the bone marrow using the 
LymphoprepTM density gradient medium relies upon a number of factors. Accurate layering of 
the bone marrow sample onto the LymphoprepTM density gradient medium prior to 
centrifugation is required. Contamination at this stage prevents the separation of the 
components of the bone marrow. In addition, the recovery of the mononuclear component of 
the bone marrow is reliant upon the presence of a defined layer of mononuclear cells post 
centrifugation. Furthermore, there is a potential to lose cells during the extraction of the cells 
from the LymphoprepTM density gradient medium. Based on these experiments, the decision 
was made to use the BD PhosflowTM Lyse/Fix buffer to perform the red cell lysis and isolated the 
mononuclear cellular component of the bone marrow.  
3.4 Other methods for isolating CTCs from blood 
3.4.1 ParsortixTM 
There are a number of methods to isolate CTCs from whole blood as described previously. CTCs 
can be isolated based on their morphological characteristics, eg size, shape. CTCs are 
hypothesised to be larger than white blood cells, approximately > 8 µm in size. The ParsortixTM 
isolates CTCs from whole blood based on the difference in size and compressibility between 
CTCs and white blood cells. Whole blood stored in a EDTA tube is passed through a filtration 
cassette that consists of a network of capillaries. As the blood passes through the capillaries, 
cells that are > 10 um in size are trapped within the lumen and captured in the filtration cassette. 
There are two potential methods for identification and isolation of the CTCs post filtration. The 
cells captured in the cassette can be stained directly with up to four different fluorescent 
antibodies and visualised on a light microscope. The cells captured in the cassette can be 
collected directly into an Eppendorf for further analysis. The ParsortixTM has a number of 
potential benefits when compared to the CellSearchTM method. CTCs are isolated based on their 
size and not their biomarker expression. Thus CTCs undergoing EMT or which express 
mesenchymal markers are isolated. In addition, the time taken for the process is short when 
62 
compared to the immunomagentic depletion method, approximately 3 hours to process 10 ml 
of blood.  
The following experiment compared the efficiency of recovery of SK-GT-4 cells added to blood 
between ParsortixTM and Easy SepTM immunomagnetic depletion. SK-GT-4 cells cultured in 
RPMI medium and fixed in 4% paraformaldehyde were labelled with CellTracker™ Green 
CMFDA (5-chloromethylfluorescein diacetate). Ten thousand SK-GT-4 cells were added to 5 ml 
of blood from a healthy human volunteer. The sample was placed in the ParsortixTM. Cells post 
filtration were collected from the cassette into a 1.5ml Eppendorf. The cells were imaged on 
the high resolution imaging flowcytometer. A cell count was performed. The experiment was 
repeated with 5 000 SK-GT-4 cells. The experiment was repeated with the standard protocol 
for Easy SepTM immunomagnetic depletion as described before. The cells were imaged on the 
high resolution imaging flowcytometer post enrichment. A cell count was performed. Figure 
3.3.1.1 illustrates the difference in recovery of SK-GT-4 cells between the two methods.  
No of SK-GT-4 cells added 
to 5mls of blood 
Easy SepTM 
immunomagnetic depletion 
– No of SK-GT-4 cells 
recovered (%) 
ParsortixTM – No of SK-GT-4 
cells recovered (%) 
10 000 5 240 (54%) 3 158 (32%) 
5 000 2 350 (47%) 1 350 (27%) 
The number of SKT-4 cells recovered was less with the ParsortixTM when compared to the Easy 
SepTM immunomagnetic depletion, 32% versus 52%. The lower rate of enrichment could be 
attributed to the additional step of recovering the cells from the filtration cassette with the 
ParsortixTM and imaging with the high resolution imaging flow cytometer rather than direct 
visualisation of the cells in the cassette with confocal microscopy. With clinical samples, positive 
identification of the CTCs is required with epithelial and/or mesenchymal biomarkers 
conjugated with fluorophores. This can be carried out by incubating the cells isolated within the 
cassette with antibodies conjugated with fluorophores. The CTCs are visualised directly in the 
Figure 3.4.1.1: Comparison of enrichment and recovery of SK-GT-4 cells from blood between 
ParsortixTM and Easy SepTM immunomagnetic depletion  
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cassette using a confocal microscope.  However only a limited range of fluorophores that can 
be imaged on the confocal microscope. Thus the number of biomarkers that can be used is 
limited. The other method of positive identification of CTCs, involves recovering the cells from 
the cassette post filtration into an Eppendorf. Labelling the cells with biomarkers which can be 
visualised on the high resolution imaging flow cytometer which has a wider spectrum of 
fluorophores that can be detected when compared to the confocal microscope.  
The next experiment focused on labelling cells with antibodies post filtration in the ParsortixTM 
and comparing it with Easy SepTM immunomagnetic depletion and subsequent imaging on the 
high resolution imaging flow cytometer. Ten thousand SK-GT-4 cells cultured in RPMI and fixed 
in 4% paraformaldehyde were added to 5 ml of blood. The sample was placed in the ParsortixTM. 
The cells isolated in the cassette post filtration were collected in a 1.5ml Eppendorf and 
incubated with the following antibodies for 30 minutes: Alexa Fluor 488 conjugated anti-human 
CD326 (EpCAM) antibody (Cat # 324210), PE/Cy7 conjugated anti-human (CD 45) antibody (Cat# 
324414) and DAPI (10 µg/ml). The cells were then imaged on a high resolution imaging flow 
cytometer. The experiment was repeated with 5 000 and 1 000 SK-GT-4 cells. Figure 3.4.1.2 
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The ParsortixTM had significantly lower rates of recovery when compared to the Easy SepTM 
immunomagnetic depletion irrespective of the number of SK-GT-4 cells being present in the 
blood. Identification of biomarkers present in the nucleus and/or cytoplasm of cells requires an 
additional step of permeabilisation with saponin or PermwashTM to allow the antibodies to 
traverse the cell wall. This is an additional step in the process of labelling antibodies and would 
not be possible with the cells isolated in the casette with ParsortixTM. The following experiment 
evaluated the difference in recovery with this additional step between ParsortixTM and Easy 
SepTM immunomagnetic depletion. Ten thousand FLO1 cells were added to 1 ml of blood and 
placed in the ParsortixTM. The cell suspension post isolation was labelled with the following 
antibodies: PE/Cy7 conjugated anti-human (CD 45) antibody (Cat# 324414), DAPI (10 µg/ml) and 
Figure 3.4.1.2: Comparison of enrichment and recovery of SK-GT-4 from blood between ParsortixTM and 
Easy SepTM immunomagnetic depletion 
 Ten thousand SK-GT-4 cells were cultured in RPMI medium and fixed with 4% paraformaldehyde were added 
to 5 ml of blood from a healthy volunteer. The sample was placed in the Parsotix™. The cell suspension 
isolated post filtration was collected in a 1.5 ml Eppendorf and incubated with the following antibodies for 
30 minutes: Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) antibody (Cat # 324210) at 1 in 100 
dilution, PE/Cy7 conjugated anti-human (CD 45) antibody (Cat# 324414) at 1 in 100 dilution and DAPI (10 
µg/ml) at 1 in 100 dilution. The SK-GT-4 cells were visualised and a count was performed on the high 
resolution imaging flow cytometer. The experiment was repeated with 5 000 and 1 000 SK-GT-4 cells.  
The experiment was repeated with ten thousand SK-GT-4 cells cultured in RPMI medium fixed with 4% 
paraformaldehyde were added to 5 ml of blood from a healthy volunteer. Red blood cells were lysed with the 
BD PhosflowTM Lyse/Fix buffer. The cell pellet isolated post red cell lysis underwent Easy SepTM 
immunomagnetic depletion. Post enrichment, the cells were labelled with the following antibodies for 30 
minutes: Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) antibody (Cat # 324210) at 1 in 100 dilution, 
PE/Cy7 conjugated anti-human (CD 45) antibody (Cat# 324414) at 1 in 100 dilution and DAPI (10 µg/ml) at 1 
in 100 dilution. The SK-GT-4 cells were visualised and a count was performed on the high resolution imaging 
flow cytometer. The experiment was repeated with 5 000 and 1 000 SK-GT-4 cells.  
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Cytokeratin Monoclonal PE Antibody (Clone C-11)( CAY10478-1 ea). Figure 3.4.1.3 illustrates the 
difference in recovery between ParsortixTM and Easy SepTM immunomagnetic depletion 
 











Figure 3.4.1.3: Comparison of enrichment and recovery of FLO1 cells from blood between ParsortixTM and 
Easy SepTM immunomagnetic depletion  
 Ten thousand FLO1 cells were cultured in DMEM medium and fixed with 4% paraformaldehyde were added 
to 5 ml of blood from a healthy volunteer. The sample was placed in the Parsotix™. The cell suspension, 
approximately 120 µl was isolated post filtration was collected in a 1.5ml Eppendorf and was centrifuged at 
500 g for 5 min. There was no visible cell pellet post centrifugation. 20 µl was removed and 100 µl of  
PermwashTM was added and incubated with the following antibody for 30 minutes: Cytokeratin Monoclonal 
PE Antibody (Clone C-11)( CAY10478-1 ea) at 1 in 20 dilution. After 30 minutes, the cell suspension was 
centrifuged at 500 g for 5 min and 100 µl was discarded. The cell suspension was then incubated with the 
following antibodies: PE/Cy7 conjugated anti-human (CD 45) antibody (Cat# 324414) at 1 in 100 dilution and 
DAPI (10 µg/ml) at 1 in 100 dilution. The FLO1 cells were visualised and a count was performed on the high 
resolution imaging flow cytometer. The experiment was repeated with 5 000 FLO1 cells.  
The experiment was repeated with the Easy SepTM immunomagnetic depletion. Labelling of the cell 
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Both experiments highlighted a number of issues with the ParsortixTM. Recovery of cells pre-
labelled with the CellTracker™ Green CMFDA (5-chloromethylfluorescein diacetate) was lower 
with the ParsortixTM. Furthermore, labelling cells isolated within the cassette was challenging. 
Only a small number of fluorophores could be employed to identify cells using the confocal 
microscope. The secondary option was to recover the cells from the cassette directly into a 1.5 
ml Eppendorf. The manufacturer commented that approximately 20% of cells were lost during 
this transfer. This contributes to the overall lower recovery when compared to Easy SepTM 
immunomagnetic depletion. In addition, there was no visible cell pellet in the Eppendorf post 
isolation and thus downstream labelling of antibodies with the standard protocol proved 
challenging. Overall, ParsortixTM proved to be less successful in practice than predicted.  
3.4.2 EasySep™ Direct Human CTC Enrichment  
EasySep™ Direct Human CTC Enrichment enriches CTCs directly from whole blood by negative 
selection using immunomagentice beads. Haematopoietic cells and platelets within the blood 
are separated from CTCs with antibodies recognizing CD2, CD14, CD16, CD19, CD45, CD61, 
CD66b, and Glycophorin A surface markers. The antibodies are combined with EasySep™ Direct 
RapidSpheres™, and separated using an EasySep™ magnet. This method contains no fixative 
agent and thus CTCs isolated can be placed directly into culture. The following experiements 
evaluated the efficacy of this method to isolate CTCs from blood.  
The first experiment compared the recovery of SK-GT-4 cells with EasySep™ Direct Human CTC 
Enrichment and Easy SepTM immunomagnetic depletion. Three hundred thousand SK-GT-4 cells 
were added to 2 ml of blood from a healthy volunteer. The sample underwent immunomagnetic 
separation with the EasySep™ Direct Human CTC Enrichment as per the standard protocol. Post 
enrichment, the cells were labelled with the following antibodies: Alexa Fluor 488 conjugated 
anti-human CD326 (EpCAM) antibody (Cat # 324210), PE/Cy7 conjugated anti-human (CD 45) 
antibody (Cat# 324414) and DAPI (10µg/ml). The cells were visualised on the high resolution 
imaging flow cytometer. The experiment was repeated with Easy SepTM immunomagnetic 
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Figure 3.4.2.1: Comparison of enrichment and recovery of SK-GT-4 cells from blood between EasySep™ 
Direct Human CTC Enrichment and Easy SepTM immunomagnetic depletion  
Three hundred thousand SK-GT-4 cells cultured in RPMI media and fixed with 4% paraformaldehyde were added 
to 2 ml of blood from a healthy volunteer and transferred to a 5 mL (12 x 75 mm) polystyrene round-bottom 
tube. The sample was incubated with 100 µl of EasySep™ Direct Human CTC Enrichment solution for 5 minutes 
at room temperature. After which, 100 µl EasySep™ Direct RapidSpheres™ was added and 2mls of 3% BSA was 
added to the sample. The sample was incubated for 10 minutes at room temperature and then placed in a 
EasySep™ magnet for 5 minutes. After 5 minutes, in one continuous movement, the magent and the tube is 
picked up and inverted and the the enriched cell suspension is transferred into another 5 ml tube. The process 
was repeated with another 100 µl EasySep™ Direct RapidSpheres™ added to enriched cell suspension. The cell 
suspension post immunomagentic depletion was incubated with the following antibodies for 30 minutes: Alexa 
Fluor 488 conjugated anti-human CD326 (EpCAM) antibody (Cat # 324210) at 1 in 100 dilution, PE/Cy7 
conjugated anti-human (CD 45) antibody (Cat# 324414) at 1 in 100 dilution and DAPI (10 µg/ml) at 1 in 100 
dilution. The SK-GT-4 cells were visualised and a count was performed on the high resolution imaging flow 
cytometer. The experiment was repeated with the standard protocol for Easy SepTM immunomagnetic 
depletion. 
 The graphs illustrate the proportion of SK-GT-4 cells recovered with the two method. The experiment was 
repeated with the Easy SepTM immunomagnetic depletion. Labelling of the cell suspension post enrichment was 




Population Total No of Objects 
SK-GT-4 42 605 (43%) 
CD45+ 44095 (45%) 
Debris 12 738 (13%) 
 
 
Population Total No of objects 
SK-GT-4 1261  (25%) 
CD45+ 3502  (68%) 
Debris 360 (7%) 
 




EasySep™ Direct Human 
CTC Enrichment  
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The Easy SepTM immunomagnetic depletion was superior in terms of recovery of the SK-GT-4 
cells, 43% of cells recovered versus 25% with the EasySep™ Direct Human CTC Enrichment. As 
illustrated, there was a large amount of debris present in the cell suspension with the EasySep™ 
Direct Human CTC Enrichment method. The debris conisted of a complex of the EasySep™ Direct 
RapidSpheres™ combined white blood cells. This combined with the smaller number cells being 
present post depletion contributed to the lower recovery of SK-GT-4 cells with the EasySep™ 
Direct Human CTC Enrichment. Furthermore,  EasySep™ Direct Human CTC Enrichment was not 
superior in terms of CD 45 depetion. Contanimation of white blood cells was present in both 
samples.  
The second experiment focused on the efficiency of recovery of OE19 cells from blood between 
the two methods. Ten thousand OE19 cells cultured in RPMI media were added to two ml of 
blood from a healthy volunteer and transferred to a 5 mL (12 x 75 mm) polystyrene round-
bottom tube. The sample underwent enrichment with the EasySep™ Direct Human CTC protocol 
as described before. The cell suspension post immunomagentic depletion was incubated with 
the following antibodies for 30 minutes: Alexa Fluor 488 conjugated anti-human CD326 
(EpCAM) antibody (Cat # 324210) at 1 in 100 dilution, PE/Cy7 anti-human CD340 (erbB2/HER-2) 
Antibody (Cat #324414) at 1 in 100 dilution, CD45 Alexa Fluor® 647-conjugated (Cat #304018) at 
1 in 100 dilution and DAPI (10µg/ml) at 1 in 100 dilution. The OE 19 cells were visualised and a 
count was performed on the high resolution imaging flow cytometer. The experiment was 
repeated with 5 000 and 1 000 OE 19 cells. The experiment was repeated with the standard 
protocol for Easy SepTM immunomagnetic depletion. Table 3.4.2.2 compares the recovery of 
OE19 cells between the two methods. Figure 3.4.2.3 illustrates the difference in recovery of 1 
000 OE19 cells as visualised on the high resolution imaging flow cytometer.  
 
No of OE19 cells added to 2 mls 
of blood 
Easy SepTM immunomagnetic 
depletion – No of OE19 cells 
recovered (%) 
EasySep™ Direct Human CTC 
Enrichment – No of OE19 cells 
recovered (%) 
10 000 Sample lost 980 (9.8%) 
Table 3.4.2.2: Comparison of enrichment and recovery of OE 19 cells from blood between 
EasySep™ Direct Human CTC Enrichment and Easy SepTM immunomagnetic depletion  
69 
5 000 3 400 (34%)  220 (2.2%) 



















EasySep™ Direct Human CTC Enrichment  - 1000 OE19 cells  
Population Total No of objects (28 640) 
Cells 2138  (7%) 
Debris 26 194 (92%) 
 
Population Total No of Cells (2138) 
OE19 148  (7%) 
CD45+ 1990 (93%) 
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Images of cells captured on the high resolution imaging flow cytometer post 
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Population Total No of objects (35 169) 
Cells  13 074 (37%) 
Debris 21 975 (63%) 
 
Population Total No of Cells (13 074) 
OE19 503  (4%) 
CD45+ 12 571 (96%) 
 
Images of cells captured on the high resolution imaging flow cytometer post 




The recovery of OE19 cells was lower with the EasySep™ Direct Human CTC Enrichment. As 
illustrated in Figure 3.4.2.3, only 15% of the 1 000 OE19 cells were recovered. In addition, the 
amount of contamination of the sample with white blood cells was similar. As mentioned, 
before there was a large amount of cellular debris with the EasySep™ Direct Human CTC 
Enrichment method. This contributes to the lower rates of recovery when compared to the Easy 
SepTM immunomagnetic depletion. 
The next experiment focused on the evaluating the viability of cells for culture post isolation 
with the EasySep™ Direct Human CTC Enrichment. One hundred thousand SK-GT-4 cells cultured 
in RPMI medim were added to 2 ml of blood from a healthy human volunteer. The sample 
underwent EasySep™ Direct Human CTC Enrichment under sterile conditions. A cell count was 
carried out on the cell suspension using a haemocytomter. The cell suspension post enrichment 
was placed directly into a 75cm3 Corning® flask containing 20 ml of RPMI with 20% FCS. Cells 
within the flask were imaged at this point and at the following intervals: 24, 48 and 72 hours. 
The experiment was repeated with one hundred thousand FLO1 cells. The cell suspsension post 
enrichment was placed in a 75cm3 Corning® flask containing 20 ml of DMEM with 20% FCS. 
Figure 3.4.2.4 illustrates the images of the cells obtained with light microscopy at the following 
time intervals.  
Figure 3.4.2.3: Comparison of enrichment and recovery of OE 19 cells from blood between EasySep™ 
Direct Human CTC Enrichment and Easy SepTM immunomagnetic depletion and Images of the cells 
captured on the high resolution imaging flow cytometer 
One thousand OE19 cells cultured in RPMI media were added to two ml of blood from a healthy volunteer and 
transferred to a 5 mL (12 x 75 mm) polystyrene round-bottom tube. The sample underwent enrichment with 
the EasySep™ Direct Human CTC protocol as described before. The cell suspension post immunomagentic 
depletion was incubated with the following antibodies for 30 minutes: Alexa Fluor 488 conjugated anti-human 
CD326 (EpCAM) antibody (Cat # 324210) at 1 in 100 dilution, PE/Cy7 anti-human CD340 (erbB2/HER-2) 
Antibody (Cat #324414) at 1 in 100 dilution, CD45 Alexa Fluor® 647-conjugated (Cat #304018) at 1 in 100 
dilution and DAPI (10µg/ml) at 1 in 100 dilution. The OE 19 cells were visualised and a count was performed 
on the high resolution imaging flow cytometer. The experiment was repeated with the standard protocol for 









There were 15 000 cells isolated post enrichment with the SK-GT-4 sample. There were viable 
cells present at Day 2. The cells at this stage had become adherent to flask and were dividing. 
Although there were 3000 cells isolated post enrichment with the FLO1 sample, there were no 
viable cells present at Day 3 in culture. As noted in Figure 3.3.2.4, there was a large amount of 
debris present in the sample. Results from this experiment illusrate that the cells post EasySep™ 
Direct Human CTC Enrichment are viable and able to grown in culture. However, as described 
with earlier experiments, recovery of cells with  EasySep™ Direct Human CTC Enrichment is 
poor. Less than 15% of cells are recovered from the blood. Thus a large of number of CTCs need 







FLO1 cells Day 0 FLO1 cells Day 1 
Figure 3.4.2.4: Images of SK-GT-4 and FLO 1 cells in culture following isolation with EasySep™ Direct 
Human CTC Enrichment 
One hundred thousand SK-GT-4 cells were added to 2 ml of blood. The cell suspension post enrichment was 
placed directly into a 75cm3 Corning® flask in 20 ml of RPMI with 20% FCS. Cells within the flask were 
imaged at this point and at the following intervals: 24, 48 and 72 hours. The experiment was repeated with 
one hundred thousand FLO1 cells. The cell suspsension post enrichment was placed in a 75cm3 Corning® 
flask in 20 ml of DMEM with 20% FCS. 
40 x objective 
40 x objective 40 x objective 
40 x objective 20 x objective 
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3.5 Discussion 
One of the aims of the chapter was to address the concerns regarding the lower recovery rates 
of oesophageal cancer cell lines from peripheral blood with the original protocol. The recovery 
rate varied between 20-25%. The most important modification of the protocol was the change 
in the collection and storage method used when processing the peripheral blood sample. 
Collection of the blood sample using the BD vacutainer EDTA tube and processing within four 
hours has shown to significantly improve the recovery of the cells and preserve their viability. 
Amendments to the protocol, primarily omission of the FcR blocking agent led to a reduction in 
the processing cost per sample and reduced the time for processing. Other changes during the 
protocol revision was changes to the anti-body labelling. Overall the changes to the protocol 
reduced the time taken for processing a sample in preparation for analysis on the high 
resolution imaging flow cytometer from six hours to 4 hours.  
The development of the protocol for isolating disseminated tumour cells from bone marrow 
focused on adapting previous methods described in literature. However, the recovery rates 
using the LymphoprepTM density gradient medium was poor. Adapting the protocol used for 
isolating CTCs from peripheral blood proved more successful in achieving higher rates of 
recovery whilst preserving the viability of the cells.  
As described in the literature there are various methods for isolating CTCs from blood. The 
primary focus of this chapter was to evaluate methods to isolate CTCs directly from blood into 
culture. The ParsortixTM was promising in the initial concept of isolating CTCs directly from 
peripheral blood into a filtration cassette. However, further analysis of the CTCs post isolation 
proved challenging. Labelling the isolated cells with anti-bodies was difficult and as a 
consequence the recovery of CTCs was significantly lower when compared to the Easy SepTM 
immunomagnetic depletion protocol. The EasySep™ Direct Human CTC Enrichment used a two 
stage immunomagnetic separation to isolate CTCs from blood. The processing time was less 
than the current protocol using Easy SepTM immunomagnetic depletion. However, recovery of 
oesophageal cancer cell lines from peripheral blood was lower with EasySep™ Direct Human 
CTC Enrichment when compated to Easy SepTM immunomagnetic depletion. The EasySep™ 
Direct Human CTC Enrichment was successful in isolating oesophgeal cancer cell lines directly 
into culture. This method maintains the viability of the cells as illustrated by the presence of 
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growth of the cell lines up to 48 hours post isolation from blood. Although the experiment was 
promising, the low rates of recovery means that successful culture require a high number of 
CTCs being present per ml of peripheral blood. Further evauation is required to assess the 
efficacy of this method in isolating smaller number of oesophageal cancer cells from the blood. 




















Chapter 4: Single cell Sorting 
4.1: Introduction 
The role and function of CTCs in the development and progression of cancer remains 
unknown. CTCs are a heterogeneous population of cells. The origins of the sub-populations 
remains poorly understood. It is thought that CTCs are derived from the primary tumour and 
express epithelial markers (142, 143). Previous studies have relied upon isolation of CTCs 
based on the expression of epithelial markers (128-132). However, a proportion of CTCs 
undergoing EMT express mesenchymal markers and are not detected (98). In addition, studies 
have shown that molecular expression and phenotype of CTCs can be different to that of the 
primary tumour (144-146) Isolation of individual circulating tumour cells is a challenge due to 
the low number being present in blood (65, 147). Developing a method which isolates CTCs 
using a wide array of biomarkers is vital in identifying the molecular origin of the cells and 
characterising the heterogeneity.  
The primary aim of the work described in this chapter was to develop a protocol for isolation 
of individual circulating tumour cells based on expression of epithelial biomarkers from blood 
of patients with oesophageal adenocarcinoma. The intention is to isolate singles cells from 
different populations of CTCs based on the expression of specific biomarkers that could be 
sequenced using NextSeq 500 v2 sequencing and bioinformatics analyses. An additional aim 
was to develop a protocol for culturing circulating tumour cells from blood of patients with 
oesophageal adenocarcinoma. 
The first stage of the method for red cell lysis was derived from the protocol described in 
chapter 2 for enrichment and isolation of circulating tumour cells from blood. The 
mononuclear cellular component isolated following the lysis, is labelled with fluorophores 
conjugated to anti-human CD45 antibody, epithelial biomarkers and DAPI. The cell pellet is 
suspended in 2 ml PBS and placed in a 6 ml FACS tube prior to analysis on the flow cytometer. 
The BD FACSAria™ Fusion is a high speed flow cytometer that allows single cells to be isolated. 
The machine has five lasers at wavelengths 355 nm, 405 nm, 488 nm, 561 nm and 635 nm. It 
enables the detection of up to 18 different fluorophores simultaneously which means multiple 
biomarkers can be detected. It has two forward scatter channels which enables cells to be 
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isolated based on the physical characteristics eg size and shape. The flow cytometer can 
isolate up to four different populations. The method of collection determines the number of 
populations that can be isolated (Table 4.1.1). 
 
Method of collection No of populations isolated  
1.5 ml Eppendorf 1 – 4 
Microscope slide 1 - 3 




The speed of collection is dependent upon the method of collection and the size of the nozzle 
on the flow cytometer. The smallest diameter circulating tumour cell identified from patient 
samples was 10 μm. To ensure the capture of both single circulating tumour cells and clusters, 
the 100 μm nozzle was selected.   
A compensation matrix for the fluorophores conjugated to the antibodies was created based 
upon fluorescence using eComp beads TM. A gating template was created to isolate and 
capture the cells of interest based on their size and the presence of a nucleus. The gating 
template was creased based upon flow cytometry data of circulating tumour cells from patient 
samples, oesophageal cancer cell lines and white blood cells.  
 
4.2: Isolation of oesophageal adenocarcinoma cells from blood 
The methodology was developed with oesophageal cancer cells added to healthy donor blood. 
First the ability of the BD FACSAria™ Fusion sorter to enrich and purify oesophageal cancer 
cells from whole blood was evaluated. An additional aim of the experiment was to evaluate 
the methods for imaging and identifying the cells following the single cell isolation using a high 
resolution flow cytometer and confocal microscope.  
Table 4.1.1: Number of populations of cells isolated on the BD FACSAria™ Fusion based 
on the method of collection 
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Oesophageal adenocarcinoma cell lines which express a range of epithelial markers were 
selected for the experiment. OE19 cells express EpCAM and HER2, SK-GT-4 cells express 
EpCAM and cytokeratins and FLO1 cells express Cytokeratin only. 
 
Cells are sorted in two stages. In the first stage, cells were isolated based upon their physical 
characteristics. The threshold for the minimum diameter of 10 μm for cells to be isolated was 
derived from data of circulating tumour cells and white blood cells from patient samples. 
Majority of the white blood cells are smaller than 10 μm and thus this threshold allows 
effective enrichment. Cells with diameter greater than 10 μm and the presence of a nucleus 
were selected for further analysis. This population contained both white blood cells and the 
oesophageal cancer cells. Figure 4.2.1 illustrates two distinct populations of cells which have 
been gated based upon their expression of HER2 and CD 45. Cells which express HER2 and do 











Figure 4.2.1: Isolation of individual oesophageal adenocarcinoma cells from blood based on the 
positive expression of epithelial human epidermal growth factor (HER2) and negative expression 
of CD 45.  
One thousand OE19 cells were cultured in RPMI medium, trypsinised, counted and added to one ml 
of blood from a healthy volunteer. Red blood cells were lysed with BD Phospholyse fix buffer and 
permeabilised with BD phosphoflow Perm/Wash buffer for one hour at room temperature. The cell 
pellet was incubated with Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) antibody (Cat # 
324210) at 1 in 100 dilution, PE/Cy7 conjugated anti-human (HER-2) antibody (Cat# 324414) at 1 in 
100 dilution, APC-Fire™ 750 anti-human CD45 antibody (Cat # 30406) at 1 in 100 dilution and DAPI 
(10 µg/ml) at 1 in 100 dilution. The single cell sorting was carried out on the BD FACSAria™ Fusion 
flow cytometer. Cells were sorted based on the expression of the expression of PE/Cy7 conjugated 
anti-human CD340 (erbB2/HER-2) antibody and APC-Fire™ 750 anti-human CD45 antibody. 
78 
 
A total of 1500 cells were isolated based on the selection criteria. Of which, 1000 cells were 
collected in a 1.5 ml Eppendorf and the remaining 500 cells were placed on a microscope slide.  
A total of 850 cells were imaged on the high resolution imaging flow cytometer, 550 cells were 
positively identified as OE19 cells which express EpCAM and HER2 and absence of CD45 
expression as illustrated in Figure 4.2.2. The remainder of the cells were expressed CD45 
which indicates that cells isolated based on the expression of HER2 but not CD45 are 
contaminated with white blood cells. This demonstrated a recovery of 55% of the OE19 cells 
using the method for sorting and analysis. Furthermore, the flow cytometer isolated both 









Figure 4.2.3 illustrates images of OE19 cells with a confocal microscope post single cell sorting.  
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Figure 4.2.2: Characterisation by imaging flow cytometry of populations of OE19 cells isolated 
by FACS 
A: OE19 cells   B: white blood cell 
The cell suspension collected in the 1.5 ml Eppendorf as described in legend 5.2.1 was visualised 
by imaging flow cytometry at 40x objective. The illumination intensities for the excitation lasers 
were set at 100, 200, 200 and 150 mW, respectively 405 nm, 488 nm, 561 nm and 658 nm 
















Of the 500 objects sorted onto the microscope slide, 350 OE19 cells were identified with the 
confocal microscope based on the membranous expression of EpCAM and DAPI stained nuclei. 
Imaging of the OE 19 cells using the confocal microscope revealed a lower recovery rate at 
35% when compared to 55% recovery rate with the imaging flow cytometer.  
The presence of white blood cells in the sample analyzed on the high resolution flow 
cytometer showed that the isolated cells were contaminated with white blood cells. In 
addition, HER2 not detected on the OE19 cells on the confocal microscope. The cells were 
imaged on a Leica SP8 confocal microscope which has lasers for excitation set at 458 nm, 476 
nm, 488 nm and 514 nm. The excitation peak of the PE/CY7 (erbB2/HER2) fluorophore is 565 
nm and APC-Fire™ 750 fluorophore is 650 nm which were greater than the wavelength of the 
excitation lasers present in the confocal microscope and that means that the excitation peaks 
is not detectable.  
 
Figure 4.2.3: Visualisation of the sorted OE 19 cells on the confocal microscope 
The objects isolated in Figure 4.2.1 were placed directly onto a microscope slid. Cells were visualised 
on Leica SP8 Confocal (Inverted) microscope. The images were taken using the 40x objective. 
Images were analysed on the Leica Application Suite X software  
The blue colour denotes the staining of the nucleus with DAPI. The green colour denotes the 
immunofluorescence of the antibody conjugated to EpCAM biomarker located on the membrane 





4.3 Separation of oesophageal adenocarcinoma cells that express HER2 from oesophageal 
adenocarcinoma cells that do not 
 The next experiment focused on separation of two different populations of oesophageal 
cancer cell lines based on the differential expression of a single biomarker. SK-GT-4 cells 
express EpCAM and OE19 cells express both EpCAM and HER2. One hundred SK-GT-4 and One 
hundred OE19 cells were added to blood from a healthy human volunteer and incubated with, 
Alexa Fluor 488 conjugated anti-human CD326 (EpCAM), PE/Cy7 conjugated anti-human 
CD340 (erbB2/HER2) and APC-Fire™ 750 anti-human CD45 antibody. Figure 4.3.1 illustrates 
the gating template used on the FACS machine to isolate the different populations of cells 














           
As illustrated in Figure 4.3.1, it is possible with the flow cytometer to differentiate the 
oesophageal cancer cells and white blood cells based on the expression of EpCAM and CD45.  
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Figure 4.3.1: Isolation of individual oesophageal adenocarcinoma cells blood origination from 
two oesophageal cell lines from blood based on the expression of epithelial adhesion molecule 
(EpCAM) and human epidermal growth factor receptor 2 (HER2)  
One hundred OE19 cells and one hundred SK-GT-4 cells cultured in RPMI medium were added to 1 
ml of blood obtained from a healthy human volunteer Red blood cells were lysed with BD 
Phospholyse fix buffer and permeabilised with BD phosphoflow Perm/Wash buffer. The cells were 
incubated  with the following anti-bodies: Alexa Fluor 488 conjugated anti-human CD326 (EpCAM) 
antibody (Cat # 324210) at 1 in 100 dilution, PE/Cy7 conjugated anti-human CD340 (erbB2/HER2) 
antibody (Cat# 324414) at 1 in 100 dilution, APC-Fire™ 750 anti-human CD45 antibody (Cat # 30406) 
at 1 in 100 dilution and DAPI (10 µg/ml) at 1 in 100 dilution. Cells were first isolated on the flow 
cytometer based on their physical characteristics. The cells were then separated based on their 
expression of EpCAM and CD45 (Fig 5.3.1 a). The cells with a positive expression of EpCAM and 
negative expression of CD 45 as illustrated by the gating template in Fig 5.3.1.a were then sorted 
into two populations based on their differential expression of the HER2 (Fig 5.3.1 b) and collected 
in two individual 1.5 ml Eppendorf tubes.  
Figure 4.3.2: Characterisation by imaging flow cytometry of populations of OE19 and SK-GT-4 
cells isolated by FACS 
The suspension collected in the 1.5 ml Eppendorf tubes was visualised on the imaging flow 
cytometer at 40x objective. The wavelength of excitation lasers were 405nm, 488nm, 561nm and 
658nm and the voltages set at 100, 200, 200 and 150 mW. As described in the legend to figure 5.3.1, 
two population of cells were separated based on the positive expression of EpCAM and negative 
expression of CD 45. Panel A illustrates objects isolated which expressed both EpCAM and HER2. 
Panel B illustrates objects isolated and collected which expressed EpCAM alone. There was evidence 
of contamination with white blood cells in both of the isolated cell populations as illustrated in Panel 
C.  
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Further separation of the oesophageal cancer cell population is then achieved based on the 
differential expression of HER2 between the two cell lines. Subsequent analysis of the cell 
suspension on the imaging flow cytometer identified the two oesophageal cancer cell lines as 
illustrated in Figure 4.3.2.  A total of 65 OE19 cells and 53 SK-GT-4 cells were sorted and 
separated in the above experiment which indicates a recovery of 64% and 53%.  
4.4 Isolation and culture of oesophageal adenocarcinoma cells from whole blood  
The previous experiments demonstrated that the potential of separating oesophageal cancer 
cells from whole blood based upon the expression of epithelial biomarkers. The next step was 
to develop a method that would allow the separated cells to be placed directly into culture. BD 
Phospholyse fix™ is the current buffer used to lyse red cells. This buffer contains formalin 
which fixes cells by cross linking the amino groups. This prevents cellular growth and division, 
thus makes it unsuitable for use when placing cells directly into culture. The aim of the 
experiment was to identify a red cell lysis buffer that achieves the optimum enrichment whilst 
preserving the viability of the oesophageal cancer cells for culture. Ammonium chloride is a 
buffer routinely used for red cell lysis. BD Pharm Lyse™ is chemically similar to BD Phospholyse 
fix™ but does not contain formalin.  
Six millilitres of blood was obtained from a healthy volunteer and divided equally into six 
individual 14 ml Falcon tubes pre-blocked with 3% BSA. A stock solution of 1.5M ammonium 
chloride solution was prepared as per a standard protocol and combined with 100mM sodium 
bicarbonate and 1mM Na2EDTA. The stock solution of ammonium chloride was diluted with 
sterile water to achieve a 1:10 ratio. Ten millilitres of the diluted ammonium chloride solution 
was added to two of the 14 ml Falcon tubes each containing 1 ml of blood. The solution was 
inverted gently ten times and then incubated in the dark at room temperature for 20 minutes. 
The solution was then centrifuged at 300 x g for 10 min and the supernatant was carefully 
discarded. The cell pellet was resuspended in 1 ml of PBS and the cells were counted using a 
haemocytometer. The experiment was repeated using the BD Pharm Lyse™ buffer buffer and 
BD Pharm Lyse™ fix buffer as per the standard manufacturer protocol. Six millilitres of blood 
from a healthy human volunteer was divided equally into six individual 14ml Falcon tubes 
which were pre-blocked for 20 minutes with 3% bovine serum albumin (BSA) at room 
temperature. The blood samples underwent red cell lysis as per the standard protocol for each 
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red cell lysis buffer. Cells from each of the individual cell suspensions were counted on a 
haemocytometer following the red cell lysis. The number of cells recovered from one ml of 
blood post red cell lysis for each individual buffer is noted in the Table 5.4.1. 
 
  The experiment indicated that the efficiency and enrichment of BD Pharm Lyse™ buffer was 
comparable to the BD Pharm Lyse™ fix buffer. Thus optimum enrichment could be achieved 
using the BD Pharm Lyse™ buffer in comparison to the Ammonium chloride solution.  
The next experiment on focused on comparing the efficiency of enrichment and evaluating the 
viability of the tumour cells post isolation based on the expression of an epithelial biomarker. 
Ten thousand SK-GT-4 cells were added to 1 ml of blood. The red blood cells were lysed with 
the BD Pharm Lyse™ buffer as per the standard protocol under sterile conditions. The 
experiment was repeated with ammonium chloride to compare the enrichment and viability 
of oesophageal cancer cells between the two methods of red cell lysis.  
 No of cells post red cell lysis 
– A 
No of cells post red cell lysis 
– B 
Ammonium Chloride 7.5 x 105 cells 6.5 x 105 cells 
BD Pharm Lyse™ buffer 
buffer 
2.5 x 106 cells 2 x 106 cells 
BD Pharm Lyse™ fix 
buffer buffer 
2.25 x 106 cells 
 
2.1 x 106 cells 
Table 4.4.1: Comparing the recovery of white blood cells using different methods of red cell lysis 
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The cell pellet obtained post red cell lysis was incubated with the following antibodies, Alexa 
Fluor 488 conjugated anti-human CD326 (EpCAM) antibody and Alexa Fluor 647 anti-human 
CD45 antibody. The oesophageal adenocarcinoma cells were isolated with a flow cytometer 
using the gating template derived from previous experiments as illustrated in Figure 4.4.2, 
cells were isolated based on their positive expression of EpCAM and negative expression of CD 
45.  
As illustrated in Figure 4.4.2, two population of cells were identified. Cells which express 
EpCAM and do not expression CD 45 were isolated into an individual well of a six well plate 



























Figure 4.4.2: Isolation of oesophageal adenocarcinoma cells from blood based on the expression 
of epithelial adhesion molecule (EpCAM) 
Ten thousand SK-GT-4 cells cultured in RPMI media were added to 1 ml of blood obtained from a 
healthy human volunteer. Red blood cells were lsyed with the BD Pharm Lyse™ buffer. The cell pellet 
post red blood cell lysis was incubated with the following antibodies: Alexa Fluor 488 conjugated 
anti-human CD326 (EpCAM) antibody (Cat # 324210) at 1 in 100 dilution, Alexa Fluor 647 anti-
human CD45 antibody (Cat #304018) at 1 in 200 dilution and DAPI (10 µg/ml) at 1 in 100 dilution. 
The single cells were isolated on the BD FACSAria™ Fusion flow cytometer. Objects which expressed 
EPCAM and did not express CD 45 were isolated into an individual well in a six well plate containing 
RPMI media with 20% foetal calf serum.  
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A total of 6500 objects were isolated and placed into culture from the sample in which red 
blood cells were lysed with the BD Pharm Lyse™ buffer. Only 2450 objects were sorted into 
culture from the sample in which red blood cells were lysed with the ammonium chloride 
buffer. Figure 4.4.3 illustrates images of SK-GT-4 cells in culture post single cell isolation 
following red cell lysis with ammonium chloride. Figure 4.4.4 illustrates images of SK-GT-4 cells 









Figure 4.4.4: Images of the SK-GT-4 cells in culture post single cell isolation following red 
cell lysis with BD Pharm Lyse™ buffer 
 Images of the SK-GT-4 cells obtained on the light microscope on day 0 and day 5 of culture 
post single cell sorting 
Figure 4.4.3: Images of the SK-GT-4 cells in culture post single cell isolation following red 
cell lysis with Ammonium Chloride  
Images of the SK-GT-4 cells obtained on the light microscope on day 0 and day 5 of culture 
post single cell sorting 
DAY 0 DAY 5 
DAY 0 
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SK-GT-4 cells were visible and identified based on their morphology on the light microscope 
post single cell sorting in the six well plate as illustrated in Figure 4.4.4. In addition, the 
viability of the SK-GT-4 cells post single cell sorting was confirmed with the growth of the cells 
on Day 5 of culture. In the cohort in which red blood cells were lysed with the ammonium 
chloride buffer as illustrated in Figure 5.4.4, there were no visible SK-GT-4 cells present in 
culture on Day 0. However, there were viable SK-GT-4 cells on Day 5 of culture. The 
experiment highlights the feasibility of sorting viable single tumour cells based on the 
expression of epithelial biomarkers into culture using the BD FACSAria™ Fusion flow 
cytometer.  
5.3 Discussion 
Isolating single CTCs from blood remains a challenge due to the low concentration of CTCs 
being present in patients with oesophageal adenocarcinoma  (128-132). In addition, the small 
number of CTCs isolated results in insufficient DNA and RNA being available for next 
generation sequencing. Optimising enrichment of CTCs from blood and reducing the 
contamination of white blood cells is vital. Previous studies have employed a variety of 
methods to isolate individual CTCs from patient’s blood. Positive selection of CTCs based on 
the expression of epithelial markers using flow cytometry, eg CellSearch (148, 149). 
Dielectrophoresis has been used to isolate single CTCs in patients with breast cancer (150). 
Lohr et al, used a combination of immunofluorescence 
 and laser microdissection to isolate single CTCs in patients with metastatic prostate 
cancer(151).  In this chapter, I have demonstrated the successful isolation of individual tumour 
cells from blood is possible using a combination of biomarker expression and the physical 
characteristics of the cell of interest eg size. The method of single cell isolation is able to 
achieve optimum enrichment with minimal loss with recovery rates of 53%-64%.  Multiple 
epithelial biomarkers can be employed to isolate individual population of cells. I demonstrated 
the ability to isolate two populations of oesophageal adenocarcinoma cells from whole bloods 
based on their differential expression of HER2.  
Successful culture of CTCs in the ex vivo environment unlocks a wide range of experimental 
possibilities. The potential to identify new biomarkers and to evaluate new therapeutic 
treatment regimes. CTCs in culture can be used in conjunction with animal models to better 
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understand the molecular mechanisms and transcription factors involved in the biology of 
cancer metastases. As stated before, CTCs are a rare population and methods of enrichment 
can damage the CTCs and reduce their viability. Previous studies have used the CTC-I chip to 
successfully culture CTCs in patients with metastatic breast cancer (152). This method isolates 
CTCs based upon their size and positive expression of EpCAM. Bobek et al, cultured CTCs from 
patient with oesophageal adenocarcinoma and squamous cell carcinoma (130). CTCs were 
isolated using a filtration based system and positively identified with immunofluorescence 
using epithelial biomarkers. Cells were then placed in RPMI media with 10% FBS in 5%CO2 at 
370C. The study reported that despite cell growth, confluence was not reached and cells 
became senescence after 14 days. In my study I have demonstrated successfully that 
oesophageal cancer cells can be isolated from blood and placed directly into culture using flow 
cytometry. This method achieve optimum enrichment and preserves the viability of the cancer 
cells as demonstrated by the presence of tumour cell growth at five days. The next stage 
would be to use the method to culture CTCs in patients with oesophageal adenocarcinoma.  
Comparison of the molecular phenotype of the primary tumour and the isolated CTCs would 
aid in the understanding of origin and function of the CTCs in the development of oesophageal 
cancer. In addition, sequential measurement and analysis of CTCs at each stage of the 
treatment pathway will evaluate the response to treatment and identify prognostic factors 
that influence tumour progression. At present there a number of methods used to perform 
downstream genomic analysis of the isolated single circulating tumour cells (153). The next 
stage of study would be to develop a method for next generation sequencing of the isolated 







Chapter 5: Circulating and disseminated tumour cells in patients undergoing 
curative treatment for oesophageal adenocarcinoma 
5.1 Introduction 
Patients undergoing curative treatment for oesophagogastric cancer can be divided into three 
main cohorts based on the stage of disease and the treatment modality they will receive. 
Patients with early oesophagogastric cancer clinically staged with T2 or less and with no 
evidence of nodal or metastatic disease will be considered for surgery alone. Patients with 
clinically staged T3 or greater and/or evidence of nodal disease will be considered for peri-
operative chemotherapy and surgery or surgery alone if they are unfit for multi-modality 
treatment. The aim of this chapter is to identify the presence the circulating and disseminated 
tumour cells from blood and bone marrow of patients undergoing curative treatment for 
oesophagogastric cancer within these three cohorts of patients. Secondary aims are to 
characterize the morphology of the circulating and disseminated tumour cells present and to 
investigate the correlations with prognostic factors derived about the resected tumours, eg 
presence of lymph node metastasis, tumour regression grade and presence of lymphovascular 
invasion. The overall objective will be to evaluate the extent and prognostic significance of 
circulating and disseminated tumour cells in oesophagogastric cancer. Additional objectives 
will be to identify prognostic biomarkers present which influence response to oncological 
treatment and survival in patient undergoing curative treatment for oesophagogastric cancer.  
5.2 Results 
5.2.1 Patient recruitment 
Ethical approval for the study was obtained with the Health Research Authority NHS England 
(Appendix A). The inclusion criteria for the study were patients over the age of 18 undergoing 
curative and palliative treatment for oesophagogastric adenocarcinoma. Patients were 
identified at the Northern Oesophagogastric cancer MDT in the Royal Victoria infirmary, 
Newcastle upon Tyne. Patients eligible for the study were approached prior to their surgical 
treatment. The study was discussed and a patient information sheet was provided to the 
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patient. Patients were included into the study following completion of the consent form 
(Appendix B) with the principal investigator. Blood samples were obtained prior to surgery and 
at 48-72 hours post surgery. Bone marrow from the rib excised as a routine part of an open 
oesophagectomy was collected at the time of surgery. Pathological data was obtained from 
the resected tumour. Follow up data regarding the patients was collected from clinic visits and 
the Northern Oeosophagogastric unit database. Table 6.2.1.1 illustrates the demographics of 
the patient’s recruited into the study and the clinical stage of the tumour.  
Identifier  
Number Age Sex Tumour Site Tumour Length Staging - T Staging - N Staging - M 
A1 65 F Distal Oesophagus 3 cm T3 N1 M0 
A3 54 M Mid-oesophagus 2 cm T2 N0 M0 
A4 59 M Junctional 8 cm T3 N1 M0 
A5 59 M Junctional 3 cm T3 N1 M0 
A6 69 M Distal Oesophagus 5 cm T3 N1 M0 
A7 56 M Distal Oesophagus 3 cm T3 N0 M0 
A8 49 M Distal Oesophagus 2 cm T1b N0 M0 
A9 62 M Junctional 5 cm T4a N1 M0 
A10 62 M Junctional 5 cm T4a N1 M0 
A11 68 F Distal Oesophagus 9 cm T3 N0 M0 
A12 75 M Distal Oesophagus 5 cm T3 N1 M0 
A13 66 F Junctional 2 cm T3 N2 M0 
A14 66 M Distal Oesophageal 3 cm T3 N0 M0 
Table 5.2.1.1: The demographics and the clinical stage of the tumour at presentation in patients 
with oesophageal cancer undergoing curative treatment 
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A15 59 M Junctional 2 cm T3 N2 M0 
A16 64 M Junctional 7 cm T4a N1 M0 
A17 60 M Distal oesophagus 5 cm T3 N1 M0 
A18 66 M Distal oesophagus 3 cm T1b Nx Mx 
A19 64 M Distal Oesophagus 3 cm T1b N0 M0 
A20 81 M Distal Oesophagus 3 cm T2 N0 M0 
A21 67 M Distal Oesophagus 8 cm T3 N1 M0 
A22 67 M Distal Oesophagus 5 cm T4 N0 M0 
A23 73 M Distal Oesophagus 6 cm T4 N2 M0 
A24 69 M Junctional 7 cm T4 N1 M0 
A25 73 M Distal Oesophagus 3 cm T1b N0 M0 
A26 65 M Distal Oesophagus 6 cm T3 N1 M0 
A27 62 M Distal Oesophagus 3 cm T3 N0 M0 
A28 49 M Distal Oesophagus 5 cm T3 N2 M0 
A29 56 M Distal Oesophagus 2 cm T1a N0 M0 
A30 80 M Junctional 6 cm T3 N0 M0 
A31 66 M Junctional 5 cm T3 N0 M0 
A32 66 M Distal Oesophageal 7 cm T3 N1 M0 
A33 67 M Junctional 5 cm T3 N2 M0 
A34 70 M Distal Oesophageal 6 cm T1a N0 M0 
A35 67 M Junctional 6 cm T4 N2 M0 
A36 75 M Distal Oesophagus 3 cm T3 N3 M0 
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A37 57 M Distal Oesophagus 6 cm T3 N2 M0 
A38 59 M Distal Oesophagus 4 cm Tx Nx M0 
A39 65 M Mid Oesophagus 4 cm T3 N3 M0 
A40 70 M Distal Oesophagus 5 cm T3 N1 M0 
 
A total of 39 patients undergoing planned curative resection for oesophageal adencocarcinoma 
were recruited into the study between 1st November 2016 to the 23rd August 2018. Patients 
underwent a standardized staging protocol and findings of which were discussed in a multi-
disciplinary team. Patient factors (eg medical co-morbidities) combined with the clinical stage 
of the tumour determined the subsequent treatment modality. One patient, A2 was excluded 
from the study after histology confirmed the diagnosis of squamous cell cancer made with 
biopsy specimen post recruitment. There are three cohort of patients as stated before. Tables 
5.2.1.2, 5.2.1.3 and 5.2.1.4 list the clinical and pathological stages of the tumours, operative 


























A3 T2 N0 Open T1a N0 0 41 No 
A8 T1b N0 Open T1a N0 0 39 No 
A18 T1b N0 Thoracoscopic T1a N0 0 34 No 
A19 T1b N0 Thoracoscopic T1a N0 0 36 No 
A20 T2 N0 Open T2 N1 2 54 Yes 
Table 5.2.1.2: Surgical and oncological outcomes for patients with clinical stage I and II cancer 
who underwent curative surgery alone 
* The clinical and pathological stage are based on the 8th edition AJCC guidelines. 
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A25 T1b N0 Thoracoscopic T1a N0 0 36 No 
A29 T1a N0 Open T1a N0 0 20 No 
A34 T1a N0 Open T1b N0 0 25 No 
A38 T1a N0 Open T1a N0 0 48 No 
 
Patients with clinical stage I and II cancer based on clinical staging underwent curative surgery 
alone. Three of the nine patients underwent a minimally invasive approach for the thoracic 
stage of the oesophagectomy. Three of the nine patients who had single modality based upon 
the clinical stage underwent a thoracoscopic oesophagectomy and as a consequence a rib 
sample was not obtained for these patients. Patient A20 was initially staged with T2 disease 
without nodal mestatases. However at the time of surgery there was evidence of nodal 
metastases (Table 5.2.1.2). This case illustrates the challenge in accurately staging nodal 


































A7 T3 N0 Open T3 N1 1 42 No 
A21 T3 N1 Open T3 N3 16 50 Yes 
A30 T3 N0 Open T3 N1 2 25 Yes 
A36 T3 N3 Open T3 N3 22 48 Yes 
Table 5.2.1.3: Surgical and oncological outcomes for patients with clinical stage III and III cancer 
who underwent curative surgery alone 
* The clinical and pathological stage are based on the 8th edition AJCC guidelines. 
* The clinical and pathological stage are based on the 8th edition AJCC guidelines. 
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At initial clinical staging only two of the four patients who had single modality treatment for 
locally advanced cancer because they were unfit for peri-operative chemotherapy had 
evidence of nodal disease. However, all the patients in this cohort had evidence of nodal 
disease in the resected specimen. In addition, two patients had evidence of nodal metastasis 







































A1 T3 N1 ECX 2 Open T3 N2 3 36 Yes 
A4 T3 N1 ECX 3 Open T3 N2 4 50 yes 
A5 T3 N1 ECX 1 Open T3 N2 4 34 Yes 
A6 T3 N1 ECX 1 Open T3 N0 0 25 No 
A9 T4a N1 ECX 3 Open T3 N1 1 50 No 
A10 T4a N1 ECX 3 Open T3 N0 0 22 No 
A11 T3 N0 ECX 3 Open T2 N0 0 24 No 
A12 T3 N1 ECX 3 Open T2 N1 1 33 No 
A13 T3 N2 ECX 2 Open T4a N1 1 49 Yes 
A14 T3 N0 ECX 3 Open T3 N1 1 27 Yes 
A15 T3 N2 ECX 
3 Thoracos
copic to 
open T4a N0 0 53 Yes 
A16 T4a N1 ECX 3 Open T1b N0 0 41 No 
A17 T3 N1 ECX 3 Open T4a N3 10 43 Yes 
Table 5.2.1.4: Surgical and oncological outcomes for patients with clinical stage III and IV cancer 
who underwent peri-operative chemotherapy and surgery  
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A22 T4 N0 ECX 3 Open T3 N2 5 32 Yes 
A23 T4 N2 ECX 3 Open T0 N0 0 98 No 
A24 T4 N1 ECX 3 Open T3 N1 1 36 No 
A26 T3 N1 Neo-AGIS 3 Open T3 N3 10 30 Yes 
A27 T3 N0 ECX 3 Open T3 N2 3 29 Yes 
A28 T3 N2 ECX 3 Open T3 N3 9 33 Yes 
A31 T3 N0 ECX 3 Open T1b N0 0 24 No 
A32 T3 N1 OEO2 2 Open T3 N0 0 34 Yes 
A33 T3 N2 ECX 3 open T1b N2 4 20 No 
A35 T4 N2 ECX 
3 Open and 
close           
A37 T3 N2 ECX 3 Open T3 N1 1 111 No 
A39 T3 N3 ECX 3 Open T3 N3 7 78 Yes 
A40 T3 N1 ECX 3 Open T3 N2 5 24 No 
 
A total of 25 patients underwent perioperative chemotherapy followed by surgery. Over 80% of 
the patients completed the peri-operative chemotherapy regime. Two patients received only 
one cycle of chemotherapy and three received two cycles of chemotherapy due to intolerance 
to the regime. Patients underwent a CT scan post peri-operative chemotherapy to assess the 
response of the primary tumour and lymph nodes to the treatment. Response evaluation 
criteria in solid tumours (RESCIST) was used to grade the response of the tumour to the 
chemotherapy regime. In three patients there was evidence of tumour progression following 
peri-operative chemotherapy. There was evidence of tumour regression in 32% (8) of patients 
* The clinical and pathological stage are based on the 8th edition AJCC guidelines 
** ECX chemotherapy regime (epirubicin, cisplatin, capecitabine). One patient was enrolled into the NEO-AGIS trail and 
was randomized to the peri-operative chemotherapy arm. One patient had cardiac co-morbidities and was unsuitable for 
the ECX (epirubicin, cisplatin, capecitabine) regime and hence received the OEO2 (cisplatin, fluorouracil) regime.  
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who received peri-operative chemotherapy. Patient 35 had evidence of liver metastases at the 
time of surgery and thus did not undergo resection.  Patient A23 had completed pathological 
response with no tumour being visible in the specimen. Only 28% (7) of patients had 
pathological evidence of tumour regression, TRG 3 or less at the time of resection. The majority, 
72% (18) patients had tumours which had either a poor or no response to the peri-operative 
chemotherapy regime.  
5.2.2 Circulating tumour cells in the pre and postoperative blood samples in patients 
undergoing curative resection for oesophagogastric cancer  
Circulating tumour cells in patients with oesophageal adenocarcinoma with the CellSearchR 
test. Konzalla et al evaluated CTCs in patients with non metastatic oesophageal 
adenocarcinoma (128). They identified CTCs in only 15 of 76 patients and reported that the 
presence of five or more CTCs was associated with poor survival. The CellSearchR test 
identifies a cell as a CTC if it meets the following criteria: positive expression of EpCAM, 
cytokeratins 8, 18 and/or 19 and negative expression of CD 45. This method does not take into 
account the morphological characteristics of CTCs, eg size, hyerpoloidy and the expression of 
other biomarkers, eg HER2, c Met. In addition, a cell is only classified as a CTC if it expressed 
both epithelial biomarkers, EpCAM and cytokeratins 8, 18+, and/or 19. CTCs which express 
which express only one of the epithelial biomarkers are excluded. Previous studies have 
demonstrated the presence of heterogeneity within the CTC population in patients with other 
solid organ tumours (154). In addition, there is evidence of heterogeneity within the cells in 
the primary tumour and lymph nodes of patients with oesophageal cancer (146). The 
CellSearchR test potentially underestimates the number of CTCs present and is unable to 
assess for heterogeneity of CTCs present within the blood.   
As described before, blood samples were obtained from patients 4-6 hours prior to surgery 
and between 48-72 hours postoperatively. Blood samples were processed in accordance with 
the CTC enumeration protocol and labelled with the antibodies as described in the material 
and methods chapter. The samples were analysed on the ImagestreamR high resolution 
imaging flow cytometer. There were three populations of cells were identified and classified as 
CTCs. CTCs that expressed biomarkers were divided into two populations. The first population 
of CTCs which expressed EpCAM and cytokeratins and the second population of CTCs which 
96 
expressed either one or more biomarkers present in the panel. CTCs which were biomarker 
positive consisted of 69% of the cells present. The third population of cells classified as CTCs 
did not express any of the biomarkers present in the panels but were morphologically 
different from white blood cells. This population of CTCs were larger in size and had increased 
nuclear content in comparison to the white blood cells present in the samples. CTCs were 
detected in all patients underwent curative treatment for oesophageal cancer and the 
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A39 – T3N3 – Peri-operative chemotherapy and surgery  
CTCs in pre-operative sample 
CTCs in postoperative sample 
Figure 5.2.2.1: Images of CTCs detected on the high resolution imaging flow cytometer in 
Patient A39 who received three cycles of ECX and underwent an open oesophagectomy for 
clinically staged T3N3 oesophageal adenocarcinoma.  
A: CTCs detected in the pre-operative sample B: CTCs detected in the postoperative sample. 
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In patient A39, 159 CTCs were detected in the pre-operative sample. There were two 
populations of CTCs present. One population of CTCs which expressed EpCAM and 
cytokeratins and accounted for 125 CTCs per 7.5 ml of blood. The second population 
expressed cytokeratins alone and accounted for 34 CTCs per 7.5 ml of blood. In the 
postoperative sample, the number of CTCs were higher than those present in the pre-
operative sample 200 CTCs per 7.5 ml of blood versus 159 CTCs per 7.5 ml of blood. Three 
population of CTCs were present. Majority of the CTCs (158) expressed EpCAM and 
cytokeratins. The second population of CTCs expressed cytokeratins and accounted for 13 
CTCs per 7.5 ml of blood. The third population of CTCs did not express any of the biomarkers 
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A36 – T3N3 – Surgery Alone 
CTCs in pre-operative sample 
CTCs in postoperative sample 
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In patient A 36, 33 CTCs per 7.5 ml of blood detected in the pre-operative sample. Nine CTCs 
per 7.5 ml of blood expressed Vimentin and cytokeratins and the remainder expressed EpCAM 
and cytokeratins. In the postoperative sample, all 52 CTCs per 7.5 ml of blood detected 
expressed EpCAM and cytokeratins.  
 
 
Figure 5.2.2.2: Images of CTCs detected on the high resolution imaging flow cytometer in 
Patient A36 who underwent an open oesophagectomy for clinically staged T3N3 
oesophageal adenocarcinoma.  
A: CTCs detected in the pre-operative sample B: CTCs detected in the postoperative sample. 
Figure 5.2.2.3: Images of CTCs detected on the high resolution imaging flow cytometer in 
Patient A20 who underwent an open oesophagectomy for clinically staged T2N0 
oesophageal adenocarcinoma.  
A: CTCs detected in the pre-operative sample B: CTCs detected in the postoperative sample. 
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In patient A20, 41 CTCs per 7.5 ml of blood were detected in the pre-operative sample of 
which 39 expressed EpCAM and cytokeratins and the remainder expressed cytokeratins and 
ERCC 1. In the postoperative sample, 121 CTCs per 7.5 ml of blood were present and all 
expressed cytokeratins only.  
The following figures illustrate the number of CTCs present in the pre and postoperative 
sample detected based on the clinical stage of the disease at the time of curative treatment 
and the biomarker expression of CTCs present. Figure 6.2.2.4 illustrates the number of CTCs 
detected in patients with early oesophageal cancer undergoing curative resection based on 
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All the patients had CTCs which were biomarker positive detected in either the pre and/or 
postoperative sample. There were six patients with early oesophageal adenocarcinoma who 
had cells which were biomarker negative. Of note, CTCs which expressed both EpCAM and 
cytokeratins were detected in only 4 out of 9 patients. Positive identification of CTCs based on 
the expression of both EpCAM and cytokeratins would have underestimated the number of 
CTCs present. With patient A19, approximately half the CTCs expressed both EpCAM and 
cytokeratins. In patient A20 the rise in the number of postoperative CTCs would not have been 
detected if CTCs were selected based on the expression of both EpCAM and cytokeratins. 
Approximately 67% of cells identified were biomarker negative and met the morphological 
criteria of CTCs in this group of patients.  
Figure 5.2.2.5 illustrates the number of CTCs detected in patients with locally advanced 































Figure 5.2.2.4 – The number of circulating tumour cells (CTC) in the pre-operative and 
postoperative blood sample in patients with Stage I and II cancer in 7.5 ml of blood based on 
biomarker expression.  
A: CTCs expressing EpCAM and CK biomarkers as per the CellSearchR selection criteria B: CTCs 
expressing EpCAM, CK, HER2, cMET, E-cadherin, N-cadherin, Thymidylate synthase, Vimentin C: 
Cells which are morphologically similar to CTCS but negative for epithelial and mesenchymal 
markers in the antibody panel and negative for the CD 45 biomarker. 
A 
EpCAM + cytokeratins 






In patient A21, the total number of CTCs detected was over 300 per 7.5 ml of blood in the pre 
and postoperative sample. Positive identification of CTCs based on the expression of both 
EpCAM and cytokeratins would have underestimated the number of CTCs present in all 4 
patients. In patient A30, the total number of CTCs detected was lower in the postoperative 
sample based on all biomarker expression. In this patient, the number of CTCs which met the 
expressed both EpCAM and cytokeratins increased in the postoperative sample. Furthermore, 
in three out of four patients the number of CTCs detected which expressed both EpCAM and 
cytokeratins increased in the postoperative sample. This difference in biomarker expression in 
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Figure 5.2.2.5 – The number of circulating tumour cells (CTC) in the pre-operative and 
postoperative blood sample in patients with Stage III and IV cancer who underwent surgery 
alone in 7.5 ml of blood.  
 
A: CTCs expressing EpCAM and CK biomarkers as per the CellSearchR selection criteria B: CTCs 




heterogeneity within the tumour cell population and raises the possibility of distant metastatic 
sites as a source of the CTCs. None of the patient had biomarker negative cells in this cohort. 
Figure 5.2.2.6 illustrates the number of CTCs detected in patients with locally advanced 
oesophageal cancer who received peri-operative chemotherapy and surgery based on 
biomarker expression. A pre-operative blood sample was not obtained for patient A6 due to 
medical reasons. Patient A 35 did not undergo a curative resection due to the presence of 
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There is a wide variation in the number of CTCs based on all biomarker expression detected in 
the pre-operative blood sample. Of note, the number of CTCs detected in some patients is 
comparable to the cohort of patients with early cancer. This could be attributed to the impact 
of peri-operative chemotherapy which downstages the cancer. CTCs which expressed both 
EpCAM and cytokeratins would only have been detected  in 58% (14/24) patients in both the 
pre and postoperative samples. Of interest, this cohort of patients had the highest number of 
CTCs which were biomarker negative. In patients A11 and A33, over 200 of these cells per 7.5 
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Figure 5.2.2.6 – The number of circulating tumour cells (CTC) in the pre-operative and 
postoperative blood sample in patients with Stage III and IV cancer who underwent peri-
operative chemotherapy and surgery in 7.5 ml of blood.  
A: CTCs expressing EpCAM and CK biomarkers as per the CellSearchR selection criteria B: CTCs 
expressing EpCAM, CK, HER2, cMET, E-cadherin, N-cadherin, Thymidylate synthase, Vimentin 
C: Cells which are morphologically similar to CTCS but negative for epithelial and mesenchymal 
markers in the antibody panel and negative for the CD 45 biomarker. 
*Patient A35 excluded from final analysis 
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5.2.3 Characterization of circulating tumour cells detected in patients undergoing curative 
resection for oesophagogastric cancer  
Characterizing the heterogenity within the tumour cells is of importance in understanding the 
molecular mechanisms of tumour evolution and to identify potential targets for therapeutic 
intervention. Previous studies have relied upon the CellSearchR  criteria which positively 
identifies a CTC based on the expression of both EpCAM and cytokeratins. This potentially 
results in only a proportion of CTCs present to be identified. In the study, eleven different 
biomarkers were used including EpCAM and cytokeratins to characterize the CTCs. A CTC was 
identified as biomarker positive if it expressed either one or more of the biomarkers present in 
the panel. CTCs were grouped into five individual populations based on biomarker expression. 
Figure 5.2.3.1 illustrates the heterogeneity within the CTCs detected in patients with Stage I 
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In this cohort of patients there was variation in the expression of biomarkers between the pre 
and postoperative blood sample. In the pre-operative blood samples, 50% of the CTCs 
expressed both EpCAM and cytokeratins, but this was the case in only 28% in the 
postoperative sample. There was a rise in the number of CTCs expressing cytokeratins. Less 
than 10% of CTCs expressed cytokeratins in the pre-operative sample. However, over 1/3 of 
the CTCs detected in the postoperative blood sample expressed cytokeratins. There was a rise 
in the number of biomarker negative cells between the pre and postoperative sample, 18% to 
28% respectively.   
Patient A19 underwent a thoracoscopic oesophagectomy for T1b oesophageal 
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Figure 5.2.3.1 – Heterogeneity of biomarker expression in CTCs detected in patients 
undergoing surgery alone for Stage I and II cancer. 
Biomarker expression in differentiated into five groups: EpCAM and Cytokeratin expression as 
per CellSearchR selection criteria, EpCAM alone, cytokeratin alone, Novel biomarkers +/- 
EpCAM +/- cytokeratins– HER2, c-Met, Vimentin, ERCC1, Thymidylate synthase, E-cadherin, N-
cadherin, TFF3, Novel biomarkers - HER2, c-Met, Vimentin, ERCC1, Thymidylate synthase, E-
cadherin, N-cadherin, TFF3 alone and CTCs which did not express any biomarker. A – CTCs 
detected in the pre-operative blood sample. B- CTCs detected in the postoperative sample at 
48-72 hours. 
 




Patient A19 had two of the sample population of CTCs which expressed novel biomarkers in 
both the pre and postoperative sample. CTCs which expressed c-Met and N-cadherin were 
present in both the pre and postoperative sample. However, CTCs which expressed 
60618
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/CD 45/DAPI
85405
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 VimentinCh01/E-cadherin/N cadherin/CK PE/DAPI
32461
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 VimentinCh01/E-cadherin/N cadherin/CK PE/DAPIBrig tfield              E-cadherin      Cytokeratins           -cadherin            EpCAM               DAPI                   CD45             Vimentin                  Composite 
72735
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/EpCAM/CK PE/DAPI
10 µm
40817
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/CK PE/EpCAM/Ch01/Ch01
32367
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/CK PE/EpCAM/Ch01/Ch01
Brightfield                 c-Met                      Cytokeratins                   HER 2                              EpCAM                      DAPI                           CD45                         Composite 
64464
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/CD 45/DAPI
10097
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/CK PE/EpCAM/DAPIBrightfield                 Thymidylate synthase      Cytokeratins           ER C 1                    EpCA                              DAPI                           CD45                                                Composite 
CTCs in postoperative sample 
16355
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/CD 45/DAPI
167285
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 VimentinCh01/E-cadherin/EpCAM/CK PE/DAPI
10 µm
182247
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/Vimentin/DAPI
227540
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 VimentinCh01/E-cadherin/EpCAM/CK PE/DAPI
36896
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/EpCAM/CK PE/Ch01/Ch01Brightfield                         c- et                       Cytokeratins                                                  EpCAM                      D                            CD45                         Composite 
96921
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/CD 45/DAPI
140915
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/TS/CK PE/DAPI
153110
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/TS/CK PE/DAPI
Brightfield                 Thymidylate synthase      Cytokeratins                ERCC 1                    EpCAM                             DAPI                           CD45                         TFF3                        Composite 
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Figure 5.2.3.2 – Images of CTCs detect in Patient A19 who underwent a thoracoscopic 
oesophagectomy for Stage I oesophageal cancer.  
A – Images of CTCs detected in the pre-operative blood sample. B – Images of CTCs detected in the 
postoperative blood sample at 48 hours  
Brightfield              E-cadherin          Cytokeratins           N-cadherin               EpCAM               DAPI                   CD45                    Vimentin                  Composite 
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thymidylate synthase was only present in the pre-operative sample. Of interest, the CTCs 
which expressed thymidylate synthase were present in clusters unlike the other CTCs present. 
There were biomarker negative CTCs present in the pre-operative sample but none in the 
postoperative sample. CTCs which expressed E-cadherin were present only in the 
postoperative sample. The presence of N-cadherin and E-cadherin expression in the CTCs in 
the postoperative sample indicate their origin from a distant site of possible metastases.   
Table 5.2.3.3 illustrates the heterogeneity of the novel biomarkers present in the CTCs within 
this cohort in the pre and postoperative sample. 
 




Total no of CTCs 
pre-operative 






Total no of CTCs 
postoperative sample 
– Novel biomarkers 
A18 Vimentin = 2 2   
A19 E-cadherin + Vimentin + 
EpCAM and cytokeratins 
= 3 
Vimentin + EpCAM and 
cytokeratins = 2 
c-Met = 2 
7 c-Met + EpCAM  = 
5 
E-cadherin + N-
cadherin + EpCAM 
and cytokeratins 
=  2 
N-cadherin + 
EpCAM and 
cytokeratins  = 3 
10 
A20 ERCC1 + cytokeratins= 3 3   
A25 N-cadherin = 17 17   
A29 HER2 + cytokeratins = 11 11   
Table 5.2.3.3 –The expression of novel biomarkers in CTCs in patients with Stage I and II 
oesophageal cancer undergoing surgery alone 
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A38 c-Met + EpCAM and 
cytokeratins = 5 
5   
In six of the nine patients with early oesophageal cancer, CTCs which expressed a wide range 
of epithelial and mesenchymal biomarkers were detected in the pre-operative blood sample. 
Majority of the CTCs expressed both a novel biomarker and/or EpCAM and/or cytokeratins. 
However these cells only accounted for a small proportion of the total CTC population in each 
sample. Only one patient had CTCs which expressed novel biomarkers in both the pre and 
postoperative sample. Patient A19 had different population of CTCs which expressed the novel 
biomarkers in the pre and postoperative sample  
Figure 5.2.3.4 illustrates the heterogeneity within the CTCs detected in patients with Stage III 
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There were only four patients in this cohort and over 80% of the CTCs detected in this cohort 
were present in patients A21 and A30. In the pre-operative sample, 50% of the CTCs detected 
expressed both EpCAM and cytokeratins. Of note, there is marked variation in the biomarker 
expression in CTCs detected in the pre-operative sample compared to the postoperative 
samples. The total no of CTCs increased in three out of the four patients in the postoperative 
sample. However in the postoperative sample only 40% of the CTCs detected expressed both 
EpCAM and cytokeratins. There was rise in the number of CTCs expressing novel biomarker 
and an epithelial biomarkers and in CTCs expressing cytokeratins alone. This finding suggests 
that the source of CTCs in the postoperative sample in the body could be independent of the 
primary tumour. Thus these CTCs are likely to originate from a distant metastatic site. The 
population of CTCs expressing novel biomarkers rose between the pre and postoperative 
sample, 15% to 19%. Figure 5.3.5 illustrates images of CTCs detected in patient A21.
CellSearch, 302, 40%
EpCAM , 15, 2%
Cytokeratins, 298, 39%
Novel Biomarker + Epithelial 
biomarker, 148, 19%
Figure 5.2.3.4 – Heterogeneity of biomarker expression in CTCs detected in patients undergoing 
surgery alone for Stage III and IV oesophageal cancer who underwent surgery alone.  
Biomarker expression in differentiated into five groups: EpCAM and Cytokeratin expression as per 
CellSearchR selection criteria, EpCAM alone, cytokeratin alone, Novel biomarkers +/- EpCAM +/- 
cytokeratins– HER2, c-Met, Vimentin, ERCC1, Thymidylate synthase, E-cadherin, N-cadherin, 
TFF3, Novel biomarkers - HER2, c-Met, Vimentin, ERCC1, Thymidylate synthase, E-cadherin, N-
cadherin, TFF3 alone and CTCs which did not express any biomarker. A – CTCs detected in the pre-








In Patient A21, two populations of CTCs were detected in the pre-operative sample. One 
population expressed cytokeratins and the other expressed EpCAM and cytokeratins. 
However, in the postoperative sample, there were two different population of CTCs identified. 
One population of CTCs expressed cytokeratins and the other populations consisted of CTCs 
that expressed EpCAM, cytokeratins and HER2.  
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Figure 5.2.3.5 – Images of CTCs detect in Patient A21 who underwent an open 
oesophagectomy for Stage III oesophageal cancer.  
A – Images of CTCs detected in the pre-operative blood sample. B – Images of CTCs detected 
in the postoperative blood sample at 48 hours  
CTCs in postoperative sample 
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Figure 5.2.3.6 illustrates the heterogeneity of the novel biomarkers present in the CTCs within 
this cohort in the pre and postoperative sample. 
 




Total no of 
CTCs/7.5 ml of 
blood pre-






Total no of CTCs 
/7.5 ml of blood 
postoperative 
sample – Novel 
biomarkers 
A7    HER2 + EpCAM = 
25 
27 
A21 Vimentin + 
cytokeratins = 74 
74 HER2 + EpCAM 
and cytokeratins 
* = 121 
121 
A30 Thymidylate synthase + 
EpCAM and 
cytokeratins = 23 
23   
A36 Vimentin + 
cytokeratins = 6 
6   
*A21 Post op panel C sample lost due to technical reasons 
 
Novel biomarkers were detected in three patients in the pre-operative sample.  
Patient A30 had CTCs which expressed thymidylate synthase, EpCAM and cytokeratins. Patient 
A21 and A36 had CTCs which expressed vimentin and cytokeratins. However, there were no 
CTCs detected which expressed the novel biomarkers in the postoperative samples in patient 
A30 and A36. Patients A7 and A21 had CTCs which expressed HER2 in the postoperative 
sample.  
Figure 5.2.3.6 – The expression of novel biomarkers in CTCs in patients with Stage III and IV 
oesophageal cancer undergoing surgery alone 
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Figure 5.2.3.7 illustrates the heterogeneity within the CTCs detected in patients with Stage III 
and IV oesophageal cancer who underwent surgery alone. 












































In this cohort of patients, 36% of the CTCs detected were biomarker negative in the pre and 
48% of CTCs in the postoperative samples. This high number could be attributed to the impact 
of peri-operative chemotherapy in downstaging the tumour. Tumour regression grade 
indicates response of the primary tumour to the peri-operative chemotherapy. Tumour 
regression grade three or less indicates a good response to chemotherapy and is a positive 
prognostic factor. Correlation with the tumour regression grade (TRG) and the number of 
biomarker negative cells in the pre operative blood sample using Kruskall Wallis test did not 
reveal a significant difference (p=0.19). However, in the postoperative samples patients with a 
TRG grade less than 3 had a significantly higher number of biomarker negative cells than those 
who TRG 4 or greater (p=0.03). This finding suggests that there more biomarker negative cells 
in patients who have a good response to peri-operative chemotherapy.  
The fall in the population of CTCs expressing the novel biomarkers between the pre and 
postoperative sample was similar to the cohort of patients who had locally advanced cancer 
who underwent surgery alone. Figure 6.3.9 illustrate images of CTCs present in patient A14 
who received peri-operative chemotherapy and surgery. 
Figure 5.2.3.8 illustrates the heterogeneity of the novel biomarkers present in the CTCs within 
this cohort in the pre and postoperative sample 
 
Figure 5.2.3.8 – The expression of novel biomarkers in CTCs in patients with Stage III and IV 
oesophageal cancer who received peri-operative chemotherapy and surgery.  
Figure 5.2.3.7 – Heterogeneity of biomarker expression in CTCs detected in patients undergoing 
surgery alone for Stage III and IV oesophageal cancer who received peri-operative chemotherapy 
and surgery.  
Biomarker expression in differentiated into five groups: EpCAM and Cytokeratin expression as per 
CellSearchR selection criteria, EpCAM alone, cytokeratin alone, Novel biomarkers +/- EpCAM +/- 
cytokeratins– HER2, c-Met, Vimentin, ERCC1, Thymidylate synthase, E-cadherin, N-cadherin, TFF3, 
Novel biomarkers - HER2, c-Met, Vimentin, ERCC1, Thymidylate synthase, E-cadherin, N-cadherin, 
TFF3 alone and CTCs which did not express any biomarker. A – CTCs per 7.5 ml of blood detected in 
the pre-operative blood sample. B- CTCs per 7.5 ml of blood detected in the postoperative sample 
at 48-72 hours. 
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Total no of 










Total no of CTCs/7.5 ml of 
blood postoperative 
sample – Novel 
biomarkers 
A6 No pre-op sample   HER2 = 15 15 
A9 ERCC 1 = 37 
Vimentin = 6 
43 c-Met = 10 10 
A10 HER2 + EpCAM = 17 17   
A11 Thymidylate synthase + 
cytokeratins 
14   
A12 Thymidylate synthase + 
cytokeratins = 3 
c-Met + cytokeratins = 
26 
29 Thymidylate 
synthase = 7 
7 
A13 c-Met + cytokeratins = 
31 
31   
A14 E-cadherin + EpCAM  = 
38 
HER2 + cMet + EpCAM = 
35 
HER2 + Cytokeratins = 11 
Thymidylate synthase + 
EpCAM= 3 
87 E-cadherin + EpCAM 
= 53 
HER2 + EpCAM = 21 
74 
116 
A16 HER2 + EpCAM and 
cytokeratins = 32 
32 HER2 + EpCAM and 
cytokeratins = 18 
18 
A17 Vimentin + EpCAM and 
cytokeratins = 13  
13 Thymidylate 
synthase + EpCAM 
and cytokeratins = 8 
8 
A24 HER2 + EpCAM + 
cytokeratins = 26 
26   
A26 Vimentin = 16 16   
A27 Vimentin = 1 1 Vimentin + EpCAM 
and cytokeratins = 5 
5 
A31   c-Met = 3 4 
A33   HER2 + EpCAM and 
cytokeratins = 3 
4 
A40 No pre-op sample  HER2 + EpCAM and 
cytokeratins = 85 
85 
 
A greater proportion of the patients had CTCs which expressed HER2 were present in this 
group of patients, four in the pre-operative and five in the postoperative sample. However, in 
patients A6 and A 40 no pre-operative sample was present in Panel B. Therefore presence of 





5.2.4 Characterisation of biomarker negative circulating tumour cells in patients undergoing 
curative resection for oesophagogastric cancer 
The high resolution imaging flow cytometer allows individual cells to be characterized based 
on a number of criteria. The size and shape of the cells can be analysed based on their surface 
area and diameter. An additional benefit of the high resolution imaging flow cytometer is the 
ability to quantify the intensity of immunofluorescence of individual biomarkers. Hyperploidy 
within a cell can be analysed and quantified the intensity of the nuclear stain. Quantification of 
the intensity of immunofluorescence of individual biomarkers further aids in the isolation and 
identification of CTCs within the blood. The IDEAS software is able to differentiate populations 
of CTCs based on difference in the intensity of individual biomarkers and the associated 
immunofluorescence.  
Figure 5.2.4.1 illustrates images of these cells in comparison to white blood cells and CTCs 




































CTCs in postoperative sample 
253541
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/DAPI/CD 45
138500
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/DAPI/CD 45
33689
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/CK PE/EpCAM/DAPI
10 µm
263297
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/EpCAM/CK PE/Ch01/Ch01
10 µm
Brightfield              E-cadherin      Cytokeratins           N-cadherin            EpCAM               DAPI                   CD45             Vimentin                  Composite 
58024
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/CD 45/DAPI
15903
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/EpCAM/CK PE/HER 2/DAPI
10 µm
5775
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/EpCAM/CK PE/HER 2/DAPIBrightfield                 c-Met                      Cytokeratins                   HE  2                       EpCAM                      DAPI                           CD45                         Composite 
93838
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/DAPI/CD 45
208114
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/DAPI/CD 45
55259
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/EpCAM/CK PE/DAPI
10 µm
Brightfield                 Thymidylate synthase      Cytokeratins           ERCC 1                    EpCAM                      DAPI                           CD45                         TFF3                        Composite 
14998
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/DAPI/CD 45
30527
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/DAPI/CD 45
130274
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/EpCAM/CK PE/DAPI
10 µm
A33 T3N2 – Peri-operative chemotherapy and Surgery 
CTCs in pre-operative sample 
139908
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/CD 45/Ch01
16007
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/DAPI
78387
Ch01 cMET CK PE HER 2 EpCAM DAPI CD 45 Ch01/CD 45/Ch01
10 µm
Brightfield                 c-Met                      Cytokeratins                   HER 2                       EpCAM                      DAPI                           CD45                         Composite 
40008
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/DAPI/CD 45
79185
Ch01 E-cadherin CK PE N cadherin EpCAM DAPI CD 45 Vimentin Ch01/DAPI/CD 45
65518
Ch01 TS CK PE ERCC1 EpCAM DAPI CD 45 TFF 3 Ch01/CK PE/EpCAM/DAPI
10 µm
Brightfield              E-cadherin      Cytokeratins           N-cadherin            EpCAM               D I                   CD45             Vimenti                   Composite 
Brightfield                 Thymidylate synthase      Cytokeratins           ERCC 1                    EpCAM                      DAPI                           CD45                         TFF3                        Composite 
119 
 
Figure 5.2.4.2 illustrates the difference in size between the three populations of cells identified 
in the blood.  




























CTCs which expressed a biomarker were significantly larger in size in comparison to white 
blood cells (p=<0.05) and cells which were biomarker negative (p=<0.05). The cells which were 
biomarker negative were significantly larger than white blood cells (p= 0.039). The presence of 
hyperpolidy within a cell can be evaluated by quantifying the intensity of the DAPI nuclear 
stain. This analysis enables characterisation of CTCs independent of the biomarker expression. 
Figure 5.2.4.3 illustrates the differences in the DNA nuclear content between the three 
populations of cells.  
Figure 5.2.4.1 Images of CTCs identified in the pre-operative and postoperative blood sample 
in patient A33.  
A: CTCs which express biomarker, B: CTCs which are biomarker negative C: white blood cells  
 
Figure 5.2.4.2 – The surface area of the three populations of cells detected in the blood in 
patients undergoing curative treatment of oesophageal cancer.  
The mean surface area of the CTC which were biomarker positive was 320 µm2. The mean 
surface area of CTCs which were biomarker negative was 196 µm2 and mean surface area of 











These analyses enabled the identification of cells within all three cohorts of patients that were 
morphologically similar to CTCs but did not express biomarkers.  
The biomarker negative cells were similar in size to the biomarker positive CTCs but their 
nuclear density was higher.  
Figure 5.2.4.4 illustrates the number of biomarker negative cells identified in the blood in 
patients undergoing curative treatment for oesophageal adencarcinoma based on the clinical 
stage of disease.  
Figure 5.2.4.3– Graph comparing the nuclear density of the three populations of cells 
detected in the blood in patients undergoing curative treatment of oesophageal cancer. 
Biomarker negative cells had a higher nuclear content in comparison to biomarker positive and 




In the early cohort, biomarker negative CTCs were detected in the pre-operative sample in 
44% (4/9) patients and in the postoperative sample in 44% (4/9) patients. There was a higher 
proportion of patients with biomarker negative CTCs in the postoperative sample than in the 
pre-operative sample with Stage III and IV cancer who received peri-operative chemotherapy 
and surgery, 50% (12/24) versus 38% (9/24). The total number of biomarker negative CTCs 
detected was higher in the postoperative sample. However, majority of the biomarker 
negative CTCs detected in the postoperative sample were present in Patient A33 who had 486 
biomarker negative CTCs per 7.5 ml of blood in the pre-operative sample, which accounted for 
54% of the CTCs detected. In the postoperative sample, there 1035 biomarker negative CTCs 
per 7.5 ml of blood which accounted for 53% CTCs detected. In the 7 out of the 8 remaining 
patients, the number of biomarker negative CTCs decreased between the pre and 
postoperative sample. 
There was a variation in the number of biomarker negative CTCs detected in the three cohorts 
of patients in the study. There was only one patient with Stage III and IV cancer who 
Stage I + II Stage III + IV 
Figure 5.2.4.4 Number of biomarker negative CTCs in 7.5 ml of blood detected in the pre and 
postoperative sample in patients undergoing curative treatment for oesophageal 




underwent surgery alone who had biomarker negative CTCs. Patients with Stage III and IV 
disease who received per-operative chemotherapy had a higher proportion of biomarker 
negative CTCs. Biomarker negative CTCs were present in 10 patients (48%) with locally 
advanced cancer who received peri-oeprative chemotherapy and surgery.   
Previous studies have identified CTCs in patients with oesophageal adenocarcinoma based on 
the postive expression of epithelial biomarkers. The presence of biomarker negative cells has 
not been previously described before in patients with oesophageal adenocarcinoma. The cells 
could represent CTCs undergoing EMT transition and not express the epithlial and 
mesenchymal biomarkers in the study. Further characterisation of these cells could be 
identified with the detection of transcriptions factors, eg SNAIL1, SNAIL2. In addtion, the next 
step will be to isolate this population of cells and sequence the genes to identify the molecular 
origin of the cells.  
 
5.2.5 Characterization of disseminated tumour cells detected in patients undergoing 
curative resection for oesophagogastric cancer  
Disseminated tumour cells were isolated from bone marrow of the rib section that is excised 
as part of an open oesophagectomy. Of the nine patients with early oesophageal cancer, six 
underwent an open oesophagectomy and bone marrow samples from the rib section was 
obtained for these patients. The other three patients underwent a thoracoscopic 
oesophagectomy.  
Figure 5.2.5.1 illustrates the images of CTCs identified in the pre and postoperative blood 
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Figure 5.2.5.2 illustrates the presence of two different CTC populations between the pre- and 
postoperative sample. CTCs detected in the pre-operative sample expressed both EpCAM and 
cytokeratins and CTCs in the postoperative sample expressed cytokeratin only. DTCs in the 
bone marrow expressed cMET alone and cytokeratins alone. This could explain the origin of 
CTCs in the postoperative sample originating from the bone marrow.  
Figure 5.2.5.2 illustrates the biomarker expression in the disseminated tumour cells isolated in 

















































Figure 5.2.5.1– Images of circulating tumour cells in the blood and disseminated tumour cells in 
the bone marrow of excised rib in patient A34 who underwent an open oesophagectomy for 
Stage I cancer.  
A: Biomarker positive CTCs detected in the pre and postoperative blood sample. B: white blood 
cells in the pre and postoperative blood sample C: Biomarker negative cells in the pre and 
postoperative blood sample D: DTCs detected in the bone marrow from the excised rib. E: white 
blood cells detected in the bone marrow from the excised rib 
80/110 CTCs detected in the pre-operative blood sample expressed cytokeratin and EpCAM. Three 
populations of DTCs identified in the bone marrow. DTCs which expressed c-Met alone, 
cytokeratins alone and large biomarker negative cells. There were two population of CTCs in the 
postoperative sample, one population expressed EpCAM and cytokeratins and the other were 
biomarker negative.  
EpCAM and cytokeratins 
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Patients A3, A20 and A34 had a higher number of DTCs in comparison to the other patients in 
the cohort. Patient A34, there were two populations of DTCs identified. Patient A3, had three 
populations of DTCs. The first population consisted of DTCs expressed EpCAM alone, the 
second population of DTCs expressed EpCAM and HER2 and the third population expressed 
EpCAM and cytokeratin.  
All four patients with clinical stage III and IV cancer underwent open oesophagectomy as the 
as their mainstay of curative treatment. Figure 5.2.5.3 illustrates images of CTCs and DTCs 
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Figure 5.2.5.2– The number of disseminated tumour cells in the bone marrow in patients with 
Stage I and II cancer who underwent an open oesophagectomy.  
A - DTCs that express EpCAM and cytokeratins biomarkers as per the CellSearchR test B: DTCs that 
express EpCAM, C: DTCs that express cytokeratins, D: DTCs that express novel biomarkers +/- 






CTCs in the pre-operative blood samples expressed cytokeratins alone and in the postoperative 
sample expressed EpCAM and cytokeratins. There were two population of DTCs present, one 
population expressed EpCAM and cytokeratins and the other expressed EpCAM, cytokeratins 
and Vimentin. There are two different populations of DTCs present in the bone marrow in 
patient A36. The biomarker expression in the postoperative CTCs is similar to the DTCs detected 
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Figure 5.2.5.3– Images of circulating tumour cells in the blood and disseminated tumour cells 
in the bone marrow of excised rib in patient A36 who underwent an open oesophagectomy 
for Stage III cancer.  
A: CTCs which are biomarker positive B: white blood cells in the blood. C: DTCs detected in the 
bone marrow which are biomarker positive, D: white blood cells in the bone marrow. 
CTCs in postoperative sample 
DTCs in bone marrow of excised rib 
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in the bone marrow. Of interest, only one population of CTCs were detected in the 
postoperative sample which expressed EpCAM and cytokeratins.  
Figure 5.2.5.4 illustrates the number of disseminated tumour cells identified in each patient.  
 
 
There was no significant difference in the number of biomarker positive DTCs in the bone 
marrow between patients with early and locally advanced oesophageal cancer who 
underwent surgery alone, comparison with Mann Whitney test p=0.992. The majority of DTCs 
detected in this cohort expressed both EpCAM and cytokeratins. DTCs which expressed 
cytokeratins alone were not detected.  
Twenty-four patients with Stage III and IV oesophageal cancer underwent an open 
oesophagectomy following peri-operative chemotherapy. Figure 5.2.5.5 illustrates the number 
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Figure 5.2.5.4– The number of disseminated tumour cells in the bone marrow in patients with 
Stage III and IV cancer who underwent an open oesophagectomy.  
A - DTCs that express EpCAM and cytokeratins biomarkers as per the CellSearchR test B: DTCs that 
express EpCAM, C: DTCs that express cytokeratins, D: DTCs that express novel biomarkers +/- 





There was a wide variation in the number of DTCs detected in this cohort of patients. In a 
proportion of the patients the number of DTCs detected was similar to patients with early 
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Figure 5.2.5.5– The number of disseminated tumour cells in the bone marrow in patients with 
Stage III and IV cancer who recrieved peri-operative chemotherapy and underwent an open 
oesophagectomy.  
A - DTCs that express EpCAM and cytokeratins biomarkers as per the CellSearchR test B: DTCs that 
express EpCAM, C: DTCs that express cytokeratins, D: DTCs that express novel biomarkers +/- 









Four populations of CTCs were detected in the three panels in the pre-operative sample: CTCs 
which expressed EpCAM alone, CTCs which expressed EpCAM and HER2, CTCs which 
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Figure 5.2.5.6– Images of circulating tumour cells in the blood and disseminated tumour cells in the 
bone marrow of excised rib in patient A14 who received peri-operative chemotherapy and 
underwent an open oesophagectomy for Stage III cancer.  
A: Biomarker positive CTCs detected in the pre and postoperative blood sample. B: white blood cells 
in the pre and postoperative blood sample C: Biomarker negative cells in the pre and postoperative 
blood sample D: DTCs detected in the bone marrow from the excised rib. E: white blood cells detected 
in the bone marrow from the excised rib 
DTCs in bone marrow of excised rib 




expressed E-cadherin and EpCAM and CTCs which expressed cytokeratins and HER2. This 
sample highlights the heterogeneity of biomarker expression present in the CTCs in the blood. 
The presence of different biomarkers in the three panels aids in the characterization of the 
heterogeneity. It is possible that the CTCs which express EpCAM in panel C are part of the 
same population present in panel B in which they express EpCAM and HER2 and in the panel A 
in which they expressed E-cadherin and EpCAM. 
In the bone marrow, there were five different population of DTCs present: DTCs which 
expressed EpCAM alone, DTCs which expressed cytokeratins alone, DTCs which expressed 
HER2 alone, DTCs which expressed EpCAM, cytokeratins and HER2 and DTCs which expressed 
ERCC1 alone.  
In the postoperative sample, there were four different populations of CTCs present: CTCs 
which expressed cytokeratins and HER2, CTCs which expressed cytokeratins alone, CTCs which 
expressed E-cadherin and EpCAM and CTCs which were biomarker negative.  
The preceding data suggests that the potential origin of the CTCs in the postoperative sample 
is from the bone marrow. Further correlations of the biomarker expression in DTCs and CTCs 
























Table 5.2.5.7: Table comparing the biomarkers expression of DTCs in the bone marrow in the rib 
and CTCs in the pre and postoperative sample in patients underwent an open oesophagectomy 
for Stage I and II oesophageal cancer 
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CD 45 - CD 45 - 
A20 EpCAM and cytokeratins 
Cytokeratins 
ERCC 1 + Cytokeratins 
EpCAM and cytokeratins 
Cytokeratins 
E Cadherin 





HER2 + Cytokeratins 
EpCAM  
Cytokeratins 





cMET + Cytokeratins 
Vimentin + Cytokeratins 










HER2 + Cytokeratins 
EpCAM and cytokeratins 
 
 
CD 45 - 
There was evidence of two or more different population of DTCs present in the bone marrow 
based on biomarker expression in this group of patients. In three out of the six patients, the 
biomarker expression in the pre and post-operative CTCs were similar. Patients A34 and A38 
had CTCs in the pre-operative sample which expressed two or more different biomarkers 
when compared to the post-operative CTCs which expressed only one biomarker. In two 
patients, A3 and A20 the CTCs in the post-operative sample expressed the same biomarkers as 
those present in the DTCs in the bone marrow.  
132 
Table 5.2.5.8 illustrates the biomarker expression in DTCs in the bone marrow and CTCs in the 
pre and post-operative sample in patients who underwent an open oesophagectomy for Stage 





Biomarker Expression DTC Biomarker Expression Post-
op CTC 
A7 EpCAM and cytokeratins 
 
 
EpCAM and cytokeratins 
EpCAM 
Cytokeratins 
EpCAM and cytokeratins 
EpCAM 
Cytokeratins 
HER2 + EpCAM 
A21 EpCAM and cytokeratins 
 
 
Vimentin + Cytokeratins 
EpCAM and cytokeratins 
 
 
HER2 + Cytokeratins 
EpCAM and cytokeratins 
Cytokeratins 
 
HER2 + EpCAM and 
cytokeratins 
A30 EpCAM and cytokeratins 
Cytokeratins 
Thymidylate synthase + 
EpCAM 
+ Cytokeratins 
EpCAM and cytokeratins 
 
HER2 





Vimentin + Cytokeratins 
EpCAM and cytokeratins 
 
Vimentin + Cytokeratins 




Table 5.2.5.8: Table comparing the biomarkers expression of DTCs in the bone marrow in the rib 
and CTCs in the pre and postoperative sample in patients underwent an open oesophagectomy for 
Stage III and IV oesophageal cancer 
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In three out of the four patients in this cohort, the biomarker expression was similar between 
the DTCs in the bone marrow and CTCs in the pre and post-operative sample. Furthermore, 
the biomarker expression of at least one population of CTCs in the post-operative sample and 
DTCs was the same in all four patients. In patients A7, A20 and A36, CTCs which expressed 
EpCAM and cytokeratins were present in the pre and post-operative sample and in the DTCs in 
the bone marrow.  
Table 5.2.5.9 illustrates the biomarker expression in DTCs in the bone marrow and CTCs in the 
pre and post-operative sample in patients who received peri-operative chemotherapy and 
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Table 5.2.5.9: Table comparing the biomarkers expression of DTCs in the bone marrow in the rib 
and CTCs in the pre and postoperative sample in patients who received peri-operative 
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ERCC 1, Vimentin 
CD 45 - 
TFF3 cMET 
CD 45 - 
A10  
 
HER2 + EpCAM 
CD 45 - 
Cytokeratins 





CD 45 - 
A11  
 
Thymidylate synthase + 
Cytokeratins 
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cMET+ Cytokeratins 






















cMET + Cytokeratins Thymidylate synthase  
A14 EpCAM 
 
HER2 + Cytokeratins 
E Cadherin + EpCAM  
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E Cadherin + EpCAM 
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A16 EpCAM and cytokeratins 
 





EpCAM and cytokeratins 
Cytokeratins 




EpCAM and cytokeratins 
 
Vimentin + EpCAM and 
cytokeratins 
EpCAM and cytokeratins 
Cytokeratins 
Vimentin 
EpCAM and cytokeratins 
Cytokeratins 





CD 45 - 
EpCAM and cytokeratins 
HER2 
EpCAM and cytokeratins 
 
Thymidylate synthase + 
EpCAM and cytokeratins 




EpCAM and cytokeratins 
 
EpCAM and cytokeratins 
 
CD 45 - 
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A24 EpCAM and cytokeratins 
HER2 + EpCAM and 
cytokeratins 
CD 45 - 
EpCAM and cytokeratins 
 
EpCAM and cytokeratins 
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HER2 + EpCAM 
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A39 EpCAM and cytokeratins 
Cytokeratins 
EpCAM and cytokeratins 
 
EpCAM and cytokeratins 
Cytokeratins 
CD 45 - 
A40 EpCAM and cytokeratins 
Cytokeratins 
No panel B 
EpCAM and cytokeratins 
 
Thymidylate synthase 
EpCAM and cytokeratins 
 
HER2 + EpCAM 
As described in the previous cohort of patients, there were multiple populations of DTCs 
present in the bone marrow and CTCs in the blood. In twenty out of twenty-three patients 
there was at least one population of CTCs in the postoperative sample with the same 
biomarker expression as a population of DTCs in the bone marrow. In four patients in this 
cohort, the expression of the novel biomarkers (HER2, vimentin, thymidylate synthase) was 
*A35 excluded  - metastatic disease at time of surgery and no resection was performed 
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similar between the DTCs and the CTCs in the postoperative sample. In thirteen patients, the 
biomarker expression of the CTCs of at least one population of cells in the pre-operative 
sample were similar to the cells present in the postoperative sample. However, only in 9 out of 
the 13 patients, there was at least one population of DTCs present in the bone marrow which 
expressed the same biomarkers as those present in the pre and postoperative sample.  In 
most of these patients, only the epithelial biomarkers (EpCAM, cytokeratins) remain similar 
between the CTCs in the pre and postoperative blood sample and the DTCs in the bone 
marrow. There is variation in the expression of the novel biomarkers between the three sites. 
There were biomarker negative cells in the postoperative sample in 12 out of the twenty three 
patients in comparison to only 9 out of twenty three patients in the pre-operative sample. In 8 
patients, biomarker negative cells were present in both the pre and post-operative sample.  
Kruskall Wallis analysis was performed to determine the statistical correlation of biomarker 
expression. There was no significant correlation in the biomarker expression between the pre-
operative CTCs, DTCs in the bone marrow and postoperative CTCs in patients undergoing 
treatment for early cancer (p=0.470) and locally advanced cancer who received peri-operative 
chemotherapy and surgery (p=0.655). There was a significant correlation in patients with 
locally advanced cancer who underwent surgery alone (p=<0.05). This could indicate that the 
CTCs in these patients are originating from the bone marrow rather than the primary tumour 
and thus the population of CTCs remain in the postoperative sample following resection of the 
primary tumour. Definitive conclusions are difficult due to the small cohort of patients.  
Further analysis of interest would be to compare the biomarker expression in the primary 
tumour and lymph nodes to the CTCs in the blood sample and the DTCs in the bone marrow. 
This analysis may aid in identifying the origin of the CTCs present in the circulation. In addition, 
sequencing the individual populations of CTCs and DTCs present after selection based on their 
biomarker expression would help understand the origin of these cells.   
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5.2.6 Characterisation of the morphology and biomarker expression of disseminated tumour 
cells in the bone marrow in patients undergoing curative resection for oesophagogastric 
cancer  
Two population of cells were identified within the bone marrow that from samples obtained 
from patients undergoing elective orthopaedic surgery. The first population consisted of cells 
which expressed the CD45 biomarker. The second population consisted of cells which were 
biomarker negative and smaller in size than the CD45 positive cells. Both these cell 
populations were present in the bone marrow from the rib section resected in all the cancer 
patients in the study. Figure 6.2.6.1 illustrates the difference in surface area of the three 








The majority of the DTCs were larger in size than the cells which expressed CD 45 biomarker 
and the cells which were biomarker negative (p=0.244). Furthermore, there was a wide 
variation in the surface area of the DTCs present in the bone marrow.  
Figure 5.2.6.1– The surface areas of the three populations of cells detected in the bone marrow 
in patients undergoing curative treatment of oesophageal cancer 
The three populations of cells were identified in the bone marrow obtained from the rib. The first 
population consisted of cells which expressed either one or more of the biomarkers present in the 
panel and classified as DTCs. The second population consisted of cells which were biomarker 
negative and the third population consisted of cells which expressed the CD45 biomarker.  
 




























5.2.7  Association between oncological outcomes and the presence of circulating and 
disseminated tumour cells in patients undergoing curative treatment for oesophagogastric 
cancer 
Prognostic factors which determine survival following curative surgery are determined by the 
pathological findings on the resected specimen. They are a measure of the success of the 
curative treatment that the patient has received. There are surgical guidelines that determine 
the quality of the surgery based on two pathological findings (155). Patients undergoing 
curative resection should have a minimum of 15 lymph nodes excised to stage accurately the 
tumour and a R0 resection status should be achieved which indicates that the resection 
margins are clear of tumour invasion. Standardized operative technique combined with radical 
lympadenectomy achieves this goal. The pathologist grades the specimen on the following 
criteria: pathological stage of the tumour, lymph node yield, resection margin, lymphovascular 
invasion (LVI) and tumour regression grade in patients who have received peri-operative 
chemotherapy. Each of these criteria are independent prognostic markers of survival in 
patients undergoing curative treatment for oesophagogastric cancer.  
 In the early cancer cohort, there were nine patients who were staged clinically with ≤ T2 
disease with no evidence of nodal metastases at the time of surgery. Post resection, one 
patient had evidence of nodal metastases. This patient would have been considered for peri-
operative chemotherapy at the time of surgery if the nodal metastases had been identified at 
the time of clinical staging. In the cohort of patients who had locally advanced cancer who 
underwent surgery alone, all four patients had evidence of nodal disease following resection. 
Nodal metastases had been identified in two of these patients at the time of clinical staging. 
These three cases highlight the challenges in identifying nodal metastases with the current 
staging modalities. The median lymph node yield in the study was 33 (24-105). A R0 resection 
margin was achieved in all patients undergoing curative resection. Figure 5.2.7.1 and Figure 
5.2.7.2 illustrate the correlation between the number of biomarker positive circulating tumour 













Figure 5.2.7.1– Number of biomarker positive CTCs per 7.5 ml of blood in the pre-operative 
blood sample and the clinical stage of the disease 
All the patient in the early cancer cohort were stage at T2 or < with no evidence of nodal disease. 
In the locally advanced cancer cohort, there were 7 patients with T4 disease who received peri-
operative chemotherapy and surgery of which only one patient had evidence of N3 disease.  
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There was no significant difference in the number of CTCs in the pre-operative blood sample 
between the clinical or pathological tumour stage disease (p=0.087). However, the number of 
postoperative CTCs was higher in patients in whom the primary tumour was staged 
pathologically as T3 or > compared to primary tumour staged ≤ T2 disease (p=0.002). There 
was no significant difference in the number of CTCs detected in the pre-operative blood 
sample in patients with and without nodal metastases (p=0.655). Figure 5.2.7.3 illustrates the 
correlation between the number of biomarker positive DTCs in the bone marrow and the 
pathological stage of the disease.  
  
Figure 5.2.7.2– The number of biomarker positive CTCs per 7.5 ml of blood in the pre-operative 
blood sample and the pathological stage of the disease 
Eight out of the nine patients in the early cancer cohort had T1 disease with no evidence of nodal 
metastases. All the patients in the locally advanced cancer cohort who underwent surgery alone 
had T3 disease and in two patients there was extensive nodal disease. Six out of the twenty-six 
patients who received peri-operative chemotherapy and surgery had downstaging of the primary 
tumour and in one patient there was no tumour visible in the specimen.  
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Patients with T3 disease or > had higher number of DTCs in the bone marrow when compared 
to patients early stage cancer ≤ T2 disease in the cohort (p=0.032). Three patients with locally 
advanced cancer who received peri-operative chemotherapy and surgery had similar number 
of DTCs in the bone marrow when compared to patients with early clinical stage cancer. 
Patients with nodal disease had a higher number of DTCs than patients who did not have any 
evidence of nodal metastases (p=0.041). The presence of lymphovascular invasion (LVI) in the 
primary tumour is associated with poor prognosis. Figure 5.2.7.4 illustrates the correlation 
between the number of biomarker positive CTCs in the pre-operative and postoperative blood 
and the LVI status of the resected specimen.   
Figure 5.2.7.3– The number of biomarker positive disseminated tumour cells in the bone 
marrow from the rib and pathological stage of the disease 
There were six patients in the early cohort, four patients in the locally advanced cohort who 
underwent surgery alone and twenty-three in the locally advanced cohort who received peri-
operative chemotherapy and surgery who underwent an open oesophagectomy.  
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There was no significant difference between the number of biomarker positive CTCs in the 
pre-operative sample in patients in whom the primary tumour had evidence of 
lymphovascular invasion versus patients in whom the primary tumour did not (p=0.115). The 
number of biomarker positive CTCs in the postoperative sample was significantly higher than 
in patients in whom the primary tumour had evidence of lymphovascular invasion (p=0.007). 
Presence of lymphovascular invasion is an indication of haematogenous and spread of the 
primary tumour. Such a spread could lead to metastases which could explain the presence of 
micro metastases in this cohort of patient and thus explain the higher number of CTCs in the 
postoperative sample despite resection of the primary tumour. Figure 5.2.7.5 compares the 
number of number of biomarker positive DTCs in patients based on the LVI status of the 
primary tumour.  
 
Figure 5.2.7.4– The number of biomarker positive CTCs in the pre and postoperative blood 
samples in patients based on the LVI status of the primary tumour 
There was no evidence of lymphovascular invasion in the primary tumour in patients with early 
oesophageal cancer. Fifteen patients with locally advanced cancer had evidence of 
lymphovascular in the primary tumour. The statistical differences between the two groups was 
tested with Kruskall Wallis test.  
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The number of biomarker positive DTCs in the bone marrow in rib was higher in patients in 
whom the primary tumour had evidence of lymphovascular invasion (p=0.001). Positive 
association between the postoperative CTCs and positive LVI status of the primary tumour 
in this group patients reflects the greater number of DTCs being present in the bone marrow 
which acts as reservoir for the tumour cells.   
Figure 5.2.7.6 illustrates the correlations between the number of biomarker positive CTCs in 
the pre-and postoperative blood sample and the tumour regression grade in patients with 
locally advanced cancer who received peri-operative chemotherapy and surgery.  
 
Figure 5.2.7.5 – The number of biomarker positive DTCs in the bone marrow in rib with the 
lymphovascular invasion status of the primary tumour 
There was no evidence of lymphovascular invasion in the primary tumour in patients with early 
oesophageal cancer. Fifteen patients with locally advanced cancer had evidence of 
lymphovascular invasion in the primary tumour. The statistical differences between the two 
groups was tested with Kruskall Wallis test.  
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There was no significant difference between the number of CTCs in the pre-operative sample 
in patients who had a good response to perioperative chemotherapy compared to patients 
with a TRG 4-5 (p=0.344). This applied to the postoperative sample as well (p=0.223). Figure 
5.2.7.8 illustrates the correlation between the tumour regression grade and the number of 
DTCs present in the bone marrow.  
Figure 5.2.7.6– A: Graph comparing the number of pre-operative and postoperative 
biomarker positive CTCs based on tumour regression grade of the primary tumour 
In sixteen patients (67%), the primary tumour was graded at TRG 4-5 which indicated a poor 
response to peri-operative chemotherapy. The statistical differences between the two 
groups was tested with Kruskall Wallis test.  
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There was no significant difference between the number of DTCs in the bone marrow of 
patients who had good response to peri-operative chemotherapy and those who did not 
(p=0.445). The objectives of peri-operative chemotherapy are to reduce both the local and 
distant burden of the disease. In combination with surgery, there is an improvement in disease 
free survival. Poor response to chemotherapy at the distant metastatic sites is one reason that 
could be responsible for the early relapse in this cohort of patients.  
 
Figure 5.2.7.7– The number of biomarker positive DTCs in the bone marrow and the tumour 
regression grade of the primary tumour 
 Eight out of twenty-three patients who received perioperative chemotherapy and an open 
oesophagectomy had good response to the peri-operative chemotherapy. The statistical 




5.2.8 Prognostic significance of circulating and disseminated tumour cells in patients 
undergoing curative treatment for oesophagogastric cancer 
Patients recruited into the study were followed up as part of the protocol for the Northern 
oesophagogastric unit. Patients were reviewed in clinic at three month intervals in the first 
year following surgery, six monthly intervals in the second year and annually for the next three 
years. There is no current evidence for the incorporation of routine imaging in patients with 
oesophagogastric cancer during the follow up period. In addition, there are no established 
tumour markers which can be monitored during the follow up period. Patients undergo 
imaging investigations during the follow up period if they develop clinical symptoms which 
may indicate recurrence of the cancer, eg progressive weight loss, dysphagia.  
Of the 39 patients recruited into the study, there was one in hospital mortality and another 
patient had metastatic disease at the time of surgery. Both of whom were in the cohort who 
received peri-operative chemotherapy and surgery. Follow up of the patients in the study is 
ongoing. The following data on disease free survival is calculated during the period between 
December 2016 to October 2019. The last patient was recruited into the study in March 2018. 
The minimum follow up period is 19 months.  
Only one patient in the early cancer cohort developed recurrence. However, patient A20 had 
evidence of nodal disease at the time of surgery. This patient had locally advanced cancer and 
clinical staging did not identify the presence of nodal disease. The final pathological stage 
would be Stage III. 
Three out of the four patients with locally advanced cancer who underwent surgery alone 
developed recurrence during the follow up period.  
Only 52% (12) of the patients with Stage III and IV cancer received adjuvant chemotherapy 
following peri-operative chemotherapy and surgery. Fourteen of the twenty-three patients 
who received peri-operative chemotherapy and surgery developed recurrence in the follow up 
period. Seven of these patients completed adjuvant chemotherapy.  
Figure 5.2.8.1 illustrates the Kaplan Meir curves of two year disease free survival of the three 













There was no significant difference in disease free survival in patients with stage III and IV 
disease who received peri-operative chemotherapy and surgery versus surgery alone 
(p=0.234). Disease free survival at two years in the early cohort was 89%. Of note, this 
included patient A20 who had locally advanced disease and relapsed during the follow up 
period. Current literature predicts five year disease free survival at 80% in patients with Stage I 
and II oesophageal cancer.  
Current prognostic markers which predict recurrence are the pathological nodal status, 
tumour regression grade and the presence of lymphovascular invasion (LVI). There was no 
incidence of lymphovascular invasion in patients with Stage I and II disease. Three out of the 
four patients with Stage III and IV disease who underwent surgery alone had evidence of 
lymphovascular invasion in the specimen. Thirteen out of twenty-four patients with Stage III 
and IV cancer who received peri-operative chemotherapy had evidence of lymphovascular 
invasion in the specimen. Six of these patients received adjuvant chemotherapy. Figure 5.2.8.2 
Figure 5.2.8.1. Kaplan Meir curves of two year disease free survival based on the clinical 
stage of the disease between the three cohort of patients 
The median disease free survival in the Stage III and IV patients who underwent surgery 
alone was 21 months and 23.5 months in Stage III and IV patients who received peri-
operative chemotherapy and surgery.  
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illustrates Kaplan Meir analysis of two year disease free survival based on the presence of 
lymphovascular invasion in the primary tumour.  
 
 
The presence of lymphovascular invasion was a significant prognostic factor in disease free 
survival (p=0.008).  
Only one patient in the early cancer cohort had evidence of nodal involvement following 
resection. Eight patients with Stage III and IV disease who received peri-operative 
chemotherapy and surgery had no evidence of macroscopic nodal involvement following 
surgery. In this cohort, there was one patients who had complete pathological response with 
no macroscopic evidence of tumour in the resected specimen. The remaining fifteen patients 
who received perioperative chemotherapy and surgery: six had N1 disease, five had N2 
disease and four had N3 disease. All the patients with Stage III and IV disease who underwent 
surgery alone had evidence of nodal disease: two patients had N1 and two patients had N3 
disease. Figure 5.2.8.3 illustrates Kaplan Meir analysis of two year disease free survival based 
on the presence of nodal metastases. 
Figure 5.2.8.2. Kaplan Meir curve of two year disease free survival based on the presence of 
lymphovascular invasion in the pathological specimen 
The median survival in patients with the presence of lymphovascular invasion in the pathological 










There was a significant difference in disease free survival between patients with node negative 
when compared to patients with node positive disease (p=0.023).  
Figure 5.2.8.4 illustrate the Kaplan Meir analysis of two year disease free survival based on the 







Figure 5.2.8.3. Kaplan Meir curve of two year disease free survival based on the pathological 
nodal status following resection 
The median disease free survival in patient with N1 and N2 nodal disease was 11 months. All 




The two year disease free survival was higher in patients with tumour regression grade 3 or 
less which indicates a good response to peri-operative chemotherapy.  
Patients were stratified into cohorts based on the number of CTCs present in blood in the pre 
and postoperative sample. The number of CTCs in each cohort was not normally distributed. 
The median number of CTCs per 7.5 ml of blood which expressed biomarkers in the pre-
operative blood sample was 30 (2-93) and 31 (4-137) in the postoperative sample in patients 
with early oesophageal cancer. In the locally advanced cohort, the median number of CTCs per 
7.5 ml of blood which expressed biomarkers in the pre-operative blood sample was 84 (5-284) 
and 86 (4-428) in the postoperative sample in patients with locally advanced cancer. Based on 
this data, the patients were divided into four cohorts based on the number of CTCs per 7.5 ml 
of blood which expressed a biomarker present in the pre and postoperative sample: less than 
or equal to 49 CTCs, 50-99 CTCs, 100 to 149 CTCs and greater than 150 CTCs. Figure 5.2.8.5 
and Figure 5.2.8.6 illustrates the Kaplan Meir survival analysis based on these four cohort of 
patients.  
Figure 5.2.8.4. Kaplan Meir curve of two year disease free survival based on the Mandard tumour 
regression grade 
Sixteen of the twenty-three patients in this cohort had evidence of poor response to 
chemotherapy, tumour regression grade 4 or higher. The median disease free survival in this 






Figure 5.2.8.5. Kaplan Meir analysis of two year disease free survival based on the number of 
CTCs per 7.5 ml of blood present in the pre-operative blood sample in patients who underwent 
curative treatment for oesophageal cancer 
The median survival in patients with less than 49 CTCs per 7.5 ml of blood and 50 – 100 CTCs per 
7.5 ml of blood was not reached, 100-149 CTCs per 7.5 ml of blood was 22 months and 150 or 
more CTCs per 7.5 ml of blood was 16 months. There was no significant difference between the 




Eighteen patients had fewer than 49 CTCs per 7.5 ml of blood in the pre-operative sample. Of 
these eighteen patients, eight had early cancer and two had locally advanced cancer and 
underwent surgery alone. The remaining eight patients had received peri-operative 
chemotherapy and surgery. In the pre-operative sample, there was no difference in survival 
between patient who had less than 100 CTCs per 7.5 ml of blood and patients who had more 
than 100 CTCs per 7.5 ml of blood (p=0.408). In the postoperative sample, eight out of the 
eighteen patients with less than 50 CTCs per 7.5 ml of blood had early oesophageal cancer. 
The remaining ten patients received peri-operative chemotherapy and surgery for locally 
advanced cancer.  
All the patients with Stage I and II cancer based on the pathological specimen had less than 50 
CTCs per 7.5 ml of blood in the blood. There was a significant difference in survival in patients 
who had more than 100 CTCs and those who had less than 100 CTCs per 7.5 ml of blood in the 
post-operative sample (p=0.002). Kaplan Meir survival analysis was performed based on the 
expression of epithelial biomarkers in CTCs in the pre and postoperative sample.  
There was no difference in survival based on expression of individual epithelial biomarkers in 
CTCs in the pre-operative sample (p=0.488). However, in 50% of patients there were two 
different populations of CTCs in the pre-operative sample which expressed epithelial 
biomarkers (EpCAM and/or cytokeratins). Twenty-five patients had only one population of 
CTCs which expressed an epithelial biomarkers, of which ten patients had CTCs which 
expressed both EpCAM and cytokeratins. Figure 5.2.8.7 illustrates Kaplan Meir analysis of two 
year disease free survival comparing the two cohort of patients described.  
 
 
Figure 5.2.8.6 Kaplan Meir analysis of two year disease free survival based on the number of 
CTCs per 7.5 ml of blood present in the post-operative blood sample in patients who 
underwent curative treatment for oesophageal cancer 
The median survival in patients with less than 49 CTCs per 7.5 ml of blood was not reached, 
50-99 CTCs per 7.5 ml of blood was 31 months, 100-149 CTCs per 7.5 ml of blood was 11 
months and 150 or more CTCs per 7.5 ml of blood was 13.5 months. There was a significant 




The presence of two or more populations of CTCs which expressed epithelial biomarkers in the 
pre-operative sample was associated with a significant decrease in disease free survival 
(p=0.043).  
In the postoperative sample, 48% of the patients had only one population of CTCs which 
expressed epithelial biomarkers of which 59% of patients had CTCs which expressed EpCAM or 
cytokeratins.  
Figure 5.2.8.8 illustrate Kaplan Meir analysis of two year disease free survival based on the 
number of populations of CTCs present in each postoperative sample.  
Figure 5.2.8.7. Kaplan Meir survival analysis of two year disease free survival based on the number 
of populations of CTCs which express either individual or multiple epithelial biomarkers in the pre-
operative blood sample 
The presence of two or more populations of CTCs which expressed epithelial biomarkers was 










In the postoperative sample, the number of patients with two or more populations of CTCs 
which expressed epithelial biomarkers was the same as in the pre-operative sample. However, 
there was no significant difference in disease free survival between the two cohort of patients 
based on the expression of epithelial biomarkers by CTCs in the postoperative sample 
(p=0.198).  
The most common novel biomarkers detected in CTCs in the pre and postoperative samples 
were HER2 and c-Met. There were six patients in the pre-operative sample who had CTCs 
which expressed HER2, four of whom received peri-operative chemotherapy and surgery. 
Patient A14 had two populations of CTCs both of which expressed HER2, one population 
expressed HER2 and cytokeratins and the other expressed EpCAM and HER2. There were 
seven patients with CTCs that expressed HER2 in the postoperative sample. Two of these 
patients had CTCs that expressed HER2 in the pre-operative sample. Two patient, A6 and A40 
had CTCs which expressed HER2 in the postoperative sample but no pre-operative blood 
sample was available to make a direct comparison. Patient A33 had CTCs that expressed HER2 
Figure 5.2.8.8. Kaplan Meir analysis of two year disease free survival based on the number of 
populations of CTCs which express either individual or multiple epithelial biomarkers in the 
postoperative blood sample 
There were 17 patients who had two or more population of CTCs which expressed two or more 
different epithelial biomarkers. The median survival in group of patients with two or more 








in the postoperative sample but was excluded from the final survival analysis due to in hospital 
mortality. Figure 5.2.8.9 illustrates the survival based on the CTC expression of HER2 in the pre 















The two year disease free survival was not significantly different in patients with CTCs which 
expressed HER2 in either the pre (p=0.208) or postoperative samples (p=0.314).  
Three patients had CTCs which expressed cMET in the pre-operative sample, two of whom 
received peri-operative chemotherapy and surgery. Only two patients had CTCs which 
expressed cMET in the postoperative sample. Figure 5.2.8.10 illustrates the Kapalan Meir 




Figure 5.2.8.9. Kaplan Meir analysis of two year disease free survival based on the expression 
of HER2 in CTCs.  
A: Pre-operative blood sample B: Postoperative blood sample 
Three out of the four patients with CTCs which expressed HER2 in the pre-operative sample 
relapsed in 20 months or less following surgery. The median time to relapse was 11 months. In 
the postoperative sample, five out of the seven patients relapsed during the follow up period. 





In both the pre and postoperative samples, there was no difference in disease free survival 
between patients who had CTCs that expressed c-Met versus patients with CTCs which did not.  
Thirty-two (82%) patients underwent an open oesophagectomy of whom six patients had early 
oesophageal cancer and twenty-two patients received peri-operative chemotherapy and 
surgery for locally advanced cancer. As stated in the previous section, DTCs were detected in 
all patients undergoing curative treatment for oesophageal cancer. The number of DTCs 
detected in each cohort varied and there was heterogeneity in biomarker expression within 
the DTC populations. Figure 5.2.8.11 illustrate the Kaplan Meir analysis of two year disease 
free survival based on the different populations of DTCs detected in each bone marrow 
sample.  
Figure 5.2.8.10. Kaplan Meir analysis of two year disease free survival based on the expression of 
c-Met in CTCs. 
 A: Pre-operative blood sample B: Postoperative blood sample 
 
              
               










There was no difference in survival based on the expression of either individual or multiple 
biomarkers in DTCs in the bone marrow (p=0.767).  
Twenty-two patients had populations of DTCs which expressed one or more of the novel 
biomarkers. Figure 5.2.8.12 illustrate the Kaplan Meir survival analysis based on the expression 







Figure 5.2.8.11. Kaplan Meir analysis of two year disease free survival based on the expression 
of epithelial biomarkers by DTCs in the bone marrow 
Nine patients (28%) had DTCs which expressed both EpCAM and cyokeratins (CellSearchTM 
criteria) alone. Seven patients (22%) of patients had two populations of DTCs which expressed 
epithelial markers, one population expressed cytokeratins alone and the other EpCAM alone.   
 
EpCAM and cytokeratins 
EpCAM and cytokeratins + cytokeratins 
alone 




There was no significant difference in survival between patients who had DTCs which 
expressed an epithelial and a novel biomarker compared to patients with DTCs which 
expressed epithelial biomarkers only (p=0.968). Figure 5.2.8.13 illustrate Kaplan Meir survival 










No significant difference in survival was present between the different populations of DTCs 
that expressed novel biomarkers.  
Figure 5.2.8.12. Kaplan Meir analysis of two year disease free survival based on DTCs which 
express epithelial and novel biomarkers versus DTCs which express epithelial biomarkers alone 
Twenty-two (69%) of patients had DTCs which expressed both epithelial and novel biomarkers. The 
median survival in this cohort of patients was 18 months versus 31 months in patients who had DTCs 
which expressed epithelial biomarkers.    
 
Figure 5.2.8.13. Two year disease free survival based on DTCs which express the novel biomarkers: 
HER2, Vimentin, Thymidylate Synthase 
Nine patients (41%) had DTCs that expressed HER2 only and two patients had DTCs that expressed 
HER2 and vimentin. Five patients (23%) had DTCs that expressed Vimentin and four patients (18%) 
had DTCs that expressed thymidylate synthase. The median survival in patients with DTCs which 
expressed HER2 was 13 months and thymidylate synthase was 10.5 months.  
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5.2.9 Circulating tumour cells in patients with early recurrence following curative treatment 
Fourteen out of the twenty-three patients who received peri-operative chemotherapy and 
surgery relapsed in the follow up period. The median time to recurrence in this cohort was 20 
months. Patient A10 received peri-operative chemotherapy and surgery for a junctional 
oesophageal adenocarcinoma. Postoperative histology indicated a good response to 
chemotherapy and no evidence of nodal metastases. The patient developed local recurrence 
confirmed radiologically within five months of surgery and presented with malignant pleural 
effusion. Figure 5.2.9.1 illustrates images of the CTCs identified in the pre and postoperative 
sample, CTCs identified in the blood at the time of recurrence and tumour cells in the pleural 
effusion.   
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In the pre-operative blood sample, 58 CTCs per 7.5 ml of blood were identified of which 17 
expressed EpCAM and HER2 and the remainder did not express any of the biomarkers in the 
panels.  
In the postoperative sample, there were 40 biomarker negative CTCs per 7.5 ml of blood 
identified. There were 52 CTCs per 7.5 ml of blood that were biomarker positive in the blood 
sample taken following recurrence: 16 CTCs expressed EpCAM, cytokeratins and vimentin and 
the remainder all expressed EpCAM and cytokeratins. There were two populations of tumour 
cells identified in the pleural effusion, one populations expressed EpCAM and cytokeratin and 
the other expressed E cadherin, EpCAM and cytokeratins.  
Patient A10 had low numbers of CTCs in both the pre and postoperative samples. In addition, 
there was no evidence of poor prognostic factors based on the pathology. Early relapse at the 
site of surgery in combination with the presence of a malignant pleural effusion indicates 
transcoelomic spread of the tumour. Of interest, one population of CTCs in the blood and the 
tumour cells in pleural effusion share similar biomarker expression. This evidence suggests 
that one population of CTCs may orginate from the pleural metatastes.  
Patient A20 underwent an open oesophagectomy for early oesophageal cancer, clinical stage 
was T2N0. However, there was evidence of nodal spread at the time of surgery and the 
pathological stage was T2N1. The patient relapsed within two months of surgery with 
evidence of pleural effusion and local recurrence. Figure 5.2.9.2 illustrates images of the CTCs 
identified in the pre and postoperative blood samples and CTCs identified in the blood at the 
time of recurrence. 
Figure 5.2.9.1. Images of CTCs in the blood – pre-operative, postoperative sample and at the 
time of recurrence, DTCs in the bone marrow of excised rib and tumour cells in the pleural 
effusion detected in patient A 10  
A: Biomarker positive CTCs detected in the blood from pre-operative sample, postoperative 
sample and taken at time of relapse B: white blood cells in the blood from pre-operative sample, 
postoperative sample and taken at time of relapse C: Biomarker negative CTCs detected in the 
blood from pre-operative sample, postoperative sample and taken at time of relapse D: Biomarker 
positive DTCs in the bone marrow of excised rib E: white blood cells in the bone marrow of excised 














In the pre-operative blood sample, 49 CTCs per 7.5 ml of blood were identified of which 45 
expressed EpCAM and cytokeratins. There two populations of DTCs in the bone marrow, one 
expressed cytokeratin alone and the other expressed EpCAM and cytokeratins. In the 
postoperative sample, there were 171 CTCs per 7.5 ml of blood which expressed cytokeratin 
only. Blood sample taken at the time following recurrence, identified approximately 76 CTCs 
per 7.5 ml of blood which expressed EpCAM and cytokeratins. Pleural sample was not 
obtained for this patient and thus correlation with the tumour cells in the effusion is not 
possible. The number of CTCs in the blood sample at the time of recurrence was lower than in 
the immediate postoperative period. However, there was a different population of CTCs 
present in the blood at this point when compared to the immediate postoperative period. The 
presence of DTCs which expressed both EpCAM and cytokeratin could indicate the origin of 
the CTCs from this site.  
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Figure 5.2.9.2. Images of CTCs in the blood in the pre-operative sample, postoperative sample 
and in blood after radiological evidence of relapse in patient A20 
A: Biomarker positive CTCs detected in the blood from pre-operative sample, postoperative 
sample and taken at time of relapse B: white blood cells in the blood from pre-operative sample, 
postoperative sample and taken at time of relapse C: Biomarker negative CTCs detected in the 
blood from pre-operative sample, postoperative sample and taken at time of relapse 
CTCs in the blood sample post recurrence 
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5.3 Discussion 
Two studies detected CTCs in only 20% of patients undergoing treatment for oesophageal 
adenocarcinoma (128, 129). In these studies, cells in the blood were classified as CTCs if they 
expressed both EpCAM and cytokeratins. The high resolution imaging flow cytometer enables 
the detection of cells in the blood based on the morphology of the cells and the expression of 
either individual or multiple biomarkers. Cells in the study were classified as a CTC if they 
expressed one or more epithelial and/or mesenchymal and/or novel biomarkers and/or 
morphologically similar to CTCs based on surface area and hyperpolidy. CTCs were detected in 
all patients undergoing curative treatment for oesophageal adenocarcinoma independent of 
the stage of the tumour based on this classification criteria. There were five populations of 
CTCs identified based on biomarker expression. In the pre-operative sample, positive 
expression of both EpCAM and cytokeratins were present in 50% of CTCs in patients with early 
cancer who underwent surgery alone, 50% of CTCs in patients with locally advanced cancer 
who underwent surgery alone and 25% of CTCs in patients with locally advanced cancer who 
received peri-operative chemotherapy and surgery alone. In the post operative sample, 
positive expression of both EpCAM and cytokeratins were present in 28% of CTCs in patients 
with early cancer who underwent surgery alone, 40% of CTCs in patients with locally advanced 
cancer who underwent surgery alone and 30% of CTCs in patients with locally advanced cancer 
who received peri-operative chemotherapy and surgery alone expressed both EpCAM and 
cytokeratins. The second most abundant population of CTCs expressed EpCAM only, the third 
population of CTCs expressed cytokeratins only and the fourth population expressed the novel 
biomarkers (HER2, thymidylate synthase, c-Met, Vimentin) and/or an epithelial biomarker. The 
fifth population of CTCs identified consisted of cells which did not expressed any biomarker 
but were morphologically similar to CTCs. In patients who received peri-operative 
chemotherapy and surgery, the cells accounted for 36% of the total CTC population in the pre-
operative sample and were present in 10 patients.  In the postoperative sample, 12 patients 
had biomarker negative CTCs in the blood and they accounted for 48% of CTCs detected in this 
group.    
Patients with advanced disease based on both clinical and pathological staging had a higher 
number of CTCs in the blood and DTCs in the bone marrow. LVI is a prognostic factor in 
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survival. The number of CTCs in the postoperative blood sample and DTCs in the bone marrow 
were higher in patients with evidence of lymphovascular invasion in the lymph nodes 
(p=0.223)(p=0.051). Patients with poor response to peri-operative chemotherapy based on the 
TRG 4-5 have a higher number of CTCs in the postoperative sample (p=0.344). Both these 
observations indicate the presence of micrometastases in these patients and one can 
postulate that the postoperative CTCs are arising from a site of distant metastases. 
In previous studies, the presence of one or more CTCs was reported to be of prognostic 
significance in patients undergoing curative treatment for oesophageal adenocarcinoma. In 
these studies, cells are classified as CTCs if they expressed both EpCAM and cytokeratins. In 
this study, CTCs are classified based on their morphology, size, nuclear density and individual 
biomarker expression. As a consequence, the number of CTCs detected is higher than 
documented previously. Furthermore, there was no significant difference in the number of 
CTCs in the pre-operative sample between patients with early and locally advanced cancer 
according to clinical stage. Differentiating between these two groups of patients based on 
individual number of CTCs in the preoperative sample alone is not possible. The rise or fall in 
number of CTCs between the pre and postoperative sample provides important prognostic 
information. The number of CTCs in the postoperative sample was higher in patients in who 
the primary tumour had evidence of lymphovascular invasion (p=0.007).  
Approximately 61% of patients with locally advanced cancer who received peri-operative 
chemotherapy and surgery relapsed within two years.  Prognostic information was 
determined from the results based on the presence of CTCs in the blood and DTCs in the bone 
marrow combined with the presence of heterogeneity within these populations. Patients with 
two or more different population of CTCs based on epithelial biomarker expression was 
associated with a significant reduction in two year disease free survival in the pre-operative 
blood sample (p=0.043). The presence of heterogeneity within the CTC population reflects the 
complex interaction between the primary tumour and the surrounding environment. 
Improved understanding of the morphology of the CTCs will aid in identifying the origin of the 
cells and their role in tumour development. In addition, detection of novel biomarkers such as 
HER2 and c-Met could identify potential therapeutic targets for peri- operative and adjuvant 
treatment for oesophageal adenocarcinoma.  
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Minimally invasive surgery in oesophageal cancer has been shown to be associated with lower 
number of CTCs in the intra and postoperative period. In this study, three patients underwent 
minimally invasive surgery. There was no difference in the number of CTCs detected between 
the minimally invasive and open cohort of patients in this study.  
The prognostic significance of the change in the number of CTCs in the postoperative period 
remains unknown. Previous studies have documented a rise in the CTCs in the immediate 
postoperative period being associated with poor prognosis in patients undergoing curative 
treatment for lung, gastric and colorectal cancer (156-158). However, studies with a longer 
follow up period have shown that the CTC levels fall and return to levels similar or less than in 
the pre-operative period (159). In the present study, patients with over 100 CTCs per 7.5 ml of 
blood in the postoperative blood sample had a significantly lower two year disease free 













Chapter 6: Circulating and disseminated tumour cells in patients undergoing 
palliative treatment for oesophagogastric cancer 
6.1 Introduction 
The majority of patients with oesophagogastric cancer present with disease that is not 
amenable to curative treatment. There are three main reasons why curative treatment is not 
considered. Firstly, the disease is locally advanced with the tumour invading adjacent 
structures and/or there is the presence of nodal involvement outside the surgical resection 
field. Secondly, there are distant metastases present commonly in the lung, liver or bone. A 
proportion of patients who are diagnosed with distant metastases present with symptoms 
secondary to the presence of metastatic disease, eg ascites secondary to peritoneal disease. 
Thirdly, patients who are unfit for radical curative treatment due to their medical co-
morbidities. The main aims of palliative treatment are to alleviate symptoms related to the 
cancer, reduce the systemic burden of the disease and improve survival. Palliative treatment 
modalities are focused on achieving these three main aims. Palliative chemotherapy aims to 
treat local and systemic disease. Chemotherapy regimens can vary dependant on the 
histological subtype of the tumour and its location. Patients with metastatic junctional 
oesophagogastric and gastric adenocarcinoma undergo HER2 testing of the primary tumour 
consequent to the results of the TOGA trial (51). The TOGA trial showed a survival benefit with 
trastuzumab and chemotherapy versus chemotherapy alone, in patients with metastatic 
junctional oesophageal adenocarcinoma with HER2 overexpression of the primary tumour, 
median survival 13.8 months versus 11.1 months. Palliative radiotherapy aims to treat the 
primary cancer within the oesophagus or oesophagogastric junction.  The aim is to reduce the 
size of the tumour and improve symptoms of dysphagia. Radiotherapy is used in the 
emergency setting to treat bleeding arising from the primary tumour. Other palliative 
treatment modalities aim to manage the symptoms that arise as a result of metastatic disease. 
The ascites secondary to peritoneal disease which is treated with paracentesis. A stent will 
alleviate the symptoms of dysphagia caused by an obstructing oesophageal cancer. A 
proportion of patients with medical co-morbidities present with metastatic oesophagogastric 
cancer. Poor functional status and the presence of co-morbidities preclude this group of 
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patients from receiving palliative chemotherapy and/or radiotherapy. Symptom control with 
medication is the mainstay of treatment.  
6.2 Results 
6.2.1 Circulating tumour cells in patients with advanced oesophagogastric cancer 
undergoing palliative treatment 
 Patients were recruited into the study under two different ethics with the associated consent 
forms and patient information sheets. Ethics approval for the study was obtained with the 
Health Research Authority NHS England (appendix A) and the Newcastle university biobank 
(appendix C). Patients were identified at the Northern Oesophagogastric cancer MDT and at 
the oesophagogastric ward 36, Royal Victoria infirmary, Newcastle upon Tyne. The inclusion 
criteria for the study were patients over the age of 18 with either locally advanced and/or 
metastatic oesophagogastric adenocarcinoma undergoing palliative treatment. The study was 
discussed with the patient and an information sheet was provided. Patients were entered into 
the study following completion of the consent form (Appendix B) with the principal 
investigator. Blood samples were collected prior to the start of palliative treatment.  
Exudates in the form of pleural and ascitic fluid were collected in sterile containers and 
transferred to the laboratory in a safety bag. Pathological data were obtained from the 
primary tumour. Details of the palliative treatment regimen was obtained from the Northern 
Centre for Cancer Care (NCCC).  
The study incorporated a wide range of patients with metastatic oesophagogastric cancer. 
Patients with the identifier commencing with P were recruited under the Ethics form, IRAS ID 
18535 (appendix A). The remainder of the patients were recruited under the Newcastle 
biobank ethics form. Patient P6 was excluded from the data analysis due to degradation of the 
blood sample following collection.    
Table 6.2.1.1 illustrates the demographics of the patients recruited into the study, location of 
the primary tumour, site of metastases and the palliative treatment regimen.  
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Table 6.2.1.1 Demographics of patients recruited into the study undergoing palliative treatment 










Exudate Palliative Treatment 
modality 
P1 80 M Sub-total Oesophagectomy 
2002 - T2N1 – 
Adenocarcinoma 
Liver Metastases Negative No Chemotherapy 







Negative Ascites Chemotherapy 
 
Seven out of twelve patients in this study had metastatic primary oesopahgogastric junctional 
adenocarcinoma. In five of these patients, the primary tumour had evidence of HER2 
expression. Chemotherapy was the mainstay of the palliative treatment in this group of 
patients. Patient P8 had a distal oesophageal cancer with anaemia secondary to bleeding at 
the site of the primary tumour and hence underwent radiotherapy. There were two patients 
who had developed recurrence post curative treatment. Patient P1 underwent an 
oesophagectomy in 2002 for a Stage II adenocarcinoma of the oesophagus and developed liver 
metastases in 2016. Patient JR underwent a sub-total gastrectomy for Stage IV 
adenocarcinoma of the distal stomach in January 2017. Patient JR had received neo-adjuvant 
and adjuvant chemotherapy. There was evidence of peritoneal recurrence with ascites in 
September 2017 following emergency admission with abdominal pain.  


















Table 6.2.1.2 Demographics of patients recruited into the study undergoing palliative treatment for 
oesophagogastric cancer following recurrence after previous surgery.  
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Patients SH1 and BB1 presented with ascites secondary to peritoneal disease. Both patients 
had multiple medical co-morbidities and poor functional status. They were unfit for palliative 
treatment. 
6.2.2 Characterisation of circulating tumour cells in patients with metastatic 
oesophagogastric cancer 
Two patients, SH1 and BB1 had over 800 CTCs per 7.5 ml of blood. These patients had 
evidence of metastatic adenocarcinoma of the gastrooesophageal junction and were medically 
unfit for palliative treatment. Figure 6.2.2.1 illustrates CTCs identified in blood sample 
obtained from patient SH1 who had a HER2 positive junctional oesophagogastric 
adenocarcinoma Figure 6.2.2.2 illustrates CTCs identified in the blood sample from patient BB1 
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Figure 6.2.2.1 – Images of CTCs and a white blood cells identified by high resolution imaging 
flow cytometer in the blood sample in patient SH1 
 A large proportion of the CTCs were present in clusters. The CTCs were significantly larger 
than the white blood cells. There was only one population of CTCs which expressed EpCAM 
and HER2. The primary tumour in patient SH1 was HER2 positive.  
 
 
SH1 - T4N3M1 – Junctional oesophagogastric adenocarcinoma 
with ascites 
      




The presence of large number of CTCs combined with the presence of CTC clusters reflects 
presumably the stage of advanced oesophagogastric malignancy in patients who did not 
receive any treatment. CTC clusters were identified in five out of 12 patients being treated 
with palliative intent. All of the patients had evidence of metastatic disease. Of note, in all five 
patients the blood samples were taken prior to the commencement of any palliative 
treatment.  
Figure 6.2.2.3  illustrates the number of circulating tumour cells identified in patients with 
metastatic oesophagogastric cancer. 
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Figure 6.2.2.2– Images of CTCs and a white blood cells identified by high resolution imaging 
flow cytometer in the blood sample in patient BB1 
 There were CTC clusters present in the blood sample.  The primary tumour was HER2 
negative. One population of CTCs identified in the sample which expressed EpCAM and 
cytokeratins. The CTCs did not express any of the other biomarkers in the panel.  
 
 
BB1 - T4N3M1 – Junctional oesophagogastric adenocarcinoma 
with ascites 
      




There is a wide variation in the number of CTCs present in this cohort of patients. Of note, 
patient JT had fewer than 50 CTCs per 7.5 ml of blood in his blood which is comparable to 
patients undergoing curative treatment as illustrated in Chapter 5. The patients in the 
palliative cohort can be grouped based on the location and extent of metastatic disease. 
Patients with locally advanced disease are not amenable to curative resection if there is 
evidence of macroscopic nodal metastasis outside the field of curative resection or if there is 
local invasion of the tumour into surrounding structures. Isolated peritoneal nodules and 
ascites indicate the presence of transcoeloemic spread. Liver metastases indicate the presence 
of haematogenous spread. Figure 6.2.2.4 illustrates the sub-group analysis of CTCs detected in 
































Figure 6.2.2.3 – The number of circulating tumour cells in patient with metastatic 







The number of CTCs correlates with the location and burden of metastatic disease. Four 
patients had ascites secondary to the presence of extensive peritoneal metastases. In patients 
with distant metastases and/or ascites, the number of CTCs were higher than in the patients 
with locally advanced disease (p=0.021).  
Two patients had isolated peritoneal nodules detected on staging laparoscopy with 
histological confirmation of metastases. Patients with ascites had a significantly higher 
number of CTCs detected in the blood when compare to patients with isolate peritoneal 
nodules (p=0.029) 
Two patients had evidence of macroscopic nodal disease based on radiological imaging 
outside the field of resection and were deemed inoperable. There was no histological 
confirmation of the presence of nodal metastasis in these patients. There was no difference in 
the number of CTCs in this group of patients with locally advanced disease deemed inoperable 
compared to patients with locally advanced cancer undergoing curative treatment with 
surgery alone (p=0.344).  
Figure 6.2.2.4 – The number of circulating tumour cells in patients with metastatic 
oesophagogastric cancer in 7.5 ml of blood based on the location and extent of metastatic 
disease 
               



















In the majority of the patients in this group, there was evidence of heterogenous population of 
CTCs present in the blood sample. Figure 6.2.2.5 illustrates the biomarker expression of CTCs 




Patients BB1 and SH1 had the highest number of CTCs in the study and both had only one 
population of CTCs present. There was strong correlation with the biomarker expression of 
HER2 in the CTCs in the blood and the primary tumour. CTCs which expressed HER2 were 
present in 5 out of 7 patients with oesophgagogastric junctional adenocarcinoma whose 
primary tumour was HER2 positive. The primary tumour in Patient P4 was HER2 positive but 
the CTCs in the blood did not express any of the biomarkers in the panels tested.  
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The majority of the CTCs in patients with metastatic gastric cancer expressed cytokeratins. 
Both patients P11 and P10 had some CTCs which did not express any of the biomarkers in the 
panels. Primary tumour was HER2 negative in patients P11, P10 and P9. None of the patients 
received trastuzumab. However, patient P11 had a population of CTCs which expressed 
cytokeratins and HER2. 
 
6.2.3 Characterisation of circulating tumour cells in the blood following palliative 
chemotherapy 
Patient P3 had a locally advanced junctional oesophagogastric adenocarcinoma with 
pulmonary metastases. The primary tumour was HER2 positive and the patient received six 
cycles of HCX (trastzumab, capecitabine, cisplatin). Blood samples were obtained at prior to 
start of the treatment and at 8 weeks following completion of treatment. A CT scan performed 
following completion of treatment showed that the primary tumour had progressed but the 
pulmonary metastases had reduced in size. Figure 6.2.3.1 illustrates images of CTCs in the 
blood before and after completion of the chemotherapy regime.  
 
Figure 6.2.2.6 – Biomarker expression of CTCs in patients with metastatic gastric cancer 
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P3 – Metastatic junctional oesophagogastric adenocarcinoma with 
pulmonary metastases 
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Palliative chemotherapy regimen – Trastuzumab, cisplatin, capecitabine 
(HCX) 
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In the pre-operative sample, a total of 62 CTCs per 7.5 ml of blood were detected. There was 
one population of CTCs identified in panel C which expressed EpCAM and cytokeratins and 
accounted for 29 CTCs per 7.5 ml of blood. In panel B, there was one population of CTCs which 
expressed HER2 and EpCAM and accounted for 33 CTCs. Data from panel A was lost during the 
flow cytometry analysis. Following chemotherapy, a CT scan was performed to assess the 
response of the cancer to the chemotherapy regimen. This revealed that the primary tumour 
did had not responded to the chemotherapeutic regimen and had increased in size. However, 
the pulmonary metastases reduced in size. There were five different populations of CTCs 
present in the blood sample collected post chemotherapy treatment. The total number of 
biomarker positive CTCs increased from 62 to 79 CTCs per 7.5 ml of blood. Two populations of 
CTCs remained. CTCs which expressed EpCAM and cytokeratins decreased in number from 29 
to 14 CTCs per 7.5 ml of blood. CTCs which expressed EpCAM and HER2 increased from 33 to 
43 CTCs per 7.5 ml of blood. There were three other population of CTCs present. The first 
population expressed cytokeratins alone accounted for 16 CTCs per 7.5 ml of blood. The 
second population expressed EpCAM alone and accounted for 16 CTCs per 7.5 ml of blood. 
One can hypothesise that this population of CTCs based on their size, shape and nuclear 
density arise from the equivalent population of CTCs which express EpCAM and HER2 detected 
in panel B. There were a total of 72 biomarker negative CTCs per 7.5 ml of blood present in the 
postoperative sample.  
6.2.5 Characterisation of tumour cells in exudates in patients with metastatic 
oesophagogastric cancer 
The presence of tumour cells which have infiltrated the lining of the peritoneal and pleural 
cavities results in the production of proteinaceous fluid. Fluid within the peritoneal cavity is 
referred to as ascites. The accumulation of fluid within the cavities can cause symptoms of 
abdominal pain and bloating. Symptomatic relief can be obtained in the short term by draining 
the fluid. Long term drains can be left in the cavities to allow repeat drainage. Exudates were 
Figure 6.2.3.1– Images of CTCs and white blood cells in the blood sample of patient P3, pre 
and post palliative chemotherapy 
A: Biomarker positive CTCs in the pre and post treatment sample. B: white blood cells in the pre 
and post treatment sample. C: Biomarker negative CTCs in the pre and post treatment sample 
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obtained in four patients who underwent symptomatic drainage of ascites as illustrated in Table 
6.2.1.1. Table 6.2.5.1 illustrates details of the exudates obtained from the four patients in the study.  
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The volume of ascites and the composition of the ascitic fluid varied between patients. Patient 
JR had a large volume of ascites drained at the time of presentation. However, the fluid 
contained a large amount of cellular debris which required filtration prior to centrifugation. 
There was a wide variation in the cellular composition of the fluid between samples. The 
cellular component of the ascitic fluid was isolated and labelled with the antibodies from the 
three biomarker panels used to label CTCs. The method for isolation of the tumour cells from 
the ascites is found in Chapter 2, Section 2.2.2.  Figure 6.2.5.2 illustrates images of CTCs in the 
blood and tumour cells in the ascites of patient P10. 
Table 6.2.5.1 Demographics of patients recruited into the study undergoing palliative treatment 





There were three populations of CTCs present in the blood in patient P10. One population of 
CTCs expressed EpCAM, the second expressed EpCAM and cytokeratins and the third 
population of CTCs did not express any of the biomarkers in the panels. The ascites had  
heterogenous population of cells in the blood which expressed a number of different 
biomarkers. The primary tumour was HER2 negative but the ascites contained tumour cells 
P10 – Proximal gastric cancer – T4N2M1– Peritoneal disease with 
ascites 
  
    
 
Figure 6.2.5.2 – Images of CTCs in the blood and tumour cells in the ascites in patient P10 – 
Proximal gastric cancer with peritoneal disease and ascites 
A: Biomarker positive CTCs in the blood sample B: Biomarker negative CTCs in the blood sample 
C: tumour cells in the ascites 
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which expressed HER2, EpCAM, E-cadherin and cytokeratins. In addition, there was a 
population of CTCs which expressed thymidylate synthase and EpCAM. These tumour cells 
were present in clusters. There were no biomarker negative tumour cells in the ascites. 




         
 
         
Patient JR had only one population of CTCs in the blood, which expressed EpCAM and 
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Figure 6.2.5.3 – Images of CTCs in the blood and tumour cells in the ascites in patient JR –
Sub-total gastrectomy T4N3 adenocarcinoma, Local and peritoneal recurrence of disease 
with ascites.  
A: CTCs in the blood sample B: white blood cells in the blood sample C: tumour cells in the 
ascites 
 
JR – Sub-total Gastrectomy – 2016 – T4N3 Gastric Cancer 
       
 
 





















cytokeratins. There were multiple populations of tumour cells in the ascites in the two panels 
analysed. In panel A, two populations of tumour cells were detected. One population of 
tumour cells expressed E-cadherin, cytokeratins and EpCAM and the other expressed E-
cadherin and cytokeratins. In panel B, there were two population of tumour cells detected, 
one expressed cytokeratins and EpCAM and the other expressed cytokeratins, EpCAM and 
HER2.  
The tumour cells in the ascites were heterogenous in their morphology and biomarker 
expression. There was variation in the size of the tumour cells and their shape and in 
biomarker expression within the populations of tumour cells present.  
6.2.6 Culture of tumour cells from exudates in patients with metastatic oesophagogastric 
cancer 
Ascitic fluid was collected in sterile conditions into a sterile flask. The fluid was passed through 
a 70 micron filter to exclude the cellular debris. The suspension post filtration was placed into 
the culture medium listed in table 2.2.2.1 in Chapter 2. Details of the cell culture are present in 
Chapter 2, Section 2.2.2. Tumour cells isolated from the exudate from patient P10 were 
cultured as per the protocol The cells were imaged in the flasks with light microscopy on day 3, 
5 and at day 7. Figure 6.2.6.1 illustrates images of tumour cells from patient P10 cultured in 
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Figure 6.2.6.1 illustrates the growth and proliferation of the tumour cells in culture. The cells 
were trypsinised at day 7. The cell suspension post trypsinisation from one flask was 
centrifuged and labelled with the antibodies from the three biomarker panels. The cell 
suspension from the second flask was divided into two samples and placed into culture. Figure 
6.2.6.2 illustrates images of tumour cells from patient P10 following trypsiniation captured on 
the high resolution imaging flow cytometer.  
 
     
 
The biomarker expression of tumour cells in the ascites pre and post culture was similar as 
shown in Figure 6.2.5.2. Tumour cells detected prior to culture expressed EpCAM and E-
cadherin (panel A) and also EpCAM, cytokeratins and HER2 (panel B). Post culture, the tumour 
cells which express EpCAM, cytokeratins and HER2 remain. Tumour cells which expressed 
EpCAM and E-cadherin in the ascites pre culture in panel A, now expressed cytokeratins as 
well.  The fact that in both panel A and B, the cells expressed EpCAM and cytokeratins, one 
could hypothesise that the cells detected post culture may all be part of the same population.  
Figure 6.2.6.1 – Images of tumour cells in culture from the ascites from patient P10 
A: Images of tumour cells in culture at day 3 B: Images of tumour cells in culture at day 5 
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Figure 6.2.6.2 – Images of tumour cells from the ascites in patient P10 following culture and 
trypsinisation on the high resolution imaging flow cytometer  
A: Images of tumour cells in culture at day 3 B: Images of tumour cells in culture at day 5 
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In all four patients there was evidence of viable tumour cells based on the evaluation of cell 
proliferation using light microscopy up to passage two.  
6.3 Discussion 
There was a wide variation in the number of CTCs in patients with advanced oesophagogastric 
cancer. Patients with locally advanced disease with the presence of distant metastases had a 
significantly higher number of CTCs than patients with locally advanced cancer that was not 
amenable to curative resection (p=0.021). Of note, there was no significant difference in the 
number of CTCs in patients who had locally advanced disease with nodal metastases outside 
the field of curative resection compared to patients undergoing curative surgery alone with 
locally advanced disease (p=0.657).  
There is concordance between the biomarker expression of the primary tumour and the CTCs 
in the blood. All bar one of the patients in whom the primary tumour was HER2 positive had 
CTCs that expressed HER2. Patient P11 had CTCs in the blood which expressed HER2 but the 
primary tumour was reported negative for HER2 expression and amplification.  
A similar observation was made on the measurements of CTCs in patient P3 pre and post 
chemotherapy treatment. The primary tumour in patient P3 expressed HER2. CTCs that 
expressed HER2 were present in the blood prior to treatment with palliative chemotherapy. 
The patient received six cycles of HCX chemotherapy. Following treatment, a repeat CT 
showed that the primary tumour increased in size but the pulmonary metastases reduced in 
size. Blood samples post chemotherapy treatment revealed that CTCs which expressed EpCAM 
and HER2 remained and increased in number. Another population of CTCs which expressed 
EpCAM and cytokeratins decreased in number. In addition, three new population of CTCs were 
now present. Of note, one of these populations of cell did not express any of the biomarkers in 
the panels. These findings suggest the presence of multiple clonal populations of cells within 
the primary tumour with different biomarker expressions. This suggests that 
chemotherapeutic regimens target only a select clonal population of cells within the primary 
tumour and at sites of metastases. Tumour cells arising from a different clone which are 
resistant to the chemotherapy regime proliferate as a consequence. This would explain the 
different responses to the chemotherapy between the primary tumour and the pulmonary 
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metastases in patient P3. One can hypothesise the origin of the CTCs in the blood based on the 
change in the number of CTCs present between the pre and post treatment samples. The 
reduction in the size of the pulmonary metastases following treatment correlated with the 
reduction in the total number of CTCs which expressed EpCAM and cytokeratins alone. This 
could indicate the origin of the CTCs from the pulmonary metastases. In addition, the poor 
response of the primary tumour to the chemotherapy regime, correlates with the increase in 
the number of CTCs which expressed EpCAM and HER2 which is consistent with some of these 
cells originating from the primary tumour. There were 72 CTCs per 7.5 ml of blood post 
treatment which did not express any of the biomarkers present in the panels. The origin of 
these cells is unknown.  
The impact of chemotherapy on tumour evolution remains unknown. Characterisation of the 
biomarker expression and morphology of CTCs would aid in monitoring the response to the 
chemotherapy of the primary tumour and metastatic sites. Future work would focus upon 
isolating individual populations of CTCs based upon biomarker expression and then sequence 
the transcriptome. This would help identify therapeutic targets for the chemotherapy agents 
with the future potential for individualised cancer treatment.  
CTC clusters are hypothesised to have a longer half life in the blood compared to single cell 
CTCs (160). The formation of clusters is thought to provide protection from cells within the 
immune system and provide protection against environmental and oxidative stresses (160, 
161). CTC clusters are thought to have enhanced metastatic potential in comparison to single 
CTCs which is attributed to multiple factors. CTC clusters can contain a heterogenous 
population of CTCs that express epithelial and/or mesenchymal markers (160). This 
heterogeneity may facilitate the dissemination and proliferation of the cells from the primary 
tumour to distant sites. In this present study, CTC clusters were present in five out of the 
twelve patients with advanced oesophagogastric malignancy. The clusters identified contained 
cells with a homogenous population of CTCs.  
The successful culture of tumour cells from the ascites provides a template for developing 
suitable culture conditions and a protocol to culture CTCs from the blood. However, the 
numbers of tumour cells in ascites are far greater than the numbers of CTCs in blood and they 
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express different biomarkers. The challenge is to develop a protocol to isolate a sufficiently 






















Chapter 7: Discussion 
7.1 Assessment of Achievements  
7.1.1 Development of a reliable assay for detecting CTCs in the blood 
The first aim of the study was to develop a reliable assay to detect and characterise CTCs in 
the blood in patients undergoing curative and palliative treatment for oesophagogastric 
cancer. Refinements to the previous protocol for the analysis of CTCs in the blood after 
immunomagnetic separation of white blood cells were made which led to an improvement in 
the enrichment and recovery of cells from the blood. In addition, time taken for processing 
individual samples was reduced from 5 to 3 hours.  
Two other methods of isolation and enrichment of CTCs from blood were evaluated. In 
EasySep™ Direct Human CTC Enrichment, red and white bloods cells are removed by 
immunomagentic separation during the enrichment of CTCs from blood. The cells isolated by 
this method could be placed directly into culture. Althought the method has potential, the 
enrichment and recovery of cells was poor and consequently clinical application for the 
evaluation of CTCs is limited. ParsortixTM offered a simplified process to isolate CTCs directly 
from blood based on their size. The major limitation of the process was the difficulty in the 
positive identification of CTCs following any enrichment. Labelling the cells captured in the 
cassette post enrichment with antibodies and subsequent imaging was challenging because 
the small number numbers of cells recovered meant that they would be lost during any 
procedures involved in their analysis.  
In the present study, a protocol was developed to isolate cells by fluorescence activated cell 
sorting based upon their biomarker expression. Oesophageal carcinoma cells were isolated 
successfully from blood for imaging by confocal microscopy and high resolution imaging flow 
cytometry, and were placed into culture.  
7.1.2 Development of a reliable assay for detecting DTCs in the bone marrow of excised rib 
The protocol for isolation and enrichment of DTCs from bone marrow was as adaption of the 
method used to analyse CTCs. Enrichment and recovery of DTCs from the bone marrow in the 
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initial experiments was approximately 50% based on the optimization experiments. DTCs were 
detected in the bone marrow of all patients undergoing curative treatment open 
oesophagectomy for oesophageal adenocarcinoma.  
7.1.3 Characterisation of the heterogeneity within the CTCs in the blood and DTCs in the 
bone marrow 
The high resolution imaging flow cytometer had multiple channels which could detect in 
principle up to 10 different biomarkers and characterise cells based on their size and 
morphology. A wide range of biomarkers were incorporated into the study which helped to 
identify and characterise the heterogeneity within the CTC population. CTCs were detected in 
all patients undergoing curative and palliative treatment for oesophageal cancer. There was 
variation in the biomarker expression within the CTC populations isolated in both the curative 
and palliative treatment cohort of patients. In the curative treatment cohort, less than 50% of 
CTCs detected expressed both EpCAM and cytokeratins. In addition, 50% of patients in the 
curative cohort had a heterogeneous population of CTCs which was associated with a poor 
prognosis. The study identified a population of cells that did not express any of the biomarkers 
included in the panel but had similar morphological characteristics to CTCs. These biomarker 
negative CTCs were present in patients undergoing curative and in patients undergoing 
palliative treatment. In the curative treatment cohort, the biomarker negative cells were 
present both in patients with early cancer and in patients with locally advanced oesophageal 
cancer who had received peri-operative chemotherapy.   
7.1.4 Prognostic significance of CTCs in the blood and DTCs in the bone marrow 
In this study, two year disease free survival in patients Stage III and IV cancer who underwent 
surgery alone was 25%. In those who received peri-operative chemotherapy and surgery, two 
year disease free survival was 48%. Fourteen out of the twenty-three patients who received 
peri-operative chemotherapy and surgery developed recurrence within the two year follow up 
period, median time to recurrence was 21 months. For patients staged clinically with Stage III 
and IV disease, two year disease free survival was 38% and median time to recurrence was 20 
months.  
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Patients with 100 or more CTCs per 7.5 ml of blood in the postoperative sample had a 
significant shorter two year disease free survival (p=0.012) than patients with fewer than 100 
CTCs per 7.5 ml of blood. In addition, patients with a heterogeneous population of CTCs in the 
pre-operative sample based on biomarker expression had a significant shorter two year 
disease free survival (p=0.043).  
The presence of lymphovascular invasion and poor response to peri-operative chemotherapy 
based on the tumour regression grade are recognized poor prognostic factors in patients 
undergoing curative treatment for oesophagogastric cancer.  
The number of DTCs and CTCs in the postoperative samples were significantly higher in 
patients with the presence of lymphovascular invasion (p=0.051) (p=0.010). This observation 
suggests that in patients with evidence of lymphovascular invasion in the primary tumour, 
there is dissemination of tumour cells from the primary tumour to distant sites. This could 
explain the rise in the postoperative CTCs in patients with evidence of lymphovascular invasion 
in primary tumour despite the resection of the primary tumour (p=0.007). This suggests that 
the origin of the CTCs in the postoperative sample are from a distant metastatic site.  
There was a rise in the number of CTCs between the pre and postoperative samples in patients 
who had a poor response to peri-operative chemotherapy based upon TRG scores of 4 or 5. In 
contrast, the total number of CTCs fell between the pre and postoperative samples in patients 
who had a good response to chemotherapy and had a TRG score of 3 or less. However, there 
was no significant difference between the total number of postoperative CTCs in patients who 
had a poor response to chemotherapy and those who had a good response to chemotherapy. 
If CTCs originated from the primary tumour, one might expect CTCs in the blood to fall 
following resection of the primary tumour. The rise in the number of CTCs in the postoperative 
sample in patients would be consistent with the source of CTCs being a site other than the 
primary tumour. The bone marrow is a potential reservoir for tumour cells following resection 
and could be the source of the disseminated tumour cells that lead to early relapse after 
resection of the primary tumour in patients who do not respond to chemotherapy. All twelve 
patients who had a poor response to chemotherapy based on TRG 4 or 5 who relapsed had 
the at least one population of cells in the bone marrow and the postoperative blood sample 
that expressed the same biomarkers.   
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In patients treated with palliative intent, the number of CTCs correlated with the tumour 
burden. Patient with the presence of distant metastases and ascites had a significantly higher 
number of CTCs compared to patients with locally advanced cancer that was not amenable to 
curative surgical resection (p=0.021). Sequential measurements of CTCs in one patient who 
received palliative chemotherapy revealed a difference in heterogeneity in biomarker 
expression of CTCs identified before and after chemotherapy treatment. In patient P3, the 
primary tumour was HER2 positive and the patient received HCX chemotherapy regimen. 
There was progression of the primary tumour burden based upon a CT scan which following 
chemotherapy. However, there was regression of the pulmonary metastases on the CT scan 
indicating a response of these metastases to the chemotherapy. There was a rise in the total 
number of CTCs between the pre and post treatment sample, 62 to 151 CTC per 7.5 ml of 
blood. There was an increase in the number of CTCs that expressed EpCAM and HER2 but a fall 
in the number of CTCs that expressed EpCAM and cytokeratins. In addition, there was a new 
population of CTCs which expressed cytokeratins and a population of biomarker negative 
CTCs. These observations indicate the presence of heterogeneous population of tumour cells 
within the primary tumour and distant metastatic site. The difference in response of the 
primary tumour and distant metastatic sites is reflected by the change in the total number of 
CTCs and the different populations of CTCs based on biomarker expression present in the 
circulation before and after treatment.  
In the future, characterising the biomarker expression in the CTCs could help identify 
therapeutic targets for chemotherapy regimens. Sequential monitoring of CTCs will provide 
the ability to monitor response to treatment and modify therapeutic regimens during 
treatment to target tumour cells that have not been eliminated by the initial therapy.  
 
7.2 Comparison between outcomes of present studies with those reported in the literature 
7.2.1 CTC detection rates in oesophageal adenocarcinoma 
Four studies have detected CTCs in patients undergoing curative treatment for oesophageal 
adenocarcinoma.  Two studies reported CTCs detected based upon the combined expression 
of two epithelial makers combined, EpCAM and cytokeratins as per the CellSearchR test (128, 
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129). Cells were classified as CTCs only if they expressed both EpCAM and cytokeratins. In the 
study by Reeh et al, 20% (14/68) patients with oesophageal adenocarcinoma had CTCs (129). 
This was similar to the findings of the study by Konczella et al, 20% (15/76) patients had CTCs 
(128). In both studies small numbers of CTCs were detected and the presence of one or more 
CTCs was deemed significant. Both studies concluded that the presence of CTCs was 
associated with shorter relapse free and overall survival. Two other studies, enriched CTCs 
from the blood using a size based filter. Cells greater than 8 microns in diameter were isolated 
and stained with nuclear and cytoplasmic markers. Detection rate of CTCs were higher in these 
studies. Bobek et al reported detection of CTCs in 75% (15/20) patients (130). Kuvendjiska et 
al, reported detection of CTCs in 60% (12/20) of patients who underwent curative treatment 
for oesophageal adenocarcinoma (132).     
In the present study, CTCs were present in all patients undergoing curative treatment for 
oesophageal adenocarcinoma. The proportion of CTCs which expressed both EpCAM and 
cytokeratins varied depending upon the clinical stage of disease at the time of surgery and 
between the pre and postoperative blood samples. In patients with early oesophageal cancer, 
CTCs which expressed both EpCAM and cytokeratins were present in only 44% (4/9) patients 
in the pre-operative sample and 33% (3/9) patients in the postoperative sample. In patients 
who received peri-operative chemotherapy and surgery, CTCs which expressed both EpCAM 
and cytokeratins were present in 45% (11/24) patients in the preoperative sample and in 63% 
(15/24) patients in the postoperative sample. Overall, detection rate of CTCs which expressed 
both EpCAM and cytokeratins alone in patients undergoing curative treatment was 49% in the 
pre-operative sample and 60% in the postoperative sample. This is higher than in previous 
studies which only detected CTCs using this criteria in 20% of patients.  
The use of multiple biomarkers combined with the high resolution imaging flow cytometer 
enables the detection and characterisation of multiple populations of CTCs in the circulation. 
This could explain the overall higher detection rates of CTCs in this study when compared to 
the literature. In this present study, heterogeneous populations of CTCs were detected in the 
pre-operative blood sample in 24 patients and in the postoperative blood sample in 23 
patients. The presence of heterogeneous population in the preoperative sample was 
associated with shorter disease free survival (p=0.043). In addition, this present study 
highlights the fact that there are CTCs in the blood which do not express EpCAM. 
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A previous study reported the presence of HER2 expression in CTCs in patients with potentially 
curative gastric cancer in whom the primary tumour was HER2 negative. Subsequent 
treatment with trastuzumab in patients where the primary tumour did not express HER2 but 
the CTCs expressed HER2 revealed a comparable response to the findings of the TOGA trial 
(162). In the present study, the biomarkers most frequently detected in addition to EpCAM 
and cytokeratins in the CTCs, were c-Met and HER2. CTCs which expressed HER2 were present 
in four patients in the pre and seven patients in the postoperative sample.  
7.2.2 Evidence that CTCs have undergone EMT 
CTCs are thought to arise from the primary tumour and undergo EMT to facilitate their 
dissemination to distant sites within the body (74, 96, 98). It is hypothesised that during this 
process, there is a change in the phenotype of the cell with subsequent loss of cell junctions 
and apical-basal polarity. The cells lose their expression of epithelial biomarkers, eg EpCAM 
and cytokeratins when they undergo EMT and enter the circulation (163). As a consequence, 
methods which rely on detection of CTCs based on epithelial biomarker expression do not 
identify this population of CTCs. These cells are also hypothesised to have the greatest 
malignant potential due to their resistance to anoikis and chemo and radiotherapy (74, 164). 
In this study, a proportion of cells detected did not express any of the biomarkers analysed but 
had the morphological characteristics of CTCs based on their size and nuclear density. The 
biomarker negative CTCs were present in 19 out of 37 patients undergoing curative resection 
for oesophagogastric cancer. However, the number of the biomarker negative CTCs in patients 
who received peri-operative chemotherapy was higher than in patients with early 
oesophagogastric cancer in both the pre and postoperative samples (p=0.023)(p=0.034). The 
findings suggest that this population of cells has undergone EMT and thus do not express the 
epithelial biomarkers present in the study. Further characterisation of the cells with additional 
mesenchymal biomarkers combined with molecular analysis by RNA sequencing will be 
interesting and will aid in identifying the origin of these cells.  
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7.2.3 Prognostic significance of CTCs in patients undergoing curative treatment for 
oesophageal adenocarcinoma 
The presence of CTCs in the blood has been associated with poor prognosis in patients 
undergoing curative treatment for oesophagogastric cancer. The threshold of the number of 
CTCs required for significance varied between studies. In the previous two studies, the 
presence of one or more CTCs was associated with a significant decrease in overall and disease 
free survival (128, 129)(p=0.001). In this study, the presence of a heterogenous population of 
CTCs in the pre-operative sample and/or the presence of 100 or more CTCs per 7.5 ml of blood 
in the postoperative sample was associated with a significant decrease in disease free survival 
(p=0.043)(p=0.001). A meta-analysis of the prognostic significance of CTCs in oesophageal 
cancer concluded that CTC status correlated with the clinical TNM and T stage but not with 
lymph node metastases (165). In the present study, there was no significant correlation 
between the CTC status and clinical TNM stage (p=0.087).  
7.2.4 Disseminated tumour cells in the bone marrow in patients with oesophageal 
adenocarcinoma 
DTC detection rates in the bone marrow from the rib from previous studies varied between 
45-88% in patients undergoing curative treatment for oesophagogastric cancer (108, 112, 114, 
116, 117). The variation in the detection rates was related to the different methods of 
isolating DTCs from the bone marrow. Two long term follow up studies came to different 
conclusion regarding the prognostic significance of DTCs. Konczella et al, reported the 
detection of DTCs from the iliac crest in 17% (13/76) patients and CTCs in the blood in 20% 
(15/76) patients with non-metastatic oesophageal cancer(128). In addition, CTCs and DTCs 
were detected together in only 3 patients in the study. The study concluded that the presence 
of one or more CTCs were an independent prognostic factor for survival. DTCs were not of 
prognostic significance.   
In the present study, DTCs were present in all patients undergoing curative resection for 
oesophagogastric cancer. There was no significant difference in the number of DTCs in 
patients with early and locally advanced oesophagogastric cancer (p=0.992). Previous studies 
have commented upon the variation in the biomarkers expression between the primary 
tumour and DTCs in the lymph node and bone marrow (146). Dreimel et al, demonstrated 
197 
variation in the expression of epithelial biomarkers between the primary tumour and DTCs in 
the bone marrow (163). In 64% of patients, the DTCs in the bone marrow did not express 
EpCAM despite the primary tumour being EpCAM positive. Molecular analysis of individual 
DTCs in the bone marrow had demonstrated poor prognosis in patients in whom the presence 
of HER2 gain was detected in the DTCs and not in the primary tumour. There was a 
heterogeneous population of DTCs present in the bone marrow from the rib in this study. 
DTCs that expressed novel biomarkers were present in 70% (23/33) patients, of which 9 
patients had DTCS that expressed HER2. Correlation of these findings with the biomarker 
expression in the primary tumour will be of interest.  
7.3 Comparison with literature on the significance of circulating tumour cells in patients 
with metastatic oesophageal adenocarcinoma 
CTCs have been reported to be independent predictors of progression free survival in patients 
with metastatic solid organ tumours (65, 66, 165). The presence of 5 or more CTC was 
associated with a significant reduction in progression free survival in patients with metastatic 
breast cancer. Previous studies have reported the presence of one or more CTCs in patients 
with metastatic oesophagogastric cancer is associated with a reduction progression free 
survival (165, 166). Detection rates of CTCs in these studies varied between 21 to 44% (165, 
166).  
In the present study, the number of CTCs detected in this group of patients varied between 40 
to 1988 CTCS per 7.5 ml of blood.  Eight out of twelve patients in the study had evidence of 
distant metastatic disease, and two of the patients had liver metastases and ascites. This 
group of patients had significantly higher number of CTCs than the patients who had locally 
advanced disease not amenable to curative resection (0.021). Of interest, there was no 
significant difference in the number of CTCs in patients with locally advanced cancer in whom 
the disease was not amenable to curative resection compared to those who underwent 
surgery for locally advanced cancer (p=0.950). Both observations indicate that the CTCs play a 
role in the dissemination of cells from the primary tumour to distant sites. The findings in the 
study supports the current literature which indicate the presence of CTCs is associated with 
poor prognosis.  
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7.4 Limitations 
As the study progressed, improvements in efficiency in the collection, storage and processing 
of samples led to improvements of enrichment and recovery of CTCs in the blood and DTCs in 
the bone marrow. The original protocol used in the processing of early patient samples which 
gave a lower recovery of CTCs as shown in Chapter 3. As a consequence, the number of CTCs 
and DTCs detected in early patient samples could be an underestimate of the total numbers 
present.  
Cells were visualized on the high resolution imaging flow cytometer and images reviewed by a 
single individual for some of the patients. Positive identification of CTCs and DTCs in this study 
was based on both morphological characteristics and biomarker expression. Although the 
classification criteria were strict, for some of the patients, the images were not reviewed by 
another individual to confirm the findings. Thus, one potential limitation in the study is that of 
observer bias.  
One of the strengths of the study was to incorporate a wider range of biomarkers to 
characterize the heterogeneity. As a consequence, three different panels of antibodies were 
analysed. Each panel incorporated EpCAM and cytokeratins but different combination of novel 
biomarkers were present. Therefore, HER 2 and c-Met expression was only assessed in 1/3 of 
the cells analysed in each sample. A limitation of the study is that the number of CTCs 
expressing the novel biomarkers may be an underestimate of the total number present.   
 
7.5 Summary of Novel Findings 
 In the present study, all patients who were diagnosed with oesophagogastric cancer had 
evidence of CTCs present in the blood. The detection rate can be attributed to the ability of 
the high resolution imaging flow cytometer to image and characterise individual cells based on 
their morphology and biomarker expression. The incorporation of a wide range of biomarkers 
helped characterize the heterogeneity of biomarker expression within the CTC and DTC 
population. In over 50% of patients who underwent curative treatment, there were two or 
more populations of CTCs based on biomarker expression were present. In the majority of 
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patients, CTCs would not have been detected if the CellSearchR method was utilised which 
only identifies a CTC if it expresses both EpCAM and cytokeratins. This finding could explain 
the higher number of CTCs detected in this study compared to previous studies in the 
reported literature.  
Our study identified biomarker negative CTCs which were morphologically similar to the CTCs 
that expressed biomarkers present in the panels. In some patients, these cells accounted for 
the majority of the CTCs present in the blood. The origin and the function of these cells 
remains unknown and warrants further study.  
In the curative cohort, the presence of 100 or more CTCs per 7.5 ml of blood in the 
postoperative sample was associated with poor prognosis. In addition, the number of CTCs 
and DTCs were higher in patients who had a poor response to chemotherapy based on the 
TRG grade. In the palliative cohort, the number of CTCs in the blood correlated with the 
burden of the disease. Patients who had evidence of locally-advanced disease had significantly 
lower numbers of CTCs than patients with extensive metastatic disease. 
7.6 Future work 
The present study highlights the clinical potential of CTCs and DTCs in the blood and bone 
marrow in patients undergoing curative treatment for oesophagogastric cancer. There are 
multiple avenues for future research. The role of CTCs in the evolution of the primary tumour 
can be evaluated further by sequential measurements of CTCs at defined intervals during the 
treatment pathway. Detection of therapeutic biomarkers, eg HER2 in CTCs and in the primary 
tumour could provide evidence for the use of trastuzumab in patients undergoing curative 
treatment for oesophageal cancer. Evaluating the change in the CTC populations and the 
biomarker expression during treatment could provide information regarding tumour biology 
and the molecular mechanisms of tumour cell dissemination.  
Different populations of CTCs could be isolated from blood by fluorescence activated cell 
sorting based on biomarker expression for subsequent genomic and transcriptomic analyses 
and to plate CTCs into culture. Successful culture of CTCs ex vivo could help develop new 
therapeutic regimens. New chemotherapy agents could be evaluated ex vivo with using CTCs 
200 
grown in culture. The overall aim would be the incorporation of the genomic and 
transcriptomic information from the primary tumour and CTCs into the current staging 
protocol. Improved prognostic information derived from the staging protocol can help counsel 
patients for the available treatment modalities.  
In the present study and literature, 50% of patients with locally advanced cancer relapse 
within two years following surgery. At present, there are no established biomarkers to predict 
recurrence in oesophagogastric cancer or defined follow up protocols for patients following 
curative resection for oesophagogastric cancer. Patients are reviewed in outpatient clinics and 
imaging is requested if they develop symptoms or signs of relapse. At this point, the tumour 
burden may be too advanced for successful treatment. Measurement of CTCs in the 
postoperative period following surgery could help identify recurrence earlier in patients 
before the patients develop symptoms. Combined with radiological imaging of these patients, 
sites of relapse could be identified earlier at a stage when they may be amenable for radical 
treatment, eg isolated pulmonary or liver metastases for surgical resection. This surveillance 
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